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Breast cancer is one of the most frequently diagnosed cancers in women. Although 
surgery and endocrine therapy lead the treatment chart, chemotherapy remains the 
preferred choice for management of advanced stages of breast cancer. However, 
chemoresistance to most clinically used drugs, result in a failure of the treatment regime. 
Chemoresistance is thus seen as a major clinical burden, necessitating a pressing need to 
identify new biomarkers and therapeutic targets, that could help predict chemoresponse 
and reverse chemoresistance. Keeping this objective in sight, we have identified DP103, a 
DEAD-Box RNA helicase, as a predictive marker and a therapeutic target of docetaxel 
response in breast cancer.  
Firstly, we analyzed the expression profile of DP103 in a retrospective phase II 
study that had 100 female breast cancer patients, subjected to alternating sequences of 
docetaxel and doxorubicin in a neoadjuvant setting. We found that clinical responders had 
significantly lower DP103 expression, both at baseline and post-chemotherapy, compared 
to non-responders. Responders observed a statistically significant change in DP103 
expression from positivity to negativity throughout chemotherapy. In contrast, DP103 
expression remained positive in non-responders. Upon stratification of the patients by 
Estrogen Receptor (ERα) status, chemotherapy-induced decrease in DP103 expression 
was observed only in ERα-positive patients, predominantly among responders. In brief, 
tumors positive for both ERα and DP103 at baseline, that remained DP103-positive even 
after chemotherapy, showed a poor clinical response than those that became DP103 
negative, suggesting that DP103 expression profile could serve to predict chemoresponse 
in tumors with ER positive status. Moreover, when the effect of the individual drugs was 
computed, DP103 expression profile served as a predictive marker only for docetaxel 
response and not doxorubicin.  
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Consistent with clinical data, docetaxel, and not doxorubicin, decreased DP103 
expression in ERα-positive breast cancer cell lines but not in ERα-negative cell lines. 
Docetaxel, however, had no effect on DP103 expression in cell lines that were made to 
acquire docetaxel resistance. Depletion of DP103 sensitized cells to docetaxel and 
conversely, overexpression of DP103 rendered the cells resistant. DP103 could be 
affecting docetaxel sensitivity by modulating caspase activity. DP103 depletion 
enhanced and DP103 overexpression subverted docetaxel-induced caspase-3/7 
activation.  
Further investigation into why DP103 expression profile predicted docetaxel 
response only in ERα-positive cases, revealed that ERα expression also exhibited a similar 
docetaxel-induced expression profile as DP103, with drug sensitivity resulting in a 
decrease in ERα. Similarity in their expression profiles suggested a cross-talk between 
DP103 and ERα. Through various biochemical assays, we identified DP103 as a novel 
estradiol-stimulated ERα-responsive gene. DP103 also involved in a feedback loop with 
ERα, with DP103 positively modulating estradiol-dependent ERα transcriptional activity 
and cell survival. However, mechanistic approach involving immunoprecipitation, 
immunofluorescence and ChIP assay, revealed neither an interaction or co-localization 
between DP103 and ERα, nor a recruitment of DP103 to ER response elements. This 
implied that DP103 is not a direct co-activator of ERα. 
Interestingly, we found that DP103 co-activates ERα through suppression of 
p53. p53 protein is known to interfere with ERα binding to the DNA, thereby decreasing 
its transcriptional activity. We demonstrate that DP103 positively modulates ERα activity 
by negating the ERα-inhibitory role of p53. We first validated DP103 as a novel 
modulator of p53 in breast cancer. We show that DP103 preferentially interacts with wild-
type p53 over mutant p53. Depletion of DP103 decreases wild-type p53 sumoylation, 
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increasing its acetylation and subsequent transcriptional activity. This induction in p53 
upon DP103 depletion was responsible for impairment in cellular proliferation, and also 
increased sensitivity to docetaxel observed earlier. In context of ERα activity, we show 
that DP103 positively modulates ERα by blocking the repressive effect of p53 on ERα, 
probably through p53 sumoylation. The three-way communication between DP103 and 
p53 and ERα, also explains why DP103 serves as a predictive biomarker of docetaxel 
response only in ERα-positive breast cancer. ERα-positive tumors generally harbor wild-
type p53, whereas, ERα-negative tumors harbor p53 mutations. Docetaxel treatment 
would activate only wild-type p53, and the activated p53 in ERα-positive tumors, would 
in turn repress ERα activity and expression of ERα-responsive genes including DP103 in 
responders. However, non-responders or resistant cell lines possibly employ a mechanism 
to keep p53 suppressed, thereby not affecting ERα activity and DP103 expression. It 
would be interesting to study if the suppressed levels of p53 in resistant tumors or cell 
lines, that we observe in our in vitro work as well, could be through DP103-mediated 
sumoylation.  
Together, my PhD findings identify DP103 as a novel biomarker of drug 
response in a selected cohort of breast cancer patients with ERα-positive status. 
DP103 expression profile in these patients through different stages of chemotherapy, 
along with a knowledge of p53 status, could help predict if the patients would continue to 
respond to the drug or acquire resistance. In the process, we have shown DP103 to be a 
novel regulator of two major transcriptional factors, ERα and p53; positively regulating 
the former and inhibiting the latter. DP103 could thus be utilized as a promising 
therapeutic target in wild-type p53 containing ERα-positive tumors. Pharmacological 
inhibition of DP103 could repress ERα activity and also activate p53, thus sensitizing 
cells to docetaxel treatment. We postulate that inhibition of wild-type p53 is one of the 
13 
 
possible mechanisms by which DP103 exerts its oncogenic role and chemoresistance in 
breast cancer. Further studies are definitely warranted to study the consequences of 
DP103-dependent p53 sumoylation in not just breast cancer, but even other wild-type p53 
containing tumors. It would also be interesting to study the relationship of DP103 with 
p53 mutants. From a clinical perspective, based on the available knowledge from this 
study, DP103 could serve as a promising and potential therapeutic target for improving 





















LIST OF TABLES 
    
PAGE 
Table 1. Breast cancer chemotherapy regimens across various studies  34 
 
Table 2. List of primers used for qPCR for ERα ChIP    144 
 
Supplementary Table 1. Correlation of DP103 mRNA expression levels with 
    clinical parameters      206 
 
Supplementary Table 2. Correlation of DP103 mRNA expression levels with 
       progression-free and overall survival   206 
 
Supplementary Table 3. Correlation of DP103 IHC status with 
    clinical parameters      208 
 
Supplementary Table 4. Correlation of DP103 IHC expression levels with 
       progression-free and overall survival   209 
 
Supplementary Table 5. Clinicopathological features of 274 cases of  
















LIST OF FIGURES 
PAGE 
Figure 1. Classification of chemotherapeutic drugs     31 
    
Figure 2. Conserved motifs amond DEAD-box RNA helicases   48 
 
Figure 3. Role of DEAD-box proteins in RNA metabolism    49 
 
Figure 4. Domain structure of Estrogen Receptors     66 
 
Figure 5. Different modes of ERα signaling      66 
 
Figure 6. Depletion of DP103 reduces cell proliferation rate    113 
 
Figure 7. Depletion of DP103 reduces clonogenic ability of breast cancer cells 114 
 
Figure 8. DP103 knockdown efficiency in MCF7 and T47D   115 
 
Figure 9. Schematic diagram for chemotherapy study    116 
 
Figure 10. IC50 of docetaxel        121 
 
Figure 11. Docetaxel and doxorubicin do not affect DP103 expression in 
       ERα-negative cell lines       123 
 
Figure 12. Docetaxel decreases DP103 mRNA expression in 
                  ERα-positive cell lines       124 
 
Figure 13. Docetaxel decreases DP103 protein expression in 
       ERα-positive cell lines       125 
 
Figure 14. Doxorubicin does not affect DP103 expression in 
       ERα-positive cell lines       126 
 
Figure 15. Characterization and effect of docetaxel on DP103 expression in 
       Docetaxel-resistant cell line      127 
 
Figure 16. Alteration in DP103 expression modulates docetaxel sensitivity  130 
 
Figure 17. Alteration of DP103 on docetaxel-inhibited 
       Clonogenic potential of cells      131 
 
Figure 18. Alteration of DP103 expression on  
      docetaxel mediated caspase-3/7 activation    132 
 
Figure 19. Effect of docetaxel on ERα expression     134 
 




Figure 21. ERα ChIP predicts an ERα-binding site on DP103 promoter  138 
 
Figure 22. Effect of DP103 alteration on ERα DNA-binding activity  141 
  
Figure 23. Effect of DP103 alteration on ERα-responsive genes   143 
 
Figure 24. Effect of DP103 depletion on ERα recruitment to the chromatin  144 
 
Figure 25. Effect of DP103 alteration on estrogen and anti-estrogen  
      dependent cell growth       146 
 
Figure 26. DP103 does not interact with ERα     147 
 
Figure 27. DP103 does not co-localize with ERα     149 
 
Figure 28. DP103 represses p53       151 
 
Figure 29. DP103 depleted cells proliferate slower due to an  
       increased expression of p53      153 
 
Figure 30. DP103 interacts with p53       155 
 
Figure 31. Effect of single and combination knockdown of DP103 and p53 on 
       ERα DNA-binding activity and expression of ERα-responsive genes 158 
 
Figure 32. Effect of single and co-expression of DP103 and p53 on 
       ERα DNA-binding activity and expression of ERα-responsive genes 161 
 
Figure 33. p53 is involved in docetaxel-mediated effects    162 
 
Figure 34. Effect of single and combination knockdown of DP103 and p53 
       on docetaxel sensitivity       163 
 
Figure 35. Effect of single and co-expression of DP103 and p53 
       on docetaxel sensitivity       165 
 
Figure 36. Comparison of DP103 interaction between wild-type and mutant p53 166 
 
Figure 37. DP103 modulates sumo/acetyl swwitch of p53    169 
 
Figure 38. Schematic model of involvement of DP103 in  




Figure S1. DP103 gene expression in  
      normal versus invasive ductal breast carcinomas    205 
 
Figure S2. DP103 gene expression in 




Figure S3. DP103 mRNA expression change in Responders vs. Non-responders 207 
 
Figure S4. DP103 mRNA expression change in ER-negative vs. Positive tumors 208 
 
Figure S5. DP103 IHC expression change      210 
 
Figure S6. Effect of doxorubicin and docetaxel on DP103 mRNA expression 211 
 
Figure S7. Clinical association between DP103 and ERα    212 
 
Figure S8. Clinical association between DP103 and CDKN1A   213 
 



























LIST OF ABBREVIATIONS 
APS   Ammonium persulfate 
ATM   Ataxia Telangiectasia Mutated 
BC   Breast cancer 
CPT   Camptothecin 
ChIP   Chromatin Immunoprecipitation 
DBD   DNA-binding domain 
DMEM  Dulbecco's modified eagle's medium 
DMSO  Dimethyl Sulfoxide 
DOCE   Docetaxel 
DOXO  Doxorubicin 
DNA   Deoxyribonucleic acid 
ER   Estrogen Receptor 
EV   Empty vector 
FBS   Fetal Bovine Serum 
H&E   Hematoxylin and eosin 
HER2   Human Epidermal Factor 2 
IDC   Invasive ductal carcinoma 
IHC   Immunohistochemistry 
IP   Immunoprecipitation 
kDA   Kilo Dalton 
K/D   Knock-down 
L   Litre 
M   Molar 
mg   milli-gram 
19 
 
ml   milli-litre 
MTT   3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium-bromide 
NEMO  NFκB essential modulator 
nM   nano-molar 
OE   over-expression 
PBS   Phosphate Buffer Saline 
PIAS   Protein Inhibitor of Activated STAT 
PR   Progesterone Receptor 
PCR   Polymerase Chain Reaction 
PTM   Post-translational modification 
qPCR   quantitative PCR 
RNA   Ribonucleic acid 
RPMI   Roswell Park Memorial Institute 
RT-PCR  Reverse Transcription-PCR 
SDS-PAGE  Sodium Dodecyl Sulphate - Polyacrylamide Gel Electrophoresis 
SENP   Sentrin-specific protease 
SF1   Steroidogenic Factor 1 
siRNA   Small Interfering RNA 
SUMO  Small Ubiquitin-like Modifier 
TMA   Tissue Microarray 
μg   micro-gram 






CHAPTER 1- INTRODUCTION 
1.1 BREAST CANCER 
Breast Cancer is a malignant state of the breast mammary tissue, occuring when 
dysregulation in key signaling events influence normal cells to undergo uncontrolled 
division and carcinogenesis. In spite of increasing awareness, better diagnostic tools and 
huge advancements in treatment options, breast cancer still remains one of the leading 
causes of cancer-related deaths in women. It is thus seen as a major health burden across 
the globe, affecting the health and lifestyle of the affected individual considerably. Often 
triggered by hormonal disturbances, genetic and environmental factors can also pre-
dispose a person to develop breast cancer. Other risk factors include an early onset of 
menarche, a very late menopause, changes in reproductive patterns such as delayed 
pregnancy and lesser children, family history, hormone therapy, lifestyle choices and 
obesity.  
1.1.1 BREAST CANCER STATISTICS  
Breast cancer (BC) is the most commonly occurring female cancer in women (1, 
2). It is also the most frequent non-skin cancer to affect women worldwide. In 2000, there 
were over a million cases of breast cancer, with close to 375,000 related deaths (3). 
According to 'American Cancer Society, Cancer Facts & Figures', there will be 300,000 
breast cancer cases in 2014 in the US alone, with 40,000 deaths predicted in the same 
year. The western world has been known to have relatively higher BC incidence rate than 
their Asian counterparts, although, incidence rate is on a steady rise in the Asian countries 
as well (4). The situation is worse in Singapore where breast cancer is the most common 
malignancy among Singaporean women, accounting for 29.4% of all diagnosed cancers 
and contributing to 18% of all cancer deaths from 2008 to 2012 (5). About 1100 new BC 
cases and 270 deaths are reported in Singapore every year (6). According to 'Singapore 
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Cancer Registry Interim Report. Trends in Cancer Incidence in Singapore 2002–2006, 
National Registry of Diseases Office' issued by the Ministry of Health, the increase in 
incidence-rate in Singapore is also one of the highest in the world, standing at 5.7% per 
year in premenopausal women and 3.9% per year in postmenopausal women, in 
contrast to only 1.5% per year in the United States.  
1.1.2 BREAST CANCER CLASSIFICATION 
Breast cancer is a heterogeneous disease, with huge variations in biological, 
morphological and clinical characteristics. Classification is based on different criteria, as 
described below.  
HISTOPATHOLOGY: 
Histopathological classification refers to the morphological and cytological 
characteristics of the tumor tissue. Under this category, one mode of classification is 
based on whether the cancer is derived from the epithelium lining the ducts or the 
lobules, referred to as ductal or lobular carcinoma, respectively. The other mode involves 
knowing whether the cancer is limited to the epithelial tissue, known as carcinoma in 
situ, or has the cancer invaded into surrounding tissues, known as invasive carcinoma. 
Invasive ductal carcinoma (IDC) is the most common type observed, representing 75% 
of all breast cancers, while invasive lobular carcinoma represents the next most frequent 
histological type.  
GRADE: 
Grading depends on the degree of similarity of microscopic appearance of breast 
cancer cells to normal breast tissue. The general rule is that, the closer any cell appears to 
the normal cells, lower is the grade of the cell, slower is their growth rate and better is 
their prognosis. Normal breast cells become differentiated to take on specific shapes and 
forms, fixing their function within the organ. Cancer cells however lose this ability to 
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differentiate. Based on a method derived by Bloom and Richardson, well differentiated 
normal tissues are graded as low grade or grade 1, moderately differentiated tissues as 
intermediate grade or grade 2 and poorly differentiated or undifferentiated tissues, 
including cancer cells, as high grade of 3 or 4. Further modifications gave rise to the 
internationally accepted Bloom-Richardson-Elston grading system, also referred to as the 
Nottingham Grading System (NGS). Under NGS, tumors are graded on features such as 
degree of tubule formation, nuclear pleomorphism and mitotic index (7), with each feature 
given a score from 1 to 3. These individual scores then add-up to give an overall final 
score and a corresponding grade.  
STAGE: 
Under this category, classification is based on the size of the primary tumor and 
the extent of its spread to the secondary site. The most widely accepted classification 
is the TNM classification, an acronym for a method that considers the presence and size 
of the tumor (T), whether or not the tumor has spread to the lymph nodes (N) located in 
the armpits, and whether the tumor has metastasized (M) to secondary locations in the 
body. The tumor tissues are usually scored from 0 to 4, with stage 0 being a pre-
cancerous condition, stage 1 to 3 being tumors confined to breast or regional lymph 
nodes, and stage 4 referring to highly aggressive metastatic cancer with less favorable 
prognosis.  
RECEPTOR STATUS: 
This is probably the most important mode of breast cancer classification. Here, 
classification is based on the status of hormone-receptors such as the Estrogen Receptor 
(ER), the Progesterone Receptor (PR) and Human Epidermal Receptor 2 (HER2), 
routinely assessed by immunohistochemistry (IHC) staining in clinical practice. Receptor 
positive breast cancers account for around 90% of all breast cancer cases, with ER- and 
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PR- positive cases accounting for 75-80%, while HER2-positive breast cancers making up 
15-20% of the total cases (8). The status of these hormone receptors is commonly 
exploited as prognostic marker for selecting treatment options. Breast cancer subtypes that 
lack these receptors are grouped as triple-negative breast cancer (TNBC). This category of 
breast cancer poses a daunting challenge to clinicians because they lack well-defined 
molecular targets such as the receptors above, and generally tend to be highly aggressive 
(9).  
MOLECULAR SUBTYPES: 
Each breast cancer has a particular molecular profile that can help predict the 
prognosis and also help determine the best treatment option. Advancement in the gene- 
and protein-expression profiling of tumors has shed light on the several molecular 
subtypes in breast cancer (10, 11). 
 Luminal A:  
Luminal A tumors are positive for Estrogen Receptor (ER+) and Progesterone 
Receptor (PR+), but negative for HER2/neu (HER2-) receptors. They possess a lower 
tumor grade of 1 or 2, and tend to grow slowly and can be usually dealt with surgery and 
radiation, giving them the best prognosis, with fairly high survival rates and low 
recurrence rates (12, 13).  
 Luminal B: 
Luminal B tumors differ from Luminal A by the presence of HER2 receptor as 
well. They have poorer tumor grade and prognosis, compared to luminal A subtypes. 
These subtypes are also positive for the proliferation marker Ki67 and hence grow 
aggressively and spread into blood vessels and the lymphatic system.  
 HER2 (also called ERBB2): 
These tumors are positive for all three receptors, with an enriched expression of 
24 
 
HER2/neu. These tumors easily invade to the nearly lymph nodes and have poor tumor 
grade, making them highly prone to recurrence and metastatic events (14, 15).  
 Basal-like: 
These tumors are defined by a robust cluster of genes expressed by epithelial cells 
in the basal or outer layer of the adult mammary gland, such as cytokeratins 5 and 17. 
They are predominantly referred to as Tripe-Negative Breast Cancer (TNBC), since they 
lack the expression of ER, PR and HER2, limiting targeted therapeutic options. These 
tumors are often highly aggressive and have a poorer prognosis compared to the luminal 
subtypes. 
 Normal breast-like: 
About six to ten percent of all breast cancers are classified as normal-like. These 
tumors express adipose and other non-epithelial genes and have high basal-like and low 
luminal gene expression (16, 17).  
 Claudin-low: 
Claudin-low subtype is linked to an aggressive phenotype with poor prognosis. 
This subtype is characterized by a low expression of genes linked to breast tumor 
initiating cells and epithelial-to-mesenchymal (EMT)-linked signatures (18).  
1.1.3 BREAST CANCER TREATMENT STRATEGIES 
Different types of treatments, the choice of which takes into consideration the 
various classifications above, are available for patients with breast cancer. 
SURGERY:  
Surgery is usually the first line of defence against breast cancer as it is the quickest 
and most complete way of removing the cancerous tissue and nearby marginal lesions. 
There are 2 surgical options: complete removal (mastectomy) of the breast or partial 
removal (breast conservation) of the tumor-affected portion of the breast. Breast 
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conservation measures are often possible for early stages of breast cancer (stage 0, 1, & 
2). Cancer with any higher tumor stage and grade would entail a complete removal. 
Alternatively,  an axillary clearance might be performed where the lymph glands under 
the armpit may be entirely removed at the time of surgery.  
RADIATION THERAPY: 
Radiotherapy is a highly effective adjuvant therapy for destruction of microscopic 
cancer cell deposits that may have escaped surgical removal. It involves the usage of high 
energy x-rays or gamma rays to help lower the chance of cancer recurrence (19). There 
are two types of radiation therapy. External Beam Radiotherapy involves directing 
radiation at the cancer mass from outside the body. On the other hand, internal 
radiotherapy involves depositing radioactive cancer-killing treatments only in the affected 
area. 
HORMONE-BASED THERAPY: 
Around 70% of breast cancers are positive for estrogen receptor (ER) and 
progesterone receptor (PR), that are receptive to the signaling hormone estrogen or 
progesterone, respectively. Measures that would interfere with either the synthesis or 
availability of these hormones to the receptors, could thus help treat hormone-positive 
tumors.  
 Drugs that block estrogen (Endocrine therapy):  
Tamoxifen: Tamoxifen is currently used for the treatment of both early and 
advanced ER positive breast cancers (20). Tamoxifen binds to ER via its active 
metabolite, 4-hydroxytamoxifen. However, it is an antagonist of ER in breast tissues, 
competing with estrogen for binding to the receptor. Tamoxifen also recruits co-repressors 
such as NCoR and SMRT to the chromatin, inhibiting ER transcriptional activity. While 
tamoxifen acts like an anti-estrogen in breast tissues, it is an agonist in other tissues, such 
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as uterus, endometrium and bones. This dual nature of tamoxifen brings them the 
reference of a selective estrogen receptor modulator or SERM. Therapeutic efficacy of 
tamoxifen, however, is limited by relapse of disease and development of resistance (21).  
Fulvestrant: Unlike tamoxifen, fulvestrant is a selective estrogen receptor down-
regulator (SERD), that blocks the estrogen receptor and eliminates it completely (22), 
irrespective of the organ tissue. Fulvestrant is approved for treatment of advanced ER-
positive breast cancer in postmenopausal women, that have become refractory to other 
endocrine therapies. Similar to tamoxifen, many breast cancer patients stop responding 
and turn resistant to prolonged fulvestrant treatment (23). 
 Drugs that interfere with estrogen production: 
Aromatase Inhibitors: This class of drugs act by blocking or inhibiting the 
function of aromatase or estrogen synthase, that are responsible for conversion and 
aromatization of androgens into estrogens. Aromatase inhibitors such as anastrozole or 
letrozole have been approved for estrogen deprivation in postmenopausal patients (24).  
Ovarian ablation: A woman's ovaries are the main source of estrogen until 
menopause. Removing (oophorectomy) or shutting down the ovaries reduces estrogen 
levels in the body. Ovarian ablation is achieved with drugs called luteinizing hormone-
releasing hormone (LHRH) analogs, such as goserelin or leuprolide. These drugs can be 
used alone or in combination with tamoxifen or aromatase inhibitors in premenopausal 
women.  
TARGETED THERAPY: 
A detailed anaylsis of gene expression profile in cancer cells have enabled the 
development of new drugs that specifically target aberrant changes in cancer cells, without 




 Anti-HER2 therapy:  
HER2-positive tumors can be targeted either with monoclonal antibodies or 
tyrosine kinase inhibitors.  
Trastuzumab: Marketed as Herceptin, this monoclonal antibody has been highly 
effective in controlling HER2-positive tumors. When trastuzumab binds to the HER2 
receptor, it blocks growth factors from binding to and stimulating the receptor, preventing 
receptor dimerization and subsequent tyrosine kinase mediated signaling cascade. Often 
administered with chemotherapy (25), several clinical trials have observed that 
trastuzumab can decrease the recurrence rate and improve survival (26).  
Pertuzumab: Pertuzumab is another monoclonal antibody targeted against HER2 
receptor, that may be combined with trastuzumab and chemotherapy to treat advanced 
breast tumors that have metastasized.  
Lapatinib: This is a tyrosine kinase inhibitor that inhibits the tyrosine kinase 
activity associated with the intracellular domains of HER2 and EGFR receptors (27). 
Lapatinib is used with other drugs to treat trastuzumab-resistant HER2-positive tumors.   
 Other targeted therapies:  
Other novel and specific targeted therapies against breast cancer include 
angiogenesis inhibitors such as Bevacizumab for blocking VEGF receptor and androgen 
receptor inhibitors such as bicalutamide. PARP inhibitors such as Iniparib and Olaparib 
are tested in clinical trails for blocking DNA repair mechanism in triple negative cancer 
cells with faulty or mutated BRCA1 or BRCA2 genes.  
CHEMOTHERAPY: 
Chemotherapy is one of the most popular methods for the treatment of a wide 
range of cancer (28, 29). The goal of chemotherapy is to shrink primary tumors, slow 
tumor progression, destroy cancer cells that may have metastasized and occasionally 
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relieve the symptoms. It involves administration of powerful drug(s) to the patient, that is 
expected to kill rapidly growing cancer cells in the body (30, 31). However, chemotherapy 
may also affect fast-growing normal cells in the body, including cells in hair follicles, 
nails, the mouth, digestive tract, and bone marrow, leading to to mild to serious side 
effects. 
Chemotherapy can be categorized into the following methods depending on the 
purpose and timing of the therapy.  
 Curative chemotherapy:  
This aims at eliminating all cancer cells from the body so that the person has a 
permanent cure. No other treatment methods are used in combination here.  
 Adjuvant chemotherapy:  
A procedure that follows surgery, this method targets cancer cells that might have 
escaped surgery, preventing recurrences. 
 Neoadjuvant chemotherapy:  
A procedure that precedes surgery, this method targets and shrinks bigger tumors 
so that they can be easily operated upon by surgery. It also helps to allow less invasive 
surgery. 
 Palliative chemotherapy:  
This approach is designed for terminal cancer patients when a cure seems unlikely 
and when the purpose of treatment shifts to alleviating certain symptoms, slowing down 
the progress of the disease, avoiding complications and prolonging survival. 
Chemotherapy administration: 
Chemotherapy is generally given as an injection or a drip into the bloodstream 
through a vein, or through tablets or capsules. Being a systemic treatment, the contents of 
chemotherapy circulate in the bloodstream, reaching cancer cells almost anywhere in the 
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body. Chemotherapy is routinely administered in treatment cycles, with each cycle 
constituting period of treatment followed by a rest period to give the body enough time to 
recover from the effects of the drug (32). At the end of the cycle, the chemo schedule 
repeats to start a next cycle. Adjuvant and neoadjuvant chemotherapy generally involve 
treatment cycles spanning 3 to 6 months. Number of cycles and the applied dosage during 
each cycle would depend on the nature of the drug, the length of pharmacological effects 
of the drug, and the time the body needs for recovery (33). Chemotherapy treatment 
schedules are often tested and optimized over various clinical trials (34), with parameters 
such as patient age, gender and race affecting them.  
1.2 CHEMOTHERAPY FOR BREAST CANCER 
In the context of BC treatment, chemotherapy is used to 
 Treat early-stage invasive breast cancer to get rid of any cancer cells that may have 
escaped surgery. Oxford meta-analysis documents the prolonged benefits of adjuvant 
chemotherapy in preventing breast cancer recurrence and improving overall survival (35).  
 Treat advanced-stage breast cancer to destroy or damage the cancer cells as much 
as possible. Some breast tumors are too big to be surgically removed at the time of 
diagnosis. These locally advanced tumors are treated and shrunk with neoadjuvant 
chemotherapy first before surgical operation. 
 Treat cancer metastasis and recurrence at both primary and secondary tumor sites. 
 Treat tumors that are resistant to hormone-based and targeted therapies. 
1.2.1 DIFFERENTIAL RESPONSE TO CHEMOTHERAPY 
Different molecular subtypes of breast cancer exhibit different responses towards 
chemotherapy. Luminal subtypes are generally believed to receive very little benefits, if 
any, from chemotherapy (36). Other studies have reported that chemotherapy is 
efficacious in ER-negative, and not in ER-positive patients (37, 38). However, conflicting 
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reports exist. Several randomized trials have reported that chemotherapy could improve 
outcome in ER-positive disease as well (39, 40). A recent 2011 overview found 
chemotherapy beneficial among all breast cancer patients irrespective of ER status (41). In 
addition, Uchida et al (42) has shown that adjuvant chemotherapy could provide a longer 
relapse-free period to patients with luminal A breast cancer. In another study, luminal B 
tumors were shown to respond well to chemotherapy in combination with tamoxifen 
based endocrine therapy (43). In comparison, HER2-enriched tumors are known to have 
higher chemosensitivity than luminal tumors. Amplification of HER2 was associated with 
clinical responsiveness to paclitaxel-containing (44) and doxorubicin-containing 
chemotherapy (45). Although one particular study (46) found no evidence to support the 
use of HER2 status for selection of chemotherapy. Finally, TNBC subtypes are known to 
possess the best response to chemotherapy. Patients with TNBC had increased 
pathological complete response rate (pCR) to neoadjuvant chemotherapy compared with 
non-TNBC patients (47). However, basal-like phenotype alone does not serve as an 
independent predictor of chemotherapy response, with a recent study reporting a low 
response rate of basal-like tumors to neoadjuvant therapy with docetaxel, doxorubicin and 
cyclophosphamide (48).  
Thus, there still exists a lot of ambiguity on the chemotherapy choice for different 
breast cancer subtypes. Further studies and bigger and more conclusive clinical trials and 
better biomarkers would be needed to utilize the molecular characteristics of the tumor to 
provide the patients the most optimal chemotherapy.  
1.2.2 DIFFERENT CHEMOTHERAPEUTIC DRUGS 
Chemotherapeutics available for treatment of breast cancer, manifest different 
mechanisms and mode of action. These drugs would either interrupt the chemical 
processes involved in cell division, damage the genes inside the nucleus, damage cells at 
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the point of splitting, or damage the cells while they are making copies of all their genes 
before they split. Based on their mode of action, most of the popular drugs fall into one of 
the following categories described in the diagram (Figure 1) and the text that follows. 
 
Figure 1 : Classification of chemotherapeutic drugs  
 
ALKYLATING AGENTS: 
These agents add an alkyl group to the guanine base of DNA, at the number 7 
nitrogen atom of the purine ring (49). This disables the strands from uncoiling and 
separating, upon which the cells cannot replicate and divide. There are different classes of 
alkylating agents (50) that include nitrogen mustards (cyclophosphamide, 
mechlorethamine and ifosfamide), nitrosoureas (carmustine and lomustine), alkyl 
sulfonates, tetrazines (dacarbazine) and aziridines (thiotepa and mytomycin). Because 






These are a class of drugs that resemble and mimic nucleotides that are the 
building blocks of nucleic acids, interfering with DNA and RNA synthesis (51). They 
exert their effect by either blocking the enzymes required for DNA synthesis or getting 
incorporated into DNA or RNA, leading to failure in DNA synthesis. Unlike alkylating 
agents, these agents damage cells only during the S phase. Examples of some popular 
anti-metabolites include 5-fluorouracil (5-FU), 6-mercaptopurine, methotrexate, 
pemetrexed, capecitabine, decitabine, gemcitabine, hydroxyurea. 
PLATINUM-BASED DRUGS: 
These antineoplastic agents act on the N-7 position of guanine, forming 
monoadducts, interstrand crosslinks, intrastrand crosslinks or DNA-protein crosslinks 
(52), resulting in an inhibition of DNA synthesis and DNA repair (53). Some of the very 
popular platinum-based drugs include cisplatin, carboplatin and oxaliplatin.  
ANTI-TUMOR ANTIBIOTICS: 
These drugs are derived from micro-organisms. They either break up DNA 
strands, slow down or stop DNA synthesis or generate highly reactive free radicals to 
damage intracellular molecules (54). These drugs fall into two categories: anthracyclines 
and non-anthracyclines. Anthracyclines that generally interfere with DNA replication, 
include drugs such as doxorubicin and daunorubicin and their derivatives such as 
epirubicin and idarubicin. Non-anthracyclines include antibiotics such as actinomycin-D, 
bleomycin and mitomycin-c. 
TOPOISOMERASE INHIBITORS: 
There are two classes of topoisomerases; enzymes that produce single- or double-
strand breaks into DNA, reducing the tension in the DNA strand during supercoiling, and 
allowing normal unwinding of DNA. The process of chromosome condensation and 
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segregation during mitosis requires the activity of topoisomerase II, whereas other 
topological modifications of the DNA molecule, such as DNA relaxation, can be 
performed by topoisomerase I. Inhibition of these enzymes using topoisomerase inhibitors 
can become highly lethal for cancer cells (55). Topoisomerase I and II inhibitors 
covalently bind to these enzymes causing irreversible stabilization of protein-DNA 
complex and inhibition of strand separation (56). Examples of topoisomerase I inhibitors 
include camptothecin, topotecan and irinotecan. Examples of topoisomerase II inhibitors 
include etoposide, doxorubicin, mitoxantrone and teniposide. 
MITOTIC INHIBITORS: 
Mitotic inhibitors or anti-microtubule agents are plant-derived chemicals, that 
interfere with microtubule equilibrium, leading to blockade of mitosis and cell cycle 
arrest. Anti-mitotic agents include vinca alkaloids and taxanes. Vinca alkaloids (e.g. 
vincristine, vinblastine, vinorelbine, vindesine and vinflunine)  prevent the formation and 
assembly of microtubules (31), whereas the taxanes (e.g. paclitaxel and docetaxel) prevent 
the microtubule disassembly (57, 58).  
1.2.3 CONVENTIONALLY USED CHEMOREGIMEN 
As discussed above, chemotherapeutic drugs act through different mechanisms. A 
combination of these drugs would thus target multiple mechanisms. This is a general 
practise in the clinic, where patients are given a combination of two or more drugs, with 
different modes of action, so that there could be a complementary (synergistic) effect (59). 
Importantly, drugs in a combinatorial regimen are administered in relatively smaller doses 
when compared to their dosage used in single applications, thus minimizing toxicities. 
Combination therapy also reduces the risk of chemoresistance, which can develop with 
prolonged use of a single drug. Various trials, listed in Table 1, have studied different 
drug combinations for the treatment of breast cancer. There is no drug regimen that is 
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considered the best, and the choice differs from case to case, taking into account various 
factors including the characteristics and nature of the cancer. 


































































Table 1 : Breast cancer chemotherapy regimens across various studies 
1.2.4 RESISTANCE TO CHEMOTHERAPY 
Resistance to chemotherapy poses a serious impediment to the treatment of various 
cancers (68). It has been described as the most common reason for discontinuation of a 
drug, accounting for 90% of treatment failures in patients with advanced breast cancer 
(69). Most patients with breast cancer respond to initial chemotherapy, with systemic 
agents being active at the beginning of therapy in 90% of primary breast cancers and 50% 
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of metastasis cases (70). However, patients are plagued by tumor progression and disease 
recurrence after a variable period of time. Chemoresistance may be intrinsic, where the 
tumor is innately resistant to various drugs and do not respond to the therapy from the 
beginning. Chemoresistance may also be acquired, where the tumor that initially responds 
to chemotherapy, shows a loss of response progressively. Several mechanisms have been 
proposed to mediate resistance to cytotoxic agents (71). Some of these include: 
 Increased levels of ATP-binding cassette (ABC) family of membrane transporters 
(72) 
 Decreased metabolism of drug to its active form (73) 
 Increased cellular drug detoxification 
 Enhanced repair of the drug-induced defects 
 Deliberate alteration of the drug target 
 Altered expression of survival genes 
1.3 DOCETAXEL 
Docetaxel (or Taxotere) is a clinically approved drug for the treatment of various 
cancers including breast cancer (74, 75). It is an anti-mitotic agent that interferes with the 
normal functioning of microtubules and disrupts mitosis-dependent cell division. It is a 
semi-synthetic analogue of paclitaxel (or Taxol), an extract from the bark of the rare 
Pacific yew tree Taxus brevifolia. Scarcity of paclitaxel lead to extensive research and 
formulation of docetaxel (76, 77) from the inactive taxoid precursor (10-deacetyl baccatin 
III) (78), obtained from the readily available European yew tree Taxus baccata. Developed 
in the 1990s and FDA-approved for breast cancer treatment in 2004, it has become an 
established therapy for the treatment of advanced breast cancer patients (79). Common 
side-effects with docetaxel treatment include oedema and fluid accumulation, including 




Microtubules are filamentous intracellular structures that are a component of the 
cytoskeleton (81). They are involved in cellular processes such as organization of 
intracellular shape and structure, intracellular transport, as well as ciliary and flagellar 
motility. They are also involved in cell division during the formation of mitotic spindles, 
which are used to correctly pull apart the chromosomes. The major component of 
microtubules is the tubulin protein polymer, that is a heterodimer of two nonidentical α 
and β subunits (82, 83). When intracellular conditions favor assembly, tubulin dimers 
polymerize end to end into linear protofilaments. A distinct polarity is maintained with the 
α-subunits of one tubulin dimer contacting the β-subunits of the next. Therefore, one end 
of the protofilament has the α-subunits exposed while the other end has the β-subunits 
exposed. These ends are designated as the (−) and (+) ends, respectively. Protofilaments, 
in turn, assemble laterally to form microtubules, with the elongation of microtubules 
typically only occurs from the (+) end (84). 
Microtubules are in a constant state of dynamic instability (85), continously 
shuttling between a state of assembly and disassembly (86). During 
assembly/polymerization phase, heterodimers are added on to the end of a microtubule, 
and during shrinkage or disassembly/depolymerization phase, heterodimers come off as 
intact subunits. During polymerization, both the α- and β-subunits are bound to a GTP 
molecule (87, 88). GTP bound α-tubulin is highly stable, however, GTP bound β-tubulin 
gets hydrolyzed to GDP shortly after assembly, resulting in the addition of new dimers. 
Since tubulin adds onto the end of the microtubule only in the GTP-bound state, there is a 
cap of GTP-bound tubulin at the tip of the microtubule, protecting it from disassembly. In 
the event of GTP hydrolysis surpassing the rate of tubulin addition, GDP-bound tubulin 
subunit at the tip of a microtubule falls off, resulting in disassembly and shrinkage. This 
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cyclic process of assembly and disassembly maintains an equilibrium in response to the 
requirements of the cell.  
1.3.1 DOCETAXEL: MECHANISM OF ACTION 
Dynamic instability of microtubules maintains the cytoskeletal structure, and also 
ensures that free tubulin subunits are constantly available for the formation of mitotic 
spindles for mitosis (89); a key feature that is exploited by the anti-mitotic drugs. On the 
one hand, vinca alkaloids bind to microtubules and shift the equilibrium towards 
disassembly and shrinkage (90). On the other hand, taxanes, including docetaxel, disrupt 
the equilibrium between free tubulin and microtubules, and shift the equilibrium towards 
assembly (91). Taxanes bind to a site on microtubules that is only present in assembled 
tubulin (92). Docetaxel treatment promotes microtubule assembly and prevents 
microtubule depolymerisation, causing the formation of abnormal bundles of microtubules 
(93). Abnormal bundles resist physiological disassembly, accumulating within tumor cells 
and inhibiting cell proliferation, leading to mitotic arrest at G2/M phase (94). Taxane 
treatment also leads to a significant decrease in free tubulin needed for microtubule 
formation, impairing mitosis between metaphase and anaphase (81, 95).  
Docetaxel is not simply an inhibitor of mitosis or microtubule dynamics, and 
numerous studies have suggested that docetaxel acts by additional mechanisms that are 
distinct from its effects on microtubules. Gan et al., observed increased p21
WAF1
 and p53 
levels (96) with docetaxel treatment, implicating a p53-dependent anti-tumor effect of 
docetaxel. Low doses of docetaxel were shown to induce transcriptional levels of p53 (97) 
or p53 targets such as Bax and p21 (98). Many other studies also found that docetaxel-
mediated apoptosis in a p53-dependent manner (99). Interestingly, docetaxel was shown to 
activate wild-type p53 by reducing its ubiquitination (100). In a prostate cancer study, cell 
lines with functionally active wild-type p53, responded well to docetaxel than cell lines 
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with mutant or p53 null expression (101). Here, docetaxel effect was mediated through an 
increase in the phosphorylation status (Ser 15) of wild-type p53. Docetaxel treatment also 
increases Bcl-2 phosphorylation and downregulates Bcl-xl, inhibiting the antiapoptotic 
function of Bcl-2 family (102, 103). Docetaxel is also known to activate caspases to 
mediate apoptotic cell death (99, 104-106). Mitotic catastrophe, a non-apoptotic 
phenomena that occurs during mitosis, is another form of cell death that follows docetaxel 
treatment (107). It is characterized by the occurrence of aberrant mitosis, missegregation 
of the chromosomes, abnormal spindle formation and deficiency in checkpoint control 
mechanisms. Nuclear envelopes form around individual chromosomes or groups of 
chromosomes forming large nonviable cells with multiple micronuclei, which are 
morphologically distinguishable from apoptotic cells. Clinically, non-apoptotic and non-
mitotic arrest based cell death has been reported to contribute to docetaxel mediated 
therapeutic response. Tumor cell lysis (necrosis) combined with marked infiltration with 
mononuclear lymphoid cells, was regarded as one of the possible mechanisms underlying 
antitumor efficacy of docetaxel (108). 
1.3.2 DOCETAXEL AND CLINICAL BENEFITS 
Docetaxel has emerged as an important anticancer modality in the treatment of 
breast cancer (109, 110), with a response rate of between 25 and 69% observed when used 
as first-line treatment (111). It has been very effective both as a single agent and in 
combination with other drugs (112). 
DOCETAXEL AS SINGLE AGENT CHEMOTHERAPY 
Numerous studies have reported the effects of docetaxel as a single-agent. 
Docetaxel was found to be better than paclitaxel on numerous occasions (113). In a study 
that had compared the two taxanes with 449 advanced breast cancer patients (114), 
docetaxel was found to be the superior taxane in terms of overall survival (OS), time to 
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progression (TTP) and overall response rate (ORR). In fact, docetaxel was found to be 
active in the treatment of paclitaxel-resistant metastatic cancers as well. In comparison 
with doxorubicin, an anthracycline that is considered as one of the current gold standards, 
docetaxel produced a superior response rate (48% versus 33%) in metastatic breast cancer 
patients (115). It was also found to be better than doxorubicin in treatment of patients 
resistant to alkylating agents (116). High levels of docetaxel antitumor activity was 
observed in anthracycline-resistant patients, confirming a substantial lack of anthracycline 
cross-resistance (117). Docetaxel has thus far been approved for the treatment of 
anthracycline-, paclitaxel- and alkylating agent-resistant metastatic breast cancer.  
DOCETAXEL IN COMBINATORIAL REGIMEN 
Incorporation of docetaxel in both adjuvant and neoadjuvant chemotherapy has 
contributed to improved patient outcome. Docetaxel containing neoadjuvant chemotherapy 
seemed to have benefited breast cancer patients, irrespective of their ER status (118, 119). 
In a Breast Cancer International Research Group adjuvant study (120), women with node-
positive breast cancer subjected to docetaxel containing adriamycin-cyclophosphamide 
(TAC) regimen, had improved disease-free and overall survival compared to 5-fluorouracil 
containing regimen (FAC), with docetaxel arm also reporting a 26% reduction in the risk 
of recurrence. In another study, 1999 patients with node-positive breast cancer were 
randomized to 6 cycles of fluorouracil, epirubicin, and cyclophosphamide (FEC) or 3 
cycles of FEC followed by 3 cycles of docetaxel (FEC-D). FEC-D arm resulted in an 
improved 5-year disease-free and overall survival rate (121).  
Numerous studies have shown improved outcome when docetaxel was combined 
with doxorubicin. In a prospective study with 43 patients (122), docetaxel and doxorubicin 
regime resulted in a complete response in 9 patients and partial response in 24 patients, 
with a significantly satisfying overall response rate of 78.6%. In another study involving 
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429 metastatic breast cancer patients, the combination of docetaxel and doxorubicin was 
compared to doxorubicin and cyclophosphamide as a first line therapy, and the docetaxel 
containing regime showed better response rate and longer time to progression and time to 
treatment failure (123). A phase II to III study also found first line docetaxel and 
doxorubicin combination to be much effective than FAC (fluorouracil, adriamycin and 
cyclophosphamide) regimen (124). Similar studies found the combination of docetaxel and 
doxorubicin to be very effective in the treatment of breast cancer, a reason why this 
combination is prevalently used in the clinical setting.  
1.3.3 CHEMORESISTANCE TO DOCETAXEL 
Docetaxel has a superior therapeutic efficacy than many other chemotherapeutics 
(79, 125). However, favourable responses are short-lived, with a time-to-progression of 6 
to 10 months observed in most cases (125, 126).  Very often, the issue of chemoresistance 
arises where patients either exhibit intrinsic or acquired resistance to docetaxel (127-129). 
Capecitabine is the only FDA approved drug administered after taxane chemoresistance. 
However, the response rate to capecitabine is also very low (20 to 30%), with no 
significant improvement in long-term outcomes (130). With no better alternative to treat 
docetaxel-refractory patients, it becomes all the more important to better understand 
docetaxel resistance and identify new biomarkers or targets to counteract docetaxel 
resistance. Various mechanisms have been implicated in docetaxel resistance. 
β-TUBULIN MUTATIONS: 
Since docetaxel targets β-tubulin to disturb microtubule dynamics, cancer cells 
develop resistance to docetaxel by acquiring mutations in the β-tubulin gene. These 
mutations occur at various important sites of drug interaction (131), leading to 
compromised drug binding or altered microtubule dynamics (132, 133). Constant building 
up of mutations and prolonged exposure to anti-mitotic agents subsequently results in a 
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loss of heterozygosity of the wild-type tubulin allele (134), heightening resistance further. 
In vitro, cancer cell lines harboring mutations in the taxane binding site (135), have been 
found to have an increased resistance to taxanes. In the clinical setting, patients with β-
tubulin gene mutations showed a poor response to taxanes (136).  
β-TUBULIN ISOTYPES: 
There are seven different known isotypes of β-tubulin gene in humans. Of these, 
isotype class III β-tubulin is found to be less stable and highly dynamic, reflected by their 
increased tendency towards depolymerization, that in principle, opposes docetaxel-
mediated polymerization. Class III β-tubulin microtubules thus require a higher ratio of 
bound taxane to induce microtubule stability, implicating that an increased expression of 
class III tubulin could be a possible mechanism of taxane resistance. In a meta-analysis of 
ten different non-small cell lung cancer studies, low levels of class III β-tubulin were 
strongly associated with favourable clinical outcome to taxane based chemotherapy (137). 
In contrast, taxane resistant ovarian and non-small cell lung cancers had increased 
expression of class III β-tubulin isotype (138). Silencing of class III β-tubulin in a taxane-
resistant lung cancer cell line, resulted in an increased sensitization to taxanes (139). 
MICROTUBULE-ASSOCIATED PROTIENS (MAPs): 
MAPs interact with microtubules and regulate their dynamics. MAPs consist of 
various subtypes, of which, tau proteins are of particular interest with respect to docetaxel 
senstivity. Tau differentially binds to the taxane-binding site on the inner surface of the 
microtubules. In the absence of taxanes, tau binds strongly to microtubules and dissociates 
slowly, whereas in the presence of taxane, tau dissociates from microtubules rapidly, 
enhancing taxane-induced polymerization. Studies found low levels of tau to be associated 
with increased response to taxane in patients (140). Conversely, high levels of tau were 
associated with residual tumor and resistance to treatment (141).  
42 
 
MULTIDRUG RESISTANCE (MDR): 
MDR is a phenomena where the patients are resistant to a wide variety of 
structurally and mechanistically unrelated anticancer drugs. One of the commonly studied 
MDR mechanisms relates to the expression of ATP-binding cassette (ABC) family of 
membrane transporters. These transporters transport a wide range of substrates across 
extra- and intracellular membranes, including drugs. MDR results from an increased 
cellular excretion of the drug by these ABC transporters. P-glycoprotein (Pgp), also called 
MDR1 or ABCB1, is a prototypic member of the family. Docetaxel and paclitaxel are both 
substrates of Pgp (142). In a study that evaluated Pgp expression levels in a 60-cell line 
drug-screening panel, lower Pgp expression correlated to increased sensitivity to paclitaxel 
(143). In contrast, over expression of Pgp in drug sensitive cells makes them resistant 
(144). In the clinical setting, one study demonstrated that increased Pgp expression levels 
were significantly associated with shortened disease-free survival in chemotherapy-naive 
breast cancer patients (145). Similarly, in a breast cancer meta-analysis, patients with 
tumors expressing Pgp were three times more likely to fail to respond to chemotherapy 
than patients whose tumors were Pgp negative (146).  
PRO-SURVIVAL PATHWAYS: 
PI3K/Akt: 
The phosphatidylinositol-3-kinase/Akt (PI3K/Akt) pathway has been implicated in 
cancer progression. With respect to chemoresistance, overexpression of Akt was shown to 
increase phosphorylation of Bad, preventing it from binding and inactivating Bcl-xL, 
resulting in increased resistance to paclitaxel in ovarian cancer (147). Activation and 
phosphorylation of Akt in breast cancer cell line MDA-MB-231, was shown to confer 
docetaxel resistance and protect the cells from apoptosis by inducing survivin protein 
expression (148). In another study, increased phosphorylation of Akt, accompanied by an 
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increased expression of its downstream target gene, Clusterin, offered cytoprotection 
against docetaxel in prostate cancer cells (149). Conversely, inhibition of the PI3K/Akt 
pathway have been shown to increase the sensitivity of cancer cells to anti-mitotic agents 
(150).  
BCL-2: 
Members of the B-cell leukaemia/lymphoma 2 (Bcl-2) gene family regulate 
proliferation, apoptosis and drug resistance. Bcl-2, the prototypical member, is an 
oncogene that exerts its anti-apoptotic effects by heterodimerizing with pro-apoptotic 
members of the Bcl-2 family (e.g. Bax) leading to their inhibition. Following treatment 
with paclitaxel, Bcl-2 is known to get phosphorylated, inhibiting its anti-apoptotic action 
by preventing heterodimerisation with Bax and enhancing apoptosis and cell death (151). 
Clinically, breast tumors having increased expression of phosphorylated Bcl-2, showed 
increased sensitivity to both paclitaxel and docetaxel (152). In contrast, higher levels of 
Bcl-2 abolished taxane-induced apoptosis (153). Forced overexpression of Bcl-xL, another 
member of the Bcl-2 family, lead to chemotherapy resistance, while its downregulation 
enhanced chemosensitivity (154). 
PRO-APOPTOSIS PATHWAY: 
P53:  
Drug resistance may develop with either overexpression of genes that block cell 
death or loss or inactivation of genes required for cell death such as TP53. Amidst all its 
role in cell death and differentiation and stress response pathways, p53 plays a lesser-
known role in microtubule dynamics. It is shown to physically associate with 
microtubules, that aid its transport to the nucleus (155). P53 status also associates with the 
degree of β-tubulin induction upon docetaxel treatment (156). Here, depletion of p53 was 
shown to result in an increased β-tubulin induction upon docetaxel treatment. This could 
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explain an increased expression of β-tubulin in docetaxel-resistant tumors that are known 
to have inactivated or mutated p53. On the other hand, it has been demonstrated that wild-
type p53 represses Pgp, whereas mutant p53 stimulates its  promoter, resulting in an 
increase in insensitivity towards cytotoxic drugs (157). Given the association of p53 to 
these players, it is highly possible that p53 plays a critical role in how cells respond to anti-
microtubules.  
Loss of p53 expression or presence of mutation in p53 has been implicated in 
chemoresistance (158, 159). Cell lines depleted of p53 exhibited increased resistance to 
docetaxel- or radiation-induced apoptosis (160, 161). Alternatively, p53 mutation status 
was associated with docetaxel and platinum-based drug resistance in breast (162) and 
ovarian cancer (163), respectively. A breast cancer study found mutant p53 containing 
tumors to be less responsive to docetaxel treatment (44%) when compaed to wild-type p53 
containing tumors (62%) (162). Thus, p53 wild-type or mutation status could be a crucial 
determinant of docetaxel sensitivity in breast cancer cells.   
1.3.4 CLINICAL INTERVENTIONS TO PREDICT AND MANAGE DOCETAXEL 
RESISTANCE 
As discussed in the section above, a number of pathways and mechanisms have 
been implicated in docetaxel resistance. One would assume that these cellular players 
could help predict docetaxel response in patients and bring in necessary intervention. 
However, some or the other problem has made the clinical application of the above 
biomarkers an unsuccessful attempt . These biomarkers have either not been reproducible 
in an in vitro scenario, or have failed as effective biomarkers in vivo, suggesting that in 
vitro analysis of these biomarkers may not correlate so well with in vivo expression and 




β-TUBULIN DEFECTS AS BIOMARKER: 
Till date, studies on tubulin defects have yielded no substantial evidence in 
contributing as major factors underlying taxane resistance. Hasegawa and group found no 
association between β-tubulin gene mutation and docetaxel resistance in most human 
breast cancers (164). There is also very little clinical evidence to indicate the role of β-
tubulin mutation in paclitaxel-resistant breast cancer patients (165). Despite the numerous 
correlation studies between class III β-tubulin overexpression and taxane resistance in 
vitro, no correlation was found between class III β-tubulin expression levels and taxane 
resistance in ovarian carcinoma xenografts, that were established using samples from 
patient before and after taxane treatment (166). One probable reason why such translations 
have failed from bench to bed-side is because, in vitro selection methods rely on very high 
concentrations of the drug, that could alter and bias the tubulin isotype composition, and 
may not reflect the action of these drugs in the clinical setting.  
Pgp EXPRESSION AS BIOMARKER: 
Pgp or MDR1 has been regarded as the key mechanism associated with resistance 
to various drugs. However, conflicting reports have emerged. One study found no 
significance between Pgp expression and response to either paclitaxel or docetaxel 
treatment in breast cancer patients (167). Pharmacological inhibition of Pgp with elacridar, 
did not alter cell susceptibility to docetaxel mediated apoptosis in prostate cancer (168), 
raising doubts on the applicability of Pgp as a docetaxel sensitivity modulator. First 
generation Pgp inhibitors such as verapamil and cyclosporin A required very high doses in 
the clinic, that resulted in high plasma concentration of these inhibitors and also increased 
toxicity. Even then, these first generation drugs failed to restore treatment response in 
MDR-1 expressing tumors (169). The second generation drugs that were developed had 
lesser toxicity. However, they influenced pharmacokinetics and biodistribution properties 
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of the primary anticancer drug. And finally, a phase II trial involving the third generation 
Pgp inhibitor 'tariquidar' for the treatment of chemoresistant advanced breast cancer 
patients, had to be halted early as patients were not showing any positive benefit (170). 
Overall, Pgp inhibition therapy has shown little clinical value overall in restoring tumor 
sensitivity, with adverse side effects associated with many Pgp inhibitors.  
BCL-2 AS BIOMARKER: 
Data on the ability of Bcl-2 to predict chemoresponsiveness has been inconclusive. 
Many studies found no association between Bcl-2 expression and drug response (171). 
Prostate cancer cell line, DU145, is inhererently resistant to paclitaxel, although these cells 
do not express any Bcl-2 (151). In complete contrast, over-expression of Bcl-2 enhanced 
the sensitivity of lung cancer cells to docetaxel (172). Yoshino et al., found another 
conflicting evidence, whereby, higher Bcl-2 expression in prostate cancer tissues at 
baseline was an independent predictor for survival following taxane chemotherapy (173). 
This suggests that the therapeutic efficacy of taxane chemotherapy may not completely 
rely on Bcl-2 expression.  
p53 AS BIOMARKER: 
The role of p53 in taxane resistance has produced conflicting results as well. A 
comprehensive meta-analysis of 26 previously published studies including 3,476 breast 
cancer cases found p53 status as a predictive marker for response to neoadjuvant 
chemotherapy (174). However, further studies have been disappointing. In one study, that 
utilized FISH and IHC techniques, p53 expression was not predictive of docetaxel 
sensitivity in advanced breast cancer patients (175), while other reported taxane-induced 
apoptosis to be independent of p53 status and activity (176, 177). Ironically, deliberate 
inactivation of p53 conferred increased chemosensitivity to paclitaxel, with increased 
G2/M arrest and apoptosis (178, 179), while p53 overexpression resulted in an abrogation 
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of docetaxel-mediated apoptosis (180). In case of breast cancer patients, tumors harboring 
wild-type p53 were shown to be unlikely to respond to paclitaxel treatment (181), and 
patients with p53 mutations often had better responses (182, 183). Increased sensitivity 
with mutant p53 is attributed to mutant p53 overriding the G1/S checkpoint control, 
leading to increased cell cycle progression into mitosis (G2/M) where anti-mitotic drugs, 
such as paclitaxel exert their action. In contrast, mutant p53 has also been associated with 
increased taxane resistance. In a randomized phase III trial in which women with node-
positive breast cancer were treated with adjuvant chemotherapy, p53 mutations were 
associated with poor prognosis (184). Mutant p53 attains a dominant gain-of-function 
phenotype, and increases taxane resistance by either losing their control over pro-apoptotic 
protein Bax, or by disrupting spindle checkpoint control (185). Clearly, there exists 
contraditory data on p53 status and its association with docetaxel resistance.  
With so much ambiguity associated with the role of available biomarkers in 
predicting docetaxel response, the clinical setup is in a dire need of new and novel 
biomarkers, that could effectively and more accurately predict docetaxel response. Also, 
there is an urgent need of more promising targetable molecules in overcoming docetaxel 
resistance. In search for new biomarkers, we identified DP103, a DEAD-box RNA 
helicase, as a novel and promising biomarker and therapeutic target of docetaxel response.  
1.4 DEAD BOX FAMILY OF RNA HELICASES 
Various genetic processes entail the unwinding of double-stranded nucleic acids 
(DNA and/or RNA) into single-stranded polynucleotides, a complex reaction that requires 
the presence of several proteins, including helicases. These helicases utilize the free energy 
change of binding and hydrolyzing a nucleotide triphosphate (NTP) to dissociate duplexes 
or displace bound proteins. There are three superfamilies of helicases, namely SF1, SF2 
and SF3. SF1 superfamily includes the DNA helicases that unwind DNA strands, whereas 
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SF2 includes the DEAD-box and the related DEAH, DExH and DExD families of RNA 
helicases that unwind RNA strands as well as RNA-DNA hybrids.  
The DEAD-box proteins were first identified as a distinct family in the late 1980s 
when alignment studies based on eight homologues of the yeast eIF4A translation 
initiation factor brought to light the presence of several conserved motifs, as shown in 
Figure 2. Family members are characterized by the presence of nine conserved motifs 
clustered in a 'central core' region, that were shown to be involved in the ATPase and 
helicase activity (186). The conserved motifs are grouped into two domains, with domain I 
consisting of Q-motif, Motif-I, Ia and Ib, II and III and domain 2 consisting of Motif-IV, V 
and VI. DEAD-box family gets its name from the conserved and characteristic 'D-E-A-D' 
(Asp-Glu-Ala-Asp) motif present in Motif II (also known as Walker B Motif). Motif III is 
known to possess helicase function and Motif VI has been thought to bind to nucleic 
acids. Motif II, together with Motif I (Walker A Motif), Q-motif and Motif VI, utilize ATP 
binding and hydrolysis to bind or remodel RNA and RNA-protein complexes. Motifs, 1a, 
1b, III, IV, and V may be involved in intramolecular rearrangements and RNA interaction.  
 
Figure 2 : Conserved motifs among DEAD-box RNA helicases 
 
Sparring the highly conserved 'central core' region, the amino- and carboxyl-
terminal extensions in DEAD-box proteins are highly variable in size, sequence, 
composition and functionality. Growing number of studies have revealed that the C-
terminus is very often a target of post-translational modifications, and is also responsible 
for rendering substrate specificity to DEAD-box proteins.  
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Members of the DEAD-box family have been identified in a wide range of 
organisms ranging from Escherichia coli to viruses and humans. In humans, this subfamily 
of RNA helicases is made up of an additional 11 DEAD-box proteins (187). Although 
these proteins share a huge degree of sequence and structure similarity amongst each other, 
they tend to be highly diverse in their biological functions. 
1.4.1 ROLE OF DEAD-BOX RNA HELICASES 
DEAD-box RNA helicases are involved in almost every aspect of RNA associated 
metabolism, including transcriptional and translational controls, pre-mRNA splicing, 
ribosome biogenesis, RNA export and decay. Patrick Linder's reviews on DEAD box 
proteins (188, 189) are a comprehensive collation on available knowledge on various 
cellular processes that these proteins are involved in. Figure 3 below and the text that 
follows, summarizes the role of DEAD-box proteins.  
      
  
Figure 3 : Role of DEAD box proteins in RNA-associated metabolisms 
 
TRANCRIPTIONAL PROCESSES: 
Members of the DEAD-box family are involved in various transcriptional 
processes. For instance, DP103 was shown to possess a domain with autonomous 
repressive function that represses the transcriptional activity of SF-1 (190). DDX5 is a 
nuclear protein which exhibits RNA helicase and annealing activity (191). It interacts with 
CBP and RNA Pol II, and stimulates CBP-mediated transcription on TPA oncogene 
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responsive unit (TORU) promoter (192). DDX5 and DDX17 were shown to interact with 
and positively modulate ERα transcriptional activity (193, 194). Interestingly, DDX5 was 
also found to be a co-activator of DNA-damage induced p53 transcriptional activity (195). 
On the other hand, interaction with Histone Deacteylase 1 (HDAC1) enables DDX5 to 
repress transcription in a promoter-specific manner (196). While ATPase or helicase 
activity of p68 is not required for the HDAC-, p53- or ERα-related transcriptional controls, 
p300-dependent transcription does require p68 to have ATPase activity. DDX5 may also 
be required in the transcriptional regulation cycle, needed to rapidly remove transcripts 
from a gene before its activity can be shut down and its chromatin reset to an inactive state 
(197).  
SPLICING: 
Splicing of pre-mRNA into a translation-ready mature mRNA, is a complex 
process that requires structural rearrangements of a large ribonucleoprotein (RNP) 
complex called the spliceosome. Several DEAD-box have been shown to play crucial 
roles at key steps of splicing. DEAD-box protein such as Prp5 is implicated in early 
events of pre-spliceosome assembly (198), whereas DDX5 (199) and DDX17 (200) are 
involved in the progression towards active spliceosome. DDX5 and DDX17 facilitate the 
pre-spliceosome to spliceosome transition by de-stabilizing the binding between U1 
snRNA and the 5′ splice site base-pairs (201, 202). Furthermore, they are also involved in 
the alternative splicing of key cellular genes such as CD44, H-ras and NFAT5. It is 
generally believed that RNA helicases are required for the unwinding of short RNA 
duplexes that are formed between different snRNAs or pre-mRNA molecules.  
RNA EXPORT: 
Protein translation happens in the cytoplasm that requires the export of respective 
mRNAs out of the nucleus into the cyoplasm. Export of mRNA through the nuclear pore 
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requires dedicated proteins to bind to them, including DEAD box protein Dbp5 (203). It is 
found at the nuclear rim interacting with the cytoplasmic fibrils of the nuclear pore, and 
shuttles between the nucleus and the cytoplasm. Dbp5 is loaded onto newly synthesized 
mRNA and travels with it to the nuclear pore. In the process, it also disassociates and 
recycles nuclear factors that coat the mRNA, allowing the export of mRNA through the 
nuclear pore.  
TRANSLATION FROM mRNA: 
DEAD-box protein, eIF4A has been shown to be required for translation initiation 
(204). eIF4A, as part of a bigger eIF4A complex, unwinds RNA and rearranges secondary 
RNA-duplex structures at the 5′ end of eukaryotic mRNA, allowing the scanning 40S 
ribosomal subunit to reach the initiation codon during translation. eIF4A also helps uncoat 
proteins from mRNA, that are loaded onto it upon its export from the nucleus (205). 
Another DEAD-box protein, Ded1 has been shown to be necessary for translation 
initiation (206), where it is speculated to assist the scanning process by melting secondary 
RNA structures or by removing other proteins bound to the mRNA.  
PROCESSING OF MICRO-RNAs: 
DEAD-box proteins are implicated in miRNA processing and function as well. 
Fukuda and colleagues discovered that DDX5 and DDX17 are indispensable for the 
processing of ribosomal RNA and a subset of 94 miRNAs (207). In their study, DDX5 and 
DDX17 co-immunoprecipitated in a complex with mouse Drosha (mDrosha), that is 
responsible for initiating the processing of micro-RNAs. Using an in vitro miRNA 
processing assay, they demonstrated that these two proteins are essential for the conversion 
of a subset of primary miRNAs into precursor miRNAs. Recently, it has been revealed that 
Argonaute-2, the catalytic component of the RNA-induced silencing complex (RISC), 
associates with only one strand of the miRNA duplex. This suggests that there are other 
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factors which might help to confer specificity to the loading of miRNA duplexes onto 
RISC. Later studies identified RNA Helicase A in unwinding the miRNA duplexes and its 
RISC loading (208). Salzman et al. showed that recombinant DDX5 can unwind let-7 
miRNA precursor duplex in vitro (209). 
IMMUNE RESPONSES: 
 DEAD-box proteins have been widely associated with processes related to 
viral pathology. Yeast and mammalian two-hybrid systems identified DDX1 as a critical 
cellular co-factor of HIV Regulator of virion (Rev) protein, that escorts unspliced viral 
mRNAs out of the nucleus of infected cells, for the formation of infectious HIV-1 virions. 
Overexpression of DDX1 led to increased viral production and its down-regulation altered 
the steady-state subcellular distribution of Rev (210). In recent years, DDX3 has also 
gained attention due to its role in the replication of viruses. It was identified as an essential 
cofactor for HIV and HCV replication (211, 212), making it a novel target for the 
development of drugs against these two viruses.  
1.4.2 ROLE OF DEAD BOX RNA HELICASES IN CANCER 
It is increasingly clear that DEAD-box proteins are multifunctional and have 
divergent roles involving RNA-associated metabolism. Understandably, there is a sizeable 
amount of evidence for the implication and involvement of DEAD-box family members in 
cancer development.  
DDX1:  
DDX1 was identified by differential screening of a cDNA library enriched in 
transcripts in two retinoblastoma (RB) cell lines (213). The same group also found its 
overexpression in neuroblastoma (NB) tumors and cell lines (214). Co-amplification of 
DDX1 with MYCN was associated with a poor disease-free survival rate (215). Further 
investigation found it to be interacting with RelA (p65) subunit of NFκB (216) and was 
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shown to require its ATP-dependent helicase activity to enhance NFκB mediated 
transcriptional activity. DDX1 was also implicated in viral replication. DDX1 was also 
shown to promote testicular tumorigenesis, by regulating the transcriptional activation of 
stem-cell associated genes such as Cyclin D2, CD9 and Nanog (217). A more recent study 
found elevated RNA and increased cytoplasmic expression of DDX1 to be relevant as 
independent prognostic markers of early breast cancer recurrence (218). However, 
oncogenic role of DDX1 was marred by contradictory reports that suggest otherwise. For 
example, high DDX1 expression in neuroblastoma was associated with a better survival 
rate (219), whereas another recent study showed that DDX1 expression was associated 
with improved local relapse-free-, distant metastasis-free- and overall survival in patients 
with early-stage node-negative breast cancer (220), suggesting a tumor suppressor role for 
DDX1. 
DDX3: 
DDX3 regulates transcription of genes that are important in cancer development. It 
is recruited to the promoter region of Interferon-β (IFNβ), the cell cycle arrest gene p21 
and the transcription factor Snail to induce their expression, whereas it represses E-
cadherin expression. Stimulation of Snail and repression of E-cadherin would promote 
epithelial-mesenchymal transition (EMT), that in turn would promote cancer invasion and 
metastasis, suggesting an oncogenic role for DDX3. In sharp contrast, induction of p21 
and IFNβ would cause cell-cycle arrest and inhibit angiogenesis, respectively, implying a 
tumor-suppressive role for DDX3. In fact, there have been numerous reports that debate 
the role of DDX3 with respect to carcinogenesis.  
DDX3 was overexpressed in a panel of hepatocellular carcinoma (HCC) tissues, 
and any ectopic overexpression of DDX3 in HCC cell lines stimulated cellular 
transformation and anchorage-independent growth (221). DDX3 was detected to be part of 
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an anti-apoptotic complex, including GSK-3 and c-IAP1, that blocked the activation of 
caspase-3 (222). Very recently, DDX3 was found to be involved in Wnt-β-catenin 
signaling pathway, where it acts as a regulatory subunit of Casein kinase 1 (CK1ε) and 
stimulates its kinase activity to phosphorylate dishevelled scaffold protein (223).  
In contrast, low expression of DDX3 was correlated to aggressive clinical 
manifestation and poor prognosis in patients with oral cancer (224). Another study 
reported a reduced expression of DDX3 in hepatitis B-positive HCC patients (225). DDX3 
also associated and interacted with p53, increasing its accumulation and stabilization, and 
positively regulating camptothecin-induced DNA damage and apoptotic signaling in cells 
expressing functional wild-type p53 (226). Indeed, DDX3 was found to be regulated by 
p53 itself, and a mutation-based inactivation of p53 in non-small-cell lung cancer, led to a 
decrease in the expression of DDX3 (227). In a separate lung cancer report, DDX3 was 
shown to stimulate p53-dependent transcription of p21 and was positively associated with 
p21 expression (228). Ectopic expression of DDX3 was found to inhibit cell growth and 
clonogenicity in a p21-dependent manner (229). These studies support a tumor suppressor 
role for DDX3.  
DDX5: 
Also known as p68, it was cloned out from MCF7 cells as a novel co-activator of 
ERα (230). DDX5 interacts with the A/B domain of ERα and enhances the activity of AF1 
domain in a ligand independent manner. DDX5 also contributed to increased malignancy 
in breast cancer (231), with the protein expression of DDX5 increasing progressively from 
luminal to basal-type breast cancer cell lines. The same study also reported a strong 
correlation of DDX5 expression with Ki67 and EGFR. In another breast cancer study, 
DDX5 was shown to regulate DNA replication and G1/S phase progression (232) by 
promoting the recruitment of RNA polymerase II to E2F-regulated gene promoters. 
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DDX5, upon phosphorylation, promoted epithelial-mesenchymal transition (EMT), by 
dissociating HDAC1 from the promoter of Snail1 and further upregulating its transcription 
(233). DDX5 also formed complexes with β-catenin and RNA polymerase II to positively 
modulate Androgen Receptor (AR) dependent gene expression in prostate cancer (234). 
On the contrary, DDX5 was shown to act as a co-activator of the tumor-suppressor protein 
p53 (195, 235) and promote its transcriptional activity; acting in complete contrast to its 
pro-oncogenic role in the studies dealt with above.  
DDX17: 
 DDX17 is structurally and functionally related to DDX5 and usually found in a 
heterodimer with DDX5. As a result, DDX17 is known to have over-lappping functions 
with DDX5. For example, both DDX5 and DDX17 are responsible for the regulation of 
ERα-dependent transcriptional activity and cell growth (230). The two genes are also co-
involved in colon cancer, where their expressions increased with increasing malignancy 
during the polyp to adenocarcinoma transition in the colon (236). In this study, DDX17 
formed complexes with DDX5 and β-catenin, and promoted the latter's transcriptional 
activity, increasing the expression of its target genes such as c-Myc, Cyclin D1, c-jun and 
fra-1. DDX17 is also recruited to AR responsive element (237) to promote AR dependent 
transcription in prostate cancer cells. DDX17 also activates MDM2 promoter in both a p53 
dependent and independent fashion (238). However, unlike DDX5, DDX17 interacts with 
p53 very weakly and has no part to play in DNA-damage dependent p53 activation (239). 
Thus far, we have discussed involvement of DEAD-box proteins in cancer 
development or regression, that may be in part or wholly due to their influence on key 
cellular events such as transcriptional or translational regulation, miRNA processing, and 
alteration of signaling pathways such as p53 axis, NFκB, Wnt, and modulation of EMT. 
Although, there have been no reports of involvement of DEAD-box RNA helicases in 
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drug-responses and resistance, their involvement in critical cellular pathways including 
p53 and NFκB, implicate a must-study role in drug responses. Having discussed the 
DEAD-box family and various members, we shall now delve into our protein of interest, 
DP103. 
1.5 DP103: FROM DISCOVERY TO STRUCTURAL AND FUNCTIONAL 
CHARACTERIZATION 
DP103 (also referred to as DDX20 or Gemin 3) is a member of the DEAD-box 
family of RNA helicases. It was cloned by several groups, and found to encode a protein 
of 824 amino acids, with a predicted molecular weight of around 92 KDa, and an 
observed molecular weight of 103 KDa upon separation by gel electrophoresis. It is 
for this reason that DDX20, that shows up as a 103 KDa protein, was referred to as 
DP103 (DEAD box protein of 103 KDa).  
1.5.1 DISCOVERY AND INITIAL CHARACTERIZATION OF DP103  
DP103 was first characterized as an interacting partner of Epstein Barr Virus 
(EBV) latent proteins, EBNA2 and EBNA3C. EBV, a ubiquitous human γ-herpesvirus, is 
one of the most common viruses in humans and is the causative agent of the infectious 
mononucleosis (glandular fever). It is also associated with a number of tumors, including 
breast carcinoma. EBNA2 and EBNA3C, belong to a group of latent viral proteins that are 
required for transcriptional regulation of both latent viral and cellular genes. Both these 
nuclear antigens are absolutely essential for the ability of EBV to transform B cells into 
lymphoblastoid cell lines (LCLs) in vitro. In search for new cellular factors that interact 
with EBNA2 and 3C, Grundoff and colleagues (240) identified DP103 as one of the 
interacting partners of both viral proteins on yeast-two-hybrid screens. Upon further 
characterization, DP103 was confirmed as a new DEAD-box protein, sharing similarity 
with other DEAD box proteins between amino acids (aa) 74 to 410. However, the flanking 
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N-terminal (aa 1 to 73) and the C-terminal region (aa 411 to 824) of DP103 were 
completely different from that of other family members. The authors also performed 
northern blot analysis and found that most human cell lines expressed DP103. 
Interestingly, neuroblastoma-derived cell line SK-NS-H and three malignant melanoma 
samples expressed DP103 at high levels. Among normal tissues, no signals were detected 
in brain, prostate, stomach and peripheral blood lymphocytes. However, DP103 expression 
was highest in the rapidly proliferating cells in testis and tonsils.  
In another study carried out by Charroux and colleagues (241), DP103 was cloned 
and characterized as Gemin 3, a new component of the survival motor neurons (SMN) 
complex. SMN complex interacts with the core proteins of the spliceosomal small 
ribonucleoproteins (snRNP) in the cytoplasm, playing a critical role in snRNP assembly. 
In the nucleus, SMN complex is concentrated in nuclear bodies called gems and is pivotal 
for regeneration of snRNPs and pre-mRNA splicing. Charroux and colleagues discovered 
that Gemin 3 directly interacted with SMN and colocalized with SMN complex in nuclear 
gems. At around the same time, another group reported interaction between murine 
homologue of DP103 and SMN through yeast-two hybrid screens (242). They mapped the 
interaction between SMN and DP103 to the C-terminus of DP103. Recently, DP103 was 
also shown to interact and colocalize with SMN complex in drosophila both in vitro and in 
vivo (243). Transposon insertion mutations in DP103 codepletes SMN, inhibits efficient 
SMN core assembly in vitro, and causes larval lethality. Transgenic overexpression of 
DP103 rescues lethality, but overexpression of SMN does not, indicating that loss of 
DP103 and not SMN, is the primary cause of death. Moreover, DP103 mutant larvae 





1.5.2 ROLE OF DP103 
DP103 IN EMBRYONIC DEVELOPMENT 
To explore the physiological function of DP103, Mouillet and group disrupted 
DP103 gene in mice (244). Homozygous DP103-null mice died early in embryonic 
development at the four-cell stage, whereas, heterozygous mice were healthy and fertile. 
However, analysis of steroidogenic tissues revealed minor abnormalities in heterozygous 
mutant females, including larger ovaries, altered estrous cycle and reduced basal secretion  
of  adrenocorticotopic hormone  (ACTH). Thus, DP103 seems to have a very important 
role during early embryonic development and also in modulation of steroidogenesis. 
DP103 AS A TRANSCRIPTIONAL MODULATOR 
Many studies have reported on the role of DP103 in transcription, more so as a 
transcriptional regulator. 
 DP103 REPRESSES SF-1  
Steroidogenic Factor 1 (SF-1) is an orphan nuclear receptor that regulates 
transcription of genes involved in reproductive and endocrine development. Loss of SF-1 
results in abnormal gonadotrope differentiation, phenotypic male-to-female sex 
reversal, low serum levels of corticosteroids and early neonatal death. DP103 was 
identified as an interacting partner of the repression domain of SF-1 using a yeast-two 
hybrid screen, and mutations in the SF-1 repression domain abolished this interaction 
(245). Two years later, it was confirmed that there is a discrete domain within the C-
terminus of DP103, that exhibits an autonomous repressive function, and is necessary for 
repressing the transcriptional activity of SF-1 (190). 
Further investigation on how DP103 represses SF-1 was carried out by Martin Lee 
and colleagues (246). In this study, DP103 was found to repress SF-1 via sumoylation, a 
ubiquitination-like post-translational modification. DP103 interacts directly through its C-
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terminus with the hinge region on SF-1 and sumoylates it. Independent of HDACs, the 
interaction between DP103 and SF-1 enhanced the sumoylation of SF-1 by PIAS E3-
SUMO ligases, leading to subnuclear relocalization of SF-1 to discrete nuclear foci. Thus, 
this study brings to light for the first time a functional mechanism coupling DP103 to 
transcriptional repression via protein sumoylation. Additionally, it was found that the 
helicase activity of DP103 was dispensable for its repressive effect on SF-1.  
 DP103 REPRESSES EGR2 MEDIATED TRANSCRIPTION 
Early growth response (Egr) transcription factors are involved in myelination of the 
peripheral nervous system and segmentation of the vertebrate hindbrain. Based on a yeast 
two hybrid study, DP103 was identified as an interacting partner of Egr-2 (247). Perhaps, 
DP103 is the only known cofactor that interacts with all four family of Egr transcription 
factors, including Egr-1, Egr-3 and Egr-4. DP103 was seen to repress Egr-2 transcriptional 
activity; however, this was not observed for all Egr-2 responsive promoters, implying that 
DP103's repressive effect exhibits promoter specificity. The mechanism of repression 
seemed to involve HDAC activity only on certain Egr-2 responsive promoters and not all, 
suggesting the involvement of HDAC-independent repression mechanism on the other 
promoters. Interestingly, the C-terminus of DP103 was sufficient in causing the repression 
of Egr-2. 
 DP103 IS REQUIRED FOR ANTI-PROLIFERATIVE EFFECTS OF METS 
Ets family of transcriptional factors regulate expression of a variety of viral and 
cellular genes, that serve as targets for Ras-MAPK signaling pathways, controlling 
proliferation and apoptosis. Mitogenic ETS transcriptional suppressor (METS), a tumor-
suppressor, contributes to growth arrest during macrophage differentiation by repressing 
Ets-dependent transcription of cell cycle control genes. Klappacher and group showed that 
the anti-proliferative effects of METS required it to interact with DP103 (248). The 
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authors found DP103 to be co-immunoprecipitating with the N-terminus repression 
domain of METS. The C-terminus of DP103 with its intrinsic transcriptional repression 
activity, was required by METS to block cell proliferation. Interestingly, they also showed 
that METS is associated with a histone deacetylase complex (HDAC) together with 
transcriptional repressors N-CoR and Sin3A, through the C-terminal of DP103, implying 
DP1033's role in recruitment of HDACs.  
 DP103 INTERACTS WITH FOXL2 TO INDUCE APOPTOSIS 
FOXL2 belongs to the Forkhead family of transcription factors, that are involved in 
embryonic development. FOXL2 is mainly involved in ovarian development and function, 
and elimination of ovarian follicles through programmed apoptosis during menopause. A 
study in 2005 found FOXL2 inducing apoptosis in both Chinese hamster ovary (CHO) 
cells and granulosa cells isolated from pregnant mare serum gonadotropin (PMSG)-treated 
rats (249). Further exploration revealed DP103 to be interacting with FOXL2. Although 
overexpression of DP103 alone did not potentiate apoptosis, co-expression of DP103 with 
FOXL2 produced a synergistic apoptotic response.  
1.5.3 ROLE OF DP103 IN CANCER 
DP103's role in cellular processes such as transcriptional regulation, post-
translational modification, interaction with viral proteins and programmed apoptosis in 
ovarian cells, was discussed above. These are important events that are widely associated 
with normal and abnormal cellular functioning. A dysregulation in these key cellular 
events, instigated by a dysregulation in DP103 expression and function in the cell, could 
thus be postulated to be associated with cancer.  
DP103 AS A TUMOR-SUPPRESSOR: 
DP103 has been defined to have tumor-suppressive role in liver cancer. An 
oncogenomics-based in vivo RNAi screen listed DP103 as one among the 13 new tumor-
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suppressor genes identified in murine liver cancers (250). A study in 2012, investigated the 
molecular mechanism behind DP103's role as a tumor suppressor. They showed that 
DP103 negatively regulated NFκB, with depletion of DP103 enhancing NFκB 
transcriptional activity (251). Micro-RNA 140 has been known to suppress NFκB, and the 
authors found DP103 to be regulating miRNA-140, by loading it onto the RISC complex, 
and inhibiting NFκB. This is the first report to connect DP103 and a specific miRNA. In a 
follow-up study by the same group (252), DNA methyltransferase-1 (Dnmt1) was 
identified as a critical target of miRNA-140, with an impairment in miRNA-140 function 
due to DP103 deficiency increasing Dnmt1 expression. Dnmt1 hypermethylates the 
promoters of metallothionein genes that keep NFκB repressed, thus activating it. DP103 
depletion mediated increase in Dnmt1 expression thus resulted in an increase in NFκB 
activity. Furthermore, DP103 is located at 1p21.1-p13.2, a frequently deleted chromosomal 
region in human hepatocellular carcinoma (HCC), establishing it as a potential tumor-
suppressor in liver cancer.  
DP103 AS AN ONCOGENE 
 DP103 AS A PROGNOSTIC BIOMARKER: 
A protein microarray performed on mantle-cell lymphoma (MCL) patient samples, 
displayed an increased expression of DP103 in these patients. DP103 was listed as one of 
the differentially expressed genes, alongside MDM2, cell cycle regulators and many heat-
shock proteins (253). DP103 was also linked to metastasis when a 2010 United States 
Patent Application (Publication Number: US 2010/0004190 Al) was filed on the use of 
compounds that blocked cancer metastasis. Based on microarray data, DP103 emerged as 





 DP103 AS A P53-REPRESSOR: 
Interestingly, DP103 was also implicated in p53 regulation. DP103 was shown to 
inhibit p53-dependent apoptosis (254). The authors demonstrated that DP103 repressed 
p53 both at transcriptional and translational levels. Depletion of DP103 increased p53 
transcript levels along with expression of p21 and Bax. Co-immunoprecipitation and GST 
pull-down assay revealed that C-terminus of DP103 interacted with DBD of p53 and 
inhibited p53 DNA-binding activity. Another study confirmed the p53-inhibitory role of 
DP103. This inhibition was mediated through Epstein-Barr nuclear antigen 3C (EBNA3C) 
(255), one of the essential latent antigens of Epstein-Barr virus (EBV), that DP103 was 
first characterized to be interacting with. Here, the authors report that EBNA3C interacts 
with DP103, stabilizing it and increasing its protein accumulation in both B-lymphoma 
cells and EBV-transformed lymphoblastoid cell lines (LCLs). Furthermore, EBNA3C 
promotes formation of a ternary complex with p53 and DP103, that blocks the DNA-
binding acivity of p53. Depletion of DP103 abrogated EBNA3C-induced repression of p53 
activity and p53-dependent apoptosis. This is for the first time that DP103 had been shown 
to be utilized or hijacked by oncogenic viruses such as EBV, to bolster proliferative and 
anti-apoptotic measures by suppressing apoptotic players such as p53.  
 DP103 AS A FACILITATOR OF METASTASIS: 
Our lab recently published and reported DP103's role in metastatic potential of 
triple-negative breast cancer (256). In this study, DP103 was found to be highly expressed 
in breast tumors, compared to their normal counterparts. Its expression was also higher in 
the highly aggressive and invasive basal-like breast cancer cell lines, compared to the non-
invasive luminal subtypes. DP103 was also identified as a novel biomarker of breast 
cancer metastasis, where depletion in DP103 expression was seen to decrease migration 
and invasion potential of breast cancer cells. Further investigation revealed DP103 to be 
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influencing metastatic events by positively modulating NFκB and its downstream target 
gene MMP9. It was also revealed that DP103 activates NFκB by enhancing TGF-β-
activated kinase-1 (TAK1) mediated phosphorylation of NFκB-activating IκB kinase 2 
(IKK2). Depletion of DP103 expression decreased phosphorylation of IKK2, and impaired 
NFκB activity and NFκB-mediated MMP9 expression. DP103 depletion also abrogated 
metastasis in a murine xenograft model. In turn, NFκB signaling induced the expression of 
DP103, suggesting a feed-back loop between the two, in maintaining constitutive NFκB 
signaling and metastasis. Moreover, a correlation was seen between DP103 and MMP9 
expression in patient samples, implying the relevance of this study in clinical scenario. In 
fact, elevated levels of DP103 also associated with reduced overall survival among 
patients, suggesting that DP103 is a novel oncogene, that is tightly linked to breast cancer 
progression and metastasis.  
The above sections suggest that DP103 can switch between tumor suppressive and 
tumor promoting roles under different cellular contexts, something which warrants further 
investigation. Although, it serves as a tumor-suppressor in liver cancer, other reports, 
including the one from our lab, has highlighted DP103's role as a potential oncogene in at 
least B-cell lymphomas and breast cancer.  
1.6 INVESTIGATION OF A NOVEL ROLE OF DP103 IN BREAST CANCER 
Not much is known about DP103's physiological role in breast cancer in events 
other than metastasis. However, we can take clues from reports on other DEAD-box 
family members. For instance, DDX5 and DDX17 were identified as coactivators of ERα 
transcriptional activity. They bind to ERα and get recruited to ERα-responsive element on 
pS2 gene promoter in an estrogen-dependent manner (257), positively modulating ERα 
activity. Their increased expression may thus enhance the oncogenic properties of ERα in 
64 
 
breast cancer. Till date, no other DEAD-box family member has been implicated in ERα-
dependent signaling.  
Surprisingly, DDX5 was also shown to co-activate p53-dependent transcription 
process (195). In this case, DDX5 interacted with p53 and ChIP assay confirmed 
recruitment of DDX5 to p53-response element on p21 gene promoter. In response to DNA 
damaging agent etoposide, DDX5 enhanced p53 dependent transcriptional activity and 
apoptosis. Another member of the family was also found to associate with and co-activate 
p53. In a study that investigated the role of DDX3 in camptothecin (CPT) induced DNA 
damage, it was found that DDX3 modulated CPT-induced caspase-7 activation in a  p53-
dependent manner (226). DDX3 interacted with p53 and silencing of DDX3 abrogated 
CPT-induced p53 accumulation and caspase-7 activation. This effect was abolished when 
cells were pre-incubated with proteosome inhibitor MG132, indicating that DDX3 
regulates p53's stabilization upon DNA damage, probably through inhibition of p53 
degradation. Conversely, overexpression of DDX3 resulted in an increased p53 
stabilization and accumulation after DNA damage.  
Thus, members of the DEAD-box family bear ERα- and p53-modulatory roles. It is 
therefore possible that DP103 could also bear roles in the regulation of these two 
transcription factors. DP103 dependent repression of p53 is particularly interesting. DP103 
could have a potential role in drug responses, that could be modulated by its repressive 
effect on p53.  
1.6.1 ESTROGEN RECEPTOR (ER) 
Cancers of the women reproductive organs are often triggered by prolonged 
exposure to reproductive hormones. For instance, close to 70% of breast cancers are 
estrogen-dependent. Estrogen's mode of action is to bind to estrogen receptors (ERs). 
Upon binding by estrogen, ER gets activated and translocates into the nucleus where it 
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dimerizes and binds to the DNA and regulates the expression of different genes including 
growth factors and growth factor receptors, cyclin/cdk factors, proteases such as cathepsin 
D and genes involved in survival and anti-apoptosis such as survivin, Bcl-xL and Bcl-2.  
Estrogen receptor belongs to the nuclear hormone family of intracellular 
transcription factors. There are two predominant forms of the ER, usually referred to as α 
and β, and encoded by ESR1 and ESR2 genes, respectively. Estrogen hormone-dependent 
stimulation can result in formation of either homodimers or heterodimers of ERα and ERβ 
receptors. While ERα is extensively studied and associated with breast cancer growth, role 
of ERβ in breast cancer remains elusive. However, the two ER receptors show a significant 
sequence homology, with each of it composed of five domains, ashown in Figure 4. Listed 
from the N-terminus to the C-terminus, first comes the A/B domain at the N-terminus, also 
referred to as the Activation Function 1 (AF-1), that is responsible for transactivation of 
ER in a ligand-independent manner (absence of estrogen). Next comes the C domain 
(DNA-binding domain or DBD) that binds to the DNA when activated ER reaches the 
nuclear chromatin. The D domain is the hinge region that connects the C domain and the E 
domain, and could also be involved in the conformational modifications of ER. Following 
is the E domain which is the second transactivation domain of ER, also referred to as AF-
2. AF-2 has ligand-binding domain (LBD) that gets bound to available ligand, and 
activates ER-dependent gene transcription only in the ligand-bound state. E domain also 
carries the binding sites for co-activators and co-repressors, needed for its transactivation 
activity at the chromatin. Finally, the F domain, whose function is not clearly known, is 




Figure 4: Domain struture of Estrogen Receptors  
 
1.6.1.1 ESTROGEN RECEPTOR SIGNALING IN BREAST CANCER 
ERα signaling comprises of a cascade of signaling events that is often triggered by 
estrogen, and culminates in causing a change in the gene expression of ER responsive 
genes. This is predominantly achieved through ERα-dependent gene transcription 
(genomic action). ER can also directly activate other signaling cascades (nongenomic 
action) for signal transduction. Different modes of ERα signaling is summarized in the 
diagram below (Figure 5) and the following text. 
 




GENOMIC ACTION:  
In its inactive state in the absence of estrogen, ER exists as monomers in the 
cytoplasm and is kept repressed in a complex with heat-shocks proteins. Estrogen, being a 
steroidal hormone, can easily pass through the phospholipid cell membrane and bind to 
ER. Estrogen-bound ER monomers undergo conformational changes to dissociate from the 
chaperone proteins and undergo phosphorylation. This triggers their translocation to the 
nucleus where they dimerize before recognizing and binding to specific DNA sequences 
known as estrogen-response elements (EREs) on the promoter or regulatory region of 
downstream target genes. The consensus ERE (cERE) has been determined to be 5′-
AGGTCANNNTGACCT-3′, where NNN is a 3 base pair (bp) spacer region separating the 
bipartite 6 bp long invert repeat sequences (258). Most of the chromatin region that ER is 
known to bind to, is in a heterochromatin state, that hinders the interaction of ER with the 
DNA. ER-dependent transcription is thus facilitated by co-operative transcription factors 
such as FOXA, GATA and AP2γ (259-261). These pioneer factors interact with the 
chromatin and expose the DNA for ERα binding. Once bound to the ERE, ERα recruits a 
complex set of proteins (262) that include co-activators such as p300/CBP and SRC, or co-
repressors such as HDACs, NcoR and SMRT, to play an important role in recruitment of 
the transcriptional machinery with the RNA polymerase enzyme, the modulation of the 
chromatin structure, and finally the regulation of gene expression (263). In contrast to 
estrogens that would involve co-activators at the promoter of downstream genes, anti-
estrogens such as tamoxifen and fulvestrant would induce a distinct conformation of ER 
that would recruit co-repressors (264), thereby shutting off gene transcription.  
In a non-classical manner, ER also contributes to regulation of gene expression by 
not necessarily binding to DNA, but interacting and modulating proteins or DNA-bound 
transcription factors associated with other signaling pathways. For example, ER signaling 
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has also been known to be mediated through its interaction with transcription factors such 
as c-Jun (265), NFκB (266, 267), specific-protein 1 (SP1) (268), and AP-1 (269), forming 
complexes to mediate transcription of genes whose promoters do not harbor EREs. For 
instance, ER regulates the expression of Cyclin D1 by liaising with CBP (270) and GRIP 
(271) in AP-1 co-activator complex, without actually binding to AP-1 response elelment 
(272). This way, it also confers estrogen responsiveness to genes encoding human 
ovalbumin, c-fos, collagenase, and insulin-like growth factor (273). ERα signaling can also 
get activated in a ligand-independent manner, either directly by growth factors such as 
EGF or IGF-1, or indirectly throuh growth factors-activated kinases such as MAPK and 
Akt. For instance, Akt2, upon activation by EGF or IGF-1, phosphorylates ERα and 
promotes its transcriptional activity, in an estrogen-independent (274). In another study, 
Akt potentiated ERα transcriptional activity on Bcl-2 promoter, leading to increased levels 
of Bcl-2 (275).  
NON-GENOMIC ACTION:  
This mode of action is devoid of changes in ER-mediated gene transcription. This 
activity is mediated, at least in part, by a small fraction of ERα (GP30) that is localized 
near or at the plasma membrane. ER has been shown to associate with cell membrane by 
attachment to caveolin-1 and form complexes with membrane-bound enzymes including 
integrins, G proteins, receptor tyrosine kinases (RTKs) such as EGFR and IGF-1R, and 
non-receptor tyrosone kinases such as Src. Membrane-bound ER transduces signal to the 
nucleus through the activation of Src/Ras/MAPK/ERK and phosphoinositide-3-kinase 
(PI3K/AKT) pathways (276, 277). For instance, ER-mediated activation of Src and PI3K 
increases proliferation and abrogates apoptosis through phosphorylation-dependent 
inactivation of the proapoptotic protein BAD (278). Various studies have shown that 
estrogen promotes an increased expression of PI3K, that in turn, stimulates the activation 
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and phosphorylation of Akt (279, 280), resulting in an increased cellular proliferation. 
Estrogen-stimulated activation of Akt pathway also enables the inhibition of ATM kinase 
pathway that controls DNA repair (281). Estrogen-stimulated Src kinase also increases 
aromatase activity (282), indicating the possibility of an autocrine loop between estrogen 
and aromatase in breast carcinogenesis. 
1.6.1.2 REGULATION OF ESTROGEN RECEPTOR 
Estrogen receptor is very tightly regulated in hormone-dependent breast cancer 
cells through various post-translational modifications (PTMs). 
PHOSPHORYLATION:  
Phosphorylation generally occurs at serine (S) or threonine (T) or tyrosine (Y) 
amino acid residues. So far, S104/106, S118, S167, S236, T311, and Y537 of ERα have 
been known to be modified by phosphorylation (283). Expression of these phoshorylated 
forms of ERα have been detected by IHC in breast tumors (283). Phosphorylation of ERα 
is often induced by upstream kinases such as MAPK, AKT and Src (284-286). In general, 
phosphorylation of ERα influences the recruitment of co-activators, resulting in enhanced 
gene transcription (287, 288). Of these sites, S118 and S167 located within the activation 
function-1 (AF-1) region seem to be very important for activation of ERα in both an 
estrogen-dependent and an estrogen-independent manner (289). Phosphorylation of ERα, 
specially at S118 and 167, serve as surrogate marker for breast tumors that are highly 
dependent on ER signaling. As a consequence, phosphorylation status of ER have also 
been associated with improved response to endocrine therapies (290-292).  
ACETYLATION:  
Acetylation of ERα at lysine residues 299, 302 and 303 by p300, promotes 
recruitment of histone acetyl transferases (HATs) for the acetylation of histones during 
gene transcription. Mutation of these residues results in an enhanced estradiol dependent 
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transcription (293), implying that acetylation of these residues suppresses ligand sensitivity 
of ER.  
UBIQUITINATION: 
ERα degradation occurs with hormone stimulation, resulting in a progressive 
decrease in ERα protein levels in ER-positive breast cancer cell lines. This downregulation 
was later attributed to ubiquitin-mediated proteosomal degradation, as pre-incubation with 
MG132 inhibited proteosomal machinery and ERα degradation (294). Proteosomal 
degradation is thought of as a requisite for ERα turnover, and maintenance of steady-state 
levels of ERα and regulation of gene transcription (295). Binding of estrogen reduces the 
half-life from 5 days for the unbound ER to a mere 3-5 hours for the bound receptor. 
Interestingly, Alarid and colleagues established a direct link between ubiquitination and 
phosphorylation of ERα (296), where phosphorylation at S118 recruits factors to mediate 
subsequent ubiquitination of ERα. MDM2 oncoprotein, in a ternary complex with p53, is 
involved in ERα turnover, stability and transcriptional activity (297), suggesting an 
involvement of p53 pathway in ERα signaling. 
1.6.2 TUMOR SUPPRESSOR PROTEIN-p53  
Over the past two decades, p53's role as a tumor-suppressor has been well 
investigated. It is fondly referred to as 'the guardian of the genome' as it maintains genomic 
stability preventing undesirable mutations. It also tightly regulates the cell cycle. It is 
activated during events of cellular stress, including chemotherapy treatment or induction of 
DNA damage. Depending on the physiological circumstances, activated p53 regulates the 
transcription of genes involved in cell cycle arrest, DNA repair, senescence or apoptosis 
(298, 299). Coherenetly, 50% of all cancers are reported to have a mutation in p53 (300). 
Aberrant expression of p53, either resulting from inactivation or mutation, is associated 
with a poor prognosis in human neoplasia.  
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1.6.2.1 STRUCTURAL ANALYSIS OF p53  
TP53 gene encodes a protein of 393 amino acids, with a predicted molecular mass 
of 43.7 KDa, and an observed molecular mass of 53 KDa on SDS-PAGE analysis, hence 
the name p53. Protein structure of p53 has various domains, that determine its 
functionality. At the N-terminus is the transcription-activation domain or TAD, that 
consists of activation domain 1 (AD1) spanning residues 1-42, and activation domain 2 
(AD2) from residues 43-63. A proline-rich domain from residues 64-92 is thought to be 
very important for regulation of pro-apoptotic activity. Then comes the DNA-binding 
domain (DBD) from residues 102-292 that is capable of binding to the chromatin to carry 
out gene transcription. Like most other transcription factors, p53 preferentially binds to a 
consensus sequence (5'-RRRCWWGYYY-N(0-13)-RRRCWWGYYY-3') on target 
promoters (301). Strikingly, 97% of cancer-associated p53 mutations fall into the DBD of 
p53, emphasizing the importance of this domain. P53 shuttles between the cytoplasm and 
the nucleus through the nuclear localization signal domain (NLS) that resides between 
residues 316-325. Activation of p53 leads to it acquiring various oligomeric states using 
the oligomerization domain (OD) from residues 307-355. Finally, the C-terminus (residues 
356-393) of p53 is highly volatile, rich in lysine residues, and constantly subjected to 
various post-translational modifications. Studies have found that the carboxy terminus of 
p53 normally folds back and inhibits the DNA-binding activity and the tumor-suppressive 
role of p53 (302).  
1.6.2.2 ACTIVATION OF P53 AND ITS FUNCTIONAL CONSEQUENCES 
In normal cells, the transactivation of p53 is kept silent or extremely low. Any kind 
of cellular stress, especially DNA damage, would activate p53. Stress could also be 
induced by agents such as carcinogenic contents, oncogenic activation, hypoxic conditions, 
UV rays, IR irradiation, and chemotherapy. Activated p53 then mediates an anti-cancer 
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effect by being a part of a large network of proteins that assesses the health and genomic 
content of the cell. Upon detection of a damage, activated p53 initiates DNA-repair 
mechanism to get the cell back on normal track. If the damage is beyond repair, p53 
initiates apoptosis and causes cell-death.  
CELL-CYCLE INHIBITION:  
P53's role in cell-cycle regulation is orchestrated through regulation of various 
target genes including p21
WAF1/CIP1 
(303). P21 is a p53-responsive gene that is a negative 
regulator of cyclin-dependent kinases (CDKs). CDKs are key regulators of the cell cycle, 
working in tandem with cyclin proteins for cell-cycle progression at various stages. The 
p21 protein binds to various CDKs, inhibiting both G1/S and G2/M transitions. p53 also 
stimulates the expression of the protein 14-3-3 sigma, which sequesters cyclin B1-CDK1 
complexes outside the nucleus and causes a G2-M arrest (304). GADD45 is also another 
p53-target gene involved in cell-cycle arrest.  
APOPTOSIS: 
There are several genes that mediate p53-induced apoptosis. One such example is 
the Bax protein that belongs to the Bcl-2 family of pro-apoptotic proteins. Transcription of 
the Bax gene is directly stimulated by p53-binding sites in the regulatory region of the 
gene (305, 306). More recently, other apoptotic proteins such as NOXA and P53AIP1, 
have also been discovered to be p53-responsive (307, 308). Other p53-regulated genes 
include PUMA, proteins with similarities to the classic 'death-signal' receptors, such as 
PIDD, the TNF (tumour necrosis factor) receptor and Fas/Apo1. P53 also mediates 
apoptosis through caspase activation. Over-expression of p53 in p53 null cells Saos-2, 
induced apoptotic cell death, characterized by phosphatidylserine externalization, DNA 
fragmentation, caspase activation and cytochrome-c release (309), suggesting involvement 
of intrinsic apoptotic pathway in p53-mediated apoptosis. In another study, apigenin, a 
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dietary flavanoid induced cell death in neuroblastoma cells in a caspase-3 dependent 
manner through the p53-Bax-caspase-3 apoptotic pathway (310).  
1.6.2.3 REGULATION OF P53 EXPRESSION AND ACTIVITY 
In normal conditions, p53 is a very labile protein with a very short half-life. 
However, activating signals produce an increase in the protein half-life of p53 with an 
increased stabilization (311). Most importantly, the sequence-specific DNA binding 
activity of p53 is dramatically enhanced. p53 activation may also involve a change in 
subcellular localization (312). Inactive p53 is cytoplasmic; whereas activation transports it 
to the nucleus, resulting in its accumulation in the nucleus for enhanced transcriptional 
activity.  
There is mounting evidence in support of post-translational modifications 
modulating p53 activity. p53 protein gets phosphorylated on multiple sites in response to 
stress stimuli (313-315). A number of kinases phosphorylate p53 at different residues, 
including casein kinase 1 at serines 6 and 9, DNA-PK at serines 15 and 37, ATM and ATR 
at serine 15, cdk2 and cdc2 at serine 315, protein kinase C at serine 378, and casein kinase 
II at serine 392. In most cases, phosphorylation of p53 results in stabilization of p53 
through inhibition of p53 ubiquitination and degradation, which will be discussed later. 
Serine 15 has been studied particularly closely, phosphorylation of which is required for 
p53 stabilization in response to ionizing radiation and other types of DNA damage (316-
319). Another covalent modification that is important in modulating p53 activity is DNA-
damage induced acetylation. Numerous studies have shown that p300/CBP binds to p53 
and acetylates it on lysine 382, in the regulatory region of its C-terminus, enhancing p53-
mediated transcriptional activity (320, 321). Acetylation of lysine 382 residue enhances 
p53 DNA-binding activity by interfering with the folding back of the C-terminus onto the 
DNA-binding domain (DBD) of p53. Interestingly, it was also found that recombinant p53 
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protein that was phosphorylated previously by DNA-PK appeared to be a better substrate 
for the acetyltransferases than unphosphorylated p53, suggesting the interdependence of 
some of these post-translational modifications in regulating p53 activity (322).  
THE p53-MDM2 LOOP 
One of the most important player in p53 regulation is its own target gene, MDM2 
(Mouse Double Minute 2 homolog). It is an oncogene that has been implicated in 
facilitating several cancers. There is a complex relationship between p53 and MDM2. On 
one hand, p53 binds to the promoter region of MDM2 gene to stimulate its transcription 
(323). On the other hand, MDM2 protein inactivates p53 (324). MDM2 achieves p53 
repression by various ways. MDM2 binds to p53 transactivation domain, thus concealing 
the activation domain from the transcriptional machinery. MDM2 being an E3 ubiquitin 
ligase, it can bind to and attach ubiquitin moieties to p53, resulting in its complete 
elimination through ubiquitination-dependent proteolytic degradation (325, 326). Part of 
the influence of MDM2 on p53 inhibition is its ability to enhance transport of p53 protein 
out of the nucleus and into the cytoplasm where it is targeted for degradation (327), or 
repress acetylation of p53 by preventing binding of p300/CBP through recruitment of 
HDAC1 (328). Thus MDM2 exerts a negative feedback loop on p53, that keeps the level 
of p53 low in the absence of p53-stabilizing signals. This loop however is interrupted by 
kinases and genes like p14 (ARF) that inactivate MDM2 (329), releasing p53 from MDM2 
inhibition. Also, phosphorylation of residues on p53, including serine 15, 20 and 37, 
positioned within the MDM2-binding pocket, may interfere with binding to MDM2 and 
lead to p53 stabilization (330). In addition, p53-mediated caspase activation results in the 
cleavage of MDM2 protein (331, 332). The cleaved MDM2 becomes dominant negative 
and loses its ability to degrade p53. 
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The negative-feedback loop between MDM2 and p53 is highly important for the 
normal functioning of the cell. Any dysregulation can have deleterious effect. Knock-out 
mice models with inactivation of the MDM2 gene resulted in early embryonal lethality, 
which was reversed completely by simultaneous inactivation of p53 (333). The loop shifts 
its balance towards MDM2 in several human cancers; where excessive MDM2 gene 
amplification or protein translation can lead to constitutive inhibition of p53, thereby 
promoting cancer. It however remains to be determined whether MDM2 operates alone or 
in concert with other proteins in regulating p53.  
1.6.2.4 PERTURBATION OF P53 SIGNALING IN BREAST CANCER 
Cancer cells have developed mechanisms to get rid of tumor-suppressive roles of 
p53. p53 remains the most commonly mutated gene in human cancers, with mutations 
occuring in 50% of all cancers. Mutations may occur in the promoter region of p53 
affecting its expression, in the regulatory region of the protein affecting its transactivation 
activity, in the DBD affecting its binding to the chromatin, and in residues or region that 
makes p53 more susceptible to degradation. A vast majority of p53 mutations occur in the 
DBD. Most p53 mutations are point-mutations leading to the synthesis of a stable, 
malfunctional and non-degradable form of p53 oncoprotein, that accumulates in tumor 
cells and does not respond to stress stimuli and does not possess sequence-specific DNA 
binding activity as well (334). Mutant p53 shows a dominant-negative effect, and represses 
the function of wild-type p53. Mutant p53 was shown to be involved in breast cancer 
development where germline mutation in p53 was detected in Li Fraumeni syndrome 
(335), that confers an increased risk of several cancers including breast carcinoma. 
Mutation of p53 gene and subsequent accumulation of the mutant protein are prognostic 
markers for poor outcome in breast cancer, with mutation rate increasing with increasing 
malignancy. For example, frequency of p53 mutation increased from around zero in low-
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grade ductal carcinoma in situ (DCIS) to 30–40% in high-grade DCIS (336). In fact, 
certain types of breast cancer are associated with higher p53 mutation frequencies. BRCA1 
and BRCA2 germ-line mutations are associated with an increased rate of p53 mutations. 
This explains why triple-negative breast cancers that possess BRCA mutations, have 
higher rate of p53 mutations.  
However, in case of breast cancer, mutation rate in p53 is only around 20% (337), 
predominantly in the ER-negative tumors. This means that most of the breast cancer cases, 
specially the ER-positive types, contain wild-type p53. Such cancer types would then be 
speculated to subvert the tumor suppressive properties of wild-type p53 through additional 
molecular mechanisms. Perturbations of wild-type p53 signaling can happen at multiple 
levels. There could be changes in p53 expression, sub-cellular localization, regulatory 
aspects involving any possible upstream regulatory protein or interacting partner, and also 
downstream stress-responsive genes.  
Many breast cancer cases have reported lower steady-state mRNA levels of p53 
mRNA when compared to the normal breast epithelium (338). This detailed study found 
HOXA5 to be regulating p53 transcriptionally. They also showed that a high proportion of 
primary breast carcinomas show a significantly reduced expression of HOXA5, due to its 
own promoter methylation events. Methylation-dependent silencing of HOXA5 would 
thus present as one of the possible mechanisms of reduced p53 expression in breast cancer. 
Another mechanism of p53 inactivation involves cytoplasmic sequestration of p53 protein, 
preventing nuclear localisation of the protein (312) and thus inhibiting its transcriptional 
activity. Upstream regulators of p53 are highly important for proper p53 signaling, and 
mutations found in ATM or Chk2 kinases (339, 340) would disrupt the activation of p53. 
Histone acetyl transferase p300 that is known to acetylate p53, is found to possess 
truncating mutations in breast cancer cell lines and primary tumors, disrupting acetylation-
77 
 
dependent activation of p53 (341). Inactivation of p53 may also be achieved by 
overexpression of MDM2 (342, 343) or by deletion or epigenetic silencing of p14
ARF 
(344). A recent study has demonstrated a new role of MDM2 in p53 activity, in which, 
MDM2 is recruited to the chromatin and binds to p53 responsive promoter regions, 
repressing p53 transcriptional activity (345). Virus-associated cancers would involve 
interaction of virally encoded proteins either directly with p53 or indirectly with other 
players involved in regulation of p53, resulting in enhanced degradation of p53. For 
instance, upon infection with SV40, viral protein known as Large T antigen (Tag) binds to 
and complexes with p53, inactivating it (346, 347). Even EBV latent proteins keep p53 
inactivated and repressed to maintain EBV latency (348). One study found MDM2-
mediated degradation of p53 to be required for EBV-induced oncogenic transformation 
(349). Mentioned earlier (255), EBV latent protein EBNA3C mediates repression of p53 
transcriptional activity through DP103, the protein of our interest. Finally, perturbations in 
the regulation of downstream target genes of p53, could result in a loss of the intended 
phenotype. One such example is that of 14-3-3-σ, that is routinely subjected to 
methylation-dependent silencing in a high proportion of primary breast carcinomas cases 
(350).  
We have so far elucidated how p53 or its activity could be controlled or repressed 
in breast cancer. The TP53 gene is shown to get mutated in just 20-30% of all breast 
malignancies. Interestingly, most of these mutations occur in ER-negative breast cancers 
(351), with wild-type TP53 tumors found to be mostly ER-receptor positive in status. 
Thus, there exists a possibility of a functional interplay between p53 and ER in receptor-




1.6.3 CROSS-TALK BETWEEN ERα AND p53 SIGNALING IN BREAST 
CANCER 
In the preceding two sections, we have discussed role of ERα and p53 in the 
carcinogenesis of breast cancer, with ERα being an oncogene that promotes proliferation 
and p53 being a tumor-suppressor (atleast the wildtype version) that impedes proliferation, 
with ERα present in 70% of all breast cancer cases and p53 present in its wildtype format 
in almost close to 80% of all breast cancers (p53 mutations seen only in 20% of all breast 
cancers), with ERα responsible for less-invasive and less-aggressive phenotypes and p53 
mutated in only highly invasive and aggressive triple-negative basal like cancers. These 
observations raise a question if there exists a cross-talk or an association between the two 
players? Could there be a relationship between them through transcriptional or 
translational avenues in regulating one another and breast cancer pathogenesis? Could they 
be modulating each other's function in promoting or subverting breast cancer? Studies 
showing that ERα and p53 share some common target genes (e.g., c-fos, c-jun, TPA and 
Bcl-2) (352), with p53 down-regulating them and ERα stimulating their expression, 
suggested that there might be a repulsive cross-talk between the two transcription factors.  
ERα AS A p53-REPRESSOR 
Estrogen stimulation of ERα-positive breast cancer cells induced functional 
inactivation of p53 by nuclear exclusion of p53, to disrupt p53 activty and facilitate G1/S 
transition and promote ERα-dependent oncogenesis (353). Liu et al (354) show that the 
AF-2 domain of ERα interacts with the C-terminus of p53 to repress its transcriptional 
activity, with ionizing radiation-stimulated activation of p53 disrupting this interaction. 
Another study elucidates mechanism of ERα antagonism towards p53 (355). The authors 
carried out sequential ChIP assays and showed that ERα is recuited to the chromatin with 
p53, and represses p53-mediated transcription through recruitment of corepressors such as 
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NCoR and SMRT, and HDAC1. Also, the repressive effect of estrogen on p53 
transcriptional activity was diametrically opposite to its known stimulating effect on ERα 
transcriptional activity. This implies that ERα employs dual strategies to promote breast 
carcinogenesis: enhancing the transcription of ERE-containing proproliferative genes and 
repressing the transcription of p53-responsive antiproliferative genes. From a clinical 
perspective, the authors also employed a retrospective approach in analyzing response to 
endocrine therapy in a subset of patients with ER-positive breast cancer expressing either 
wild-type or mutant p53. They concluded that the presence of wild-type p53 is an 
important determinant of positive therapeutic response, thus implicating a role of p53 in 
ERα-driven endocrine response. A recent paper highlighted blockade of p53-dependent 
apoptosis by ERα-driven signaling (356). Viability assays showed that estradiol inhibited 
doxorubicin-induced p53-mediated apoptotic cell death. Microarray anaysis on a genome-
wide scale upon doxorubicin treatment, showed that p53 and ER had opposing effects on 
two-sets of genes. It was found that p53 inhibited and ER activated first set of genes 
involved in proliferation. Conversely, p53 activated and ER inhibited the second set of 
genes involved in apoptosis, including ATF3 and TRAF4. ChIP assay confirmed that ER 
inhibited p53-dependent expression of pro-apoptotic genes. In another study, Sayeed et al., 
showed that ERα binds to and inhibits the repressive function of p53 on pro-survival genes 
such as survivin and MDR (357).  
p53 AS AN ERα-REPRESSOR 
On the other hand, p53 protein is also known to interact and repress the hormone-
dependent activation of nuclear receptors such as TR (Thyroid Hormone Receptor) (358) 
and GR (Glucocorticoid Receptor) (359). p53 is believed to attenuate estradiol-induced 
ERα activity, by interfering with ERα binding to the ERE on chromatin, without 
interfering with ERα dimerization or its interaction with coactivator SRC-1 (360). Another 
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group showed similar repressive effects of p53 on ERα transcriptional activity (361). 
Interestingly, overexpression of the mutant form of p53, had a lesser repressive effect on 
ER activity compared to the wild-type p53, the extent of which was dependent on the type 
of mutation. In fact, in other studies, mutant p53 was shown to repress ER expression 
through epigenetic silencing. Mutant p53 was shown to form a complex with DNMT1 and 
HDAC to hypermethylate and silence the ESR1 gene in ERα-negative cell lines (362, 
363), indicating that mutant p53 may be responsible for loss of ERα expression in breast 
tumors. With p53 being involved in negative regulation of ERα, its raised a possibility of 
the involvement of its negative regulator MDM2 in ERα regulation (364). MDM2 
significantly modulated ERα-mediated transactivation in MCF-7 and ZR751 breast cancer 
cells (365), with MDM2 overexpression and knockdown experiments exerting a positive 
and negative impact on ER activity, respectively. The authors also showed that ERα 
interacted with MDM2 in vitro in an estradiol independent manner, however, fluorescent 
resonance energy transfer (FRET) experiments in living cells showed that estradiol 
enhanced ERα-MDM2 interaction. MDM2 is also essential for ligand-dependent ERα 
turnover, that in turn, positively modulates ERα-activation cycle. It however remains to be 
seen if MDM2 modulates ER activity through p53. There are two possibilities. MDM2 
either keeps p53 inhibited, thereby releasing ERα from the inhibitory clutches of p53; or 
MDM2 modulates ERα activity in a p53-independent manner (366). A ternary complex, 
where MDM2, p53 and ERα are present in a tightly-regulated complex, is also possible. 
Thus, we observe that ERα and p53 cross-talk in maintaining breast cancer 
pathogenesis. ERα on its part keeps p53 repressed to promote oncogenesis, and p53 on the 
other hand, possibly upon some stress-signal activation, represses ERα activity to cause 
cell death. Moreover, most of the ERα-positive breast cancers are known to have wild-type 
p53, suggesting a tight regulation between the two. It is still not clear if there are other 
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players or mechanisms, involved in this tightly regulated p53-ERα axis. Another 
interesting mechanism worth studying in this cross-talk would be sumoylation, since 
sumoylation affects both ERα and p53. 
1.7 SUMOYLATION 
Sumoylation is a relatively new post-translational modification that is known to 
modify various proteins in eukaryotic organisms ranging from yeast to humans. It involves 
the reversible addition of a SUMO protein (Small Ubiquitin-like MOdifier) to the substrate 
protein. The purpose of this modification is to let the sumoylated proteins meander through 
various cellular processes including gene transcription, nuclear-cytoplasmic transport, 
hormone response, protein-protein interactions, protein stability, signal transduction, 
management of stress and cell cycle progression (367). Sumoylation substrates include a 
growing list of proteins such as RanGAP1 (Ran GTPase activating protein 1), IκBα, PML 
(Promyelocytic Leukemia Protein), SP100, ERα and also p53. SUMO modification has 
been strongly implicated in the pathogenesis of human diseases, such as cancer, 
neurodegenerative disorders and viral infection.  
SUMO proteins are a family of small proteins that are covalently attached to and 
detached from other cellular proteins to modify their function. In humans, there are 4 
confirmed SUMO isoforms, namely SUMO1, SUMO2, SUMO3 and SUMO4, which are 
ubiquituously expressed throughout the organism. SUMO proteins are first expressed in 
an immature precursor form, where their C-terminus has a stretch of varying length of 
amino acids after the Gly-Gly motif. SUMO-specific cysteine proteases (SENPs) cleave 
away this extension to allow formation of an isopeptide bond between the C-terminal 
glycine residue of SUMO and an acceptor lysine on the target protein (368). The mature 
forms of SUMO2 and SUMO3 share 97% sequence homology between them, and these 
two proteins share only 50% homology to SUMO1. Usually, sumoylation results in the 
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addition of a single SUMO protein to individual acceptor Lysine residues. However, the 
formation of poly-sumoylated chains has been observed  in case of SUMO2/3 proteins and 
not SUMO1, since SUMO1 does not contain internal SUMO consensus sites found in 
SUMO2/3. Thus, SUMO1 and SUMO2/3 (that are generally grouped together) serve 
distinct functions. Each of the SUMO proteins is around 12 KDa in size. 
1.7.1 SUMO ATTACHMENT 
Sumoylation follows a ubiquitination-like three-step enzymatic cascade that 
includes activation, conjugation and ligation of the sumo proteins to the substrate (369, 
370). The first step of sumoylation is the activation of a mature SUMO protein by the 
SUMO-specific E1 activating enzyme (SAE).  The C-terminal of this mature form has a 
diglycine motif that is required for the effective adenylation by the SUMO E1 enzyme. 
Once formed, the SUMO adenylate is attacked by a conserved Cys on the E1 enzyme 
to form an E1-SUMO thioester. Activated SUMO is then transferred to a conserved 
Cys on an E2 conjugating enzyme (Ubc9), generating an E2-SUMO thioester. Finally, an 
E3 ligase transfers the SUMO from E2 to the substrate, forming an isopeptide bond 
between the C-terminal Gly residue of SUMO and the acceptor Lys side residue of the 
target. To attain specificity, SUMO is generally attached to the lysine residue within a 
ψKX(D/E) consensus motif, where ψ is a large hydrophobic residue, K being the acceptor 
lysine, X being any amino acid and D/E being glutamate or aspartate. While E3 enzyme is 
highly essential in the ligation process during ubiquitination, evidence suggests that E2 is 
sufficient in sumoylation as long as the substrate possesses the consensus sequence. E3 
ligase probably promotes the efficiency of sumoylation and in some cases has been shown 
to direct SUMO conjugation onto non-consensus motifs.  
While there is only one E1 or E2 enzyme, multiple E3 ligases have been identified. 
SUMO E3 ligases are characterised by the presence of the SP-RING motif. SP-RING 
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ligases bind their targets and Ubc9 directly and bind SUMO non-covalently via a SUMO-
interacting motif (SIM). One of the subgroups of SP-RING ligases is the family of PIAS 
(Protein Inhibitor of Activated STAT) proteins, initially identified in studies for 
understanding the JAK/STAT pathway. In humans, the members include PIAS1, PIAS3, 
PIASxα, PIASxβ and PIASy. As their name suggests, PIAS proteins were found to 
interact with STAT proteins and inhibit STAT-mediated gene activation. Subsequently, 
studies showed that this inhibition was mediated via sumoylation . 
Once the purpose of sumoylation has been achieved, it has to be reversed to return 
to steady state. This is where de-sumoylation process comes in. Sumoylation is reversible 
and sumo proteins are removed from targets by specific SUMO proteases that possess 
hydrolase activity. So far, a single gene family that encodes SUMO-specific Cys proteases 
has been identified. In humans, the family of sentrin-specific proteases (SENPs) includes 
six members namely, SENP1, SENP2, SENP3, SENP5, SENP6 and SENP7. SENP 
proteins are also required for the maturation process of newly synthesized SUMO 
proteins.  
1.7.2 REPORTED EFFECTS OF SUMOYLATION IN CANCER 
Sumoylation is an important PTM that can bring about the following changes to the 
sumoylated protein: promote or inhibit the formation of specific protein complexes, affect 
subnuclear localization of proteins and regulate gene transcription. The most routinely 
observed effect of sumoylation is to alter the interaction or interacting partners of the 
substrate. For example, sumoylated p300 interacts with HDAC6 (371), that results in its 
transcriptional repression. Sumoylation was found to exert a positive stimulating effect on 
Akt activation. Sumoylation and subsequent activation of Akt was promoted by Ubc9 and 
PIAS1, and reversed by SENP1 (372). Sumoylation plays a critical role in metastasis 
through regulation of TGF-β signaling (373).  Kang and group identified TGF-β type I 
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receptor (TβRI) to be a SUMO target. Sumoylation of TβRI enhances receptor function by 
facilitating the recruitment and phosphorylation of Smad-3, subsequently regulating TGF-
β induced transcription and growth inhibition. NEMO, an NFκB essential modulator, and a 
regulator of NFκB activity, is sumoylated in response to genotoxic agents, which in turn 
leads to NFκB activation (374). Not just genotoxic stress, a variety of other stress 
conditions, including oxidative stress and heat shock, can also induce sumoylation of 
NEMO (375). Several nuclear receptors are also modified by sumoylation. Androgen 
receptor (AR), which is critical for prostate cancer development and progression, was 
identified to be a SUMO1 target, and sumoylation repressed hormone-induced AR 
transcriptional activity (376). HDAC1 is shown to repress AR activation, and 
overexpression of SENP1, desumoylates and deconjugates HDAC1 from AR, 
increasing the latter's activity (377). Similarly, sumoylation of Progesterone Receptor 
(PR) represses its transcriptional activity (378). Interestingly, both ERα and p53 have been 
known to be modulated by sumoylation. Reports have suggested sumoylation increasing 
ERα activity and decreasing p53 activity. 
1.7.3 INVOLVEMENT OF SUMOYLATION IN THE p53-ERα AXIS 
SUMOYLATION OF ERα: 
Sumo modification of ERα occurs at lysine resiue(s) in the AF-1 domain (379). 
Another study confirmed SUMO1, Ubc9 and PIAS1 mediated sumoylation of ERα at 
lysine residues 266 and 268 in the hinge region (380). The authors showed that 
sumoylation of ERα occurs strictly under estradiol stimulation conditions. Sumoylation of 
these residues increased the transcriptional activity of ERα, without affecting ERα nuclear 
localization thus implying that sumoylation of ERα, unlike acetylation and ubiquitination, 
may have a positive impact on ERα activity. Another study confirmed the hinge region of 
ERα to be a target for SUMO-E3 ligases PIAS1, and PIAS3 (381). In contrast, a 2014 
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study, found desumoylation to be repressing ERα activity in breast cancer. Here, SENP2 
was demonstrated to interact with ERα and repress its estradiol-induced transcriptional 
activity on promoter region of downstream target genes such as TFF1 and Cathepsin D 
(382). Thus, sumoylation of ER might have a significant role to play in ERα-dependent 
signaling and cancer development in breast cancer.  
SUMOYLATION OF p53: 
On the other hand, the exact role of p53 sumoylation is still an intensive topic of 
debate. According to some studies, sumoylation activates p53 (383, 384), and according to 
some other, the influence is either inhibitory (385) or without any effect (386). Its usually 
considered that under normal growth conditions, sumoylated p53 is barely detectable in 
cell extracts, and even under the best conditions, only a small fraction of p53 (probably 
less than 5%) is found to be modified at steady state (387), attributed to the rapid 
desumoylase activity of SENPs. Events that may specifically induce or inhibit p53 
sumoylation are presently ill defined. There have been contradictory reports of effect of 
DNA damage on p53 sumoylation status. UV irradiation of U2OS cells results in 
increased levels of both unmodified and sumoylated p53, with an unchanged ratio 
between both forms (383). Whereas, UV irradiation or doxorubicin treatment of 293 cells 
has been reported to increase only levels of sumoylated p53 (386).  
On the contrary, another study found that in response to ionizing or UV-
irradiation, Chk2 phosphorylates p53 , which in turn, repressed sumoylation of p53 (388). 
In this study, phosphorylation of p53 regulated the interaction of E2-conjugating enzyme 
Ubc9 with p53. Doxorubicin-dependent DNA damage induced p53 phosphorylation and 
importantly, repressed p53 sumoylation, attributed to reduced interaction between Ubc9 
and p53. This study model is the first of its kind that affirms that DNA damage-induced 
activation of p53 requires repression of sumoylation, suggesting an inhibitory role of 
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sumoylation on p53. In advocatory studies on sumoylation-mediated repression of p53, 
the authors report that SUMO1-conjugated p53 failed to activate p53 transcriptional 
activity because of its inability to bind to DNA. Importantly, the authors also report a 
cross-talk of sumoylation with acetylation (387, 389). The authors found that SUMO1 
dependent sumoylation of p53 at lysine 386 prevented subsequent acetylation at lysine 
382 due to steric hindrance, thus inhibiting p53 activation. Biochemical assays showed 
that sumoylation of p53 only prevents the free (unbound) form of p53 from binding to the 
DNA, without disengaging prebound p53 from DNA. Furthermore, sumoylation of 
prebound p53 recruited transcriptional corepressor mSin3A to inhibit p53 target gene 
transcription. Upon mutation, sumoylation-deficient K386R mutant exhibited higher 
transcription activity compared to the wild-type protein. The K386R mutant also bound to 
p21 promoter better that the wild-type p53. This suggests that sumoylation of p53 indeed 
represses its activity. Another study demonstrated that sumoylation promoted CRM1-
mediated nuclear export of p53 (390). This increased cytoplasmic localization of p53, 
preventing it from executing its DNA-binding activity in the nucleus. All these findings 
ascertain that sumoylation of p53 represses its activity.  
MDM2-MEDIATED SUMOYLATION OF p53 
There have also been reports of p53 sumoylation mediated through MDM2, that is 
well-known to ubiquitinate p53. MDM2 has been shown to promote SUMO1 modification 
of p53 (391). MDM2-mediated p53 sumoylation requires direct interaction between them 
and a p53 mutant that does not interact with MDM2 is poorly sumoylated. Overexpression 
of MDM2 increased levels of p53 sumoylation and targeted it to the nucleolus. In another 
study, MDM2 promoted SUMO2/3 modification of p53 (392). However, sumoylation of 
p53 with SUMO2/3, had mixed effects on p53 transcriptional activity, measured through 
luciferase assays with two p53-responsive reporter gene constructs; one regulated by a 
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series of consensus p53 binding sites-PG13, and the other under the control of the actual 
binding site on Bax promoter. It was revealed that sumoylation mutant of p53 was more 
efficient in inducing PG13 promoter compared to the wild-type p53. In contrast, an 
opposite trend was seen on the Bax-luciferase, where the wild-type had a stronger reporter 
activity. This suggested that sumoylation can modulate p53 activity, either positively or 
negatively, depending on the target promoter.   
MDM2 is itself modified by SUMO. For example, it was recently shown that 
sumoylation of MDM2 competes with its self-ubiquitination and leads to MDM2 
stabilization, resulting in increased ubiquitin ligase activity towards p53. SUMO 
conjugation of MDM2 shifts its ligase activity towards p53, while minimizing its self-
ubiquitination. This leads to enhanced p53 ubiquitination and degradation (393, 394). 
Moreover, radiation-induced DNA damage caused a decrease in MDM2 sumoylation, 
which shifts the ligase activity towards self-ubiquitination, correlating with an increased 
p53 level. This shows that sumoylation of MDM2 is critical for its intrinsic ubiquitin 
activity, and that reduced sumoylation of MDM2 upon DNA damage would result in 
increased MDM2 self-ubiquitination and an increased p53 stabilization (393, 395). This is 
probably one of the possible mechanisms that p53 is activated and stabilized upon stress 
stimulation.  
1.7.4 DEAD-BOX PROTEINS IN SUMOYLATION: 
Two DEAD-box RNA helicases, DDX5 and DP103, have been implicated in 
sumoylation process. For example, DDX5 gets sumoylated at lysine 53 to modulate its co-
activator/co-repressor role. Sumoylation was shown to increase protein stability and half-
life of DDX5 by reducing its proteosomal degradation (396). The same study also reported 
that sumoylation of DDX5 increased its ERα co-activation potential, and its sumoylation 
mutant showed a drastically reduced co-activation potential. With respect to p53, DDX5 is 
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known to co-activate p53 transcriptional activity (195), and a K53R mutant of DDX5, 
which cannot be sumoylated, is shown to a better coactivator of p53 activity, suggesting 
that sumoylation of wild-type DDX5 represses its role in p53 transcriptional regulation, 
due to recruitment of HDAC1 (397).  
Our protein of interest, DP103 was also known to play a major role in sumoylation based 
modifications. It was shown to sumoylate and repress the transcriptional activities of 
orphan nuclear receptors such as SF-1 and liver receptor homolog-1 (LRH-1). It is also 
reported that DP103 represses p53 activity (255), but the exact mechanism behind DP103-
mediated repression of p53 is not known. It would be interesting to see if DP103 involves 
in sumoylation of p53. As discussed earlier, sumoylation of p53 has been shown to repress 
its transcriptional activity. Could DP103 be involved in sumoylation-dependent repression 
of p53? Since, sumoylation of p53 has also been reported to inhibit its activity, there is a 
possibility of DP103's involvement in sumoylation-mediated repression of p53. We would 
also be interested in knowing if response to docetaxel involves an interplay of DP103 with 
ER and p53 in breast cancer. 
1.8. SCOPE OF STUDY 
Chemoresistance is a major hurdle to treatment options available in the 
management of breast cancer. Tackling and dealing with chemoresistance would involve a 
thorough understanding of molecular players implicated in breast cancer chemoresponse 
and chemoresistance. Many research groups have focussed on various biomarkers in 
predicitng chemosresponse. However, none of them have proven to be useful in the 
clinical scenario so far. The need of the hour it to immediately identify new, yet efficient 
predictive markers of chemoresponse. This would help identify patients who have a high 
probability of benefiting from chemotherapy, and distinguish them from those who are 
likely to not respond to the therapy. At least this way, the non-responders do not have to 
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go through unnecessary cytotoxicities of the drug treatment, and importantly, necessary 
intervention or different treatments could be applied on them before its too late. 
Furthermore, a better understanding of the mechanism of chemoresistance will also help 
identify candidate genes for targeted therapies, improving clinical management of the 
breast cancer disease.  
1.8.1 HYPOTHESIS AND OBJECTIVES OF STUDY 
Our protein of interest, DP103, is a member of the DEAD-box family of RNA 
helicases. Members of the family have been involved in a wide range of RNA-associated 
metabolisms. Since DP103 is still a relatively new protein, research on it is at its very 
nascent stages. With less than than 30 publications related to DP103 on pubmed, there are 
plenty of facets of DP103 that remains to be explored. Our lab recently reported DP103 to 
be upregulated in breast cancer, establishing it as a putative oncogene and a novel 
prognostic marker in breast cancer.  Across different subtypes, its expression was higher 
in triple-negative breast cancer. Both in vitro and in vivo work showed DP103 to be 
increasing breast cancer metastasis by positively modulating NFκB activity. This finding 
on DP103's novel role in modulation of metastasis and NFκB, combined with an earlier 
report on its repression of p53 activity, made us question if DP103 could also be involved 
in drug response and drug resistance. Most of the chemotherapeutic drugs, either directly 
or indirectly, activate p53 to induce cytotoxic effects. Therefore, we speculated a drug-
response modulatory role for DP103 in breast cancer through modulation of p53. This 
further prompted us to explore the various mechanisms by which DP103 could be 
involved in mediating chemoresponse, and also breast cancer oncogenicity. In this 
process, we also stumbled upon clues that DP103 could be associating with ERα 
expression and activity.  
In view of this, the objective of the study was to investigate the involvement of 
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DP103 in chemoresponse, and evaluate the applicability of DP103 as a predictive 
biomarker and a therapeutic target of chemoresponse, and to investigate the molecular 
mechanism behind DP103's role and involvement in chemoresponse and breast 
carcinogenesis. My PhD project was thus focussed on achieving the following aims in 
deciphering DP103's novel role, if any, in chemoresponse and oncogenecity in breast 
cancer. 
Aim 1: Analyze and associate DP103 expression profile with chemoresponse in breast 
cancer.  
Aim 2: Elucidate the functional consequences of a gain or loss of function of DP103 
expression on cell sensitivity to chemotherapeutic drugs.  
Aim 3: Assess if DP103 is an estrogen-inducible gene.  
Aim 4: Determine if DP103 modulates ER transcriptional activity and function and 
explore the associated mechanism. 
Aim 5: Investigate if DP103 involves sumoylation in repression of p53, and to check if 
this DP103-p53 axis is crucial in maintaining oncogenecity and chemoresponse. 
With these aims in mind, we sought to get a better understanding of DP103's 










CHAPTER 2- MATERIALS AND METHODS 
2.1 METHODOLOGY FOR PATIENT SAMPLE STUDY 
2.1.1 COMPARISON OF DP103 EXPRESSION BETWEEN NORMAL AND 
BREAST CANCER CASES 
Microarray data-set available from public domain 'The Cancer Genome Atlas', was 
used for comparison of DP103 expression between breast tumor tissues and their normal 
counterparts.  
2.1.1.1 DATA PREPROCESSING OF MICROARRAY GENE EXPRESSION 
536 invasive ductal breast cancer samples and 63 solid tissue normal on Agilent 
custom gene expression microarray G4502A_07 were downloaded from The Cancer 
Genome Atlas (TCGA; http://cancergenome.nih.gov/). The data was imported to Partek ® 
Genomics Suite 6.6 where the log ratio of gene expression value was quantile normalized 
for further analysis. Breast cancer cell line data of accession number GSE13915 was 
downloaded from Gene Omnibus (GEO). Gene expressions were extracted from the series 
matrix file provided. 
2.1.1.2 IDENTIFICATION OF BC SUBTYPES 
For BC tumor, molecular subtype signature was obtained from Prat et al., 2010 
(18). Subsequently, single sample Gene Set Enrichment Analysis (ssGSEA) was computed 
based on the BC subtype signature for each sample. Each sample was then assigned to be 
the subtype that it has the maximum ssGSEA score for. As for molecular subtype of breast 
cancer cell line, it was assigned based on the reported subtype in Neve et al., 2006 (398). 
2.1.2 PATIENT SELECTION FOR CHEMOTHERAPY STUDY 
Our collaborator Dr. Lee Soo Chin, had carried out a prospective phase II study, 
analysing serial changes in the expression of key breast cancer-related proteins in response 
to a neoadjuvant chemotherapy (399). This single-centre study recruited hundred East-
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Asian female patients from April 2002 to July 2005, with histologically or cytologically 
proven locally advanced or metastatic breast cancer. The institutional ethics committee 
approved the study protocol, and all participants provided written informed consent. These 
patients with a measurable primary breast tumor of 2 cm or greater, were randomized to 
one of two alternating sequences of doxorubicin (A) and docetaxel (T), starting with 
75mg/m
2
 of either doxorubicin or docetaxel, every 3 weeks for six cycles (A-T-A-T-A-T, 
n=49, denoted as sequence 1; T-A-T-A-T-A, n=51, denoted as sequence 2). Bi-
dimensional tumor assessments were performed at every cycle using the World Health 
Organization (WHO) criteria for tumor clinical response. Accordingly, clinical responders 
were categorized as those who achieved complete or partial response, while non-
responders were those who achieved only stable or progressive disease as their best overall 
response after 6 cycles of chemotherapy. Clinical complete response (CR) was defined as 
the disappearance of all palpable tumour deposits. Partial response (PR) was defined as 
reduction of tumour volume ≥50%. Tumour reduction <50% or increase of tumour volume 
up to 25% was scored as stable disease. An increase of >25% or the appearance of new 
lesions was designated as progressive disease. 
Tumor core biopsies were taken from each patient at 4 time points: before 
chemotherapy (baseline), 3 weeks after the first, second and sixth cycle of chemotherapy 
respectively, for immunohistochemistry and transcription analysis. The biopsies were 
carried out at approximately the same location each time for each patient. Locoregional 
treatment was planned after chemotherapy, followed by endocrine therapy as per 
institutional guidelines for patients with hormone receptor-positive disease. All patients 
were followed every 3–6 months in accordance to institutional guidelines after treatment 
completion. Progression-free survival (PFS) and overall survival (OS) were defined as the 
time between randomization date and the first documented evidence of progression, and 
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the time between randomization date and death, respectively. For patients with no 
documented disease progression or were alive at the time of analysis, PFS or OS was 
censored at the date of the last follow-up.  
2.1.2.1 DP103 GENE EXPRESSION ANALYSIS FOR CHEMOTHERAPY STUDY 
Total tumor RNA was labelled by biotin and hybridized on the Affymetrix U133+2 
microarray chip and analysed according to the manufacturer’s instructions (Santa Clara, 
California, USA), as previously described (400). Tumor DP103 expression data (probe set 
223331s_at) at baseline (T1), after cycle 1 chemotherapy (T2), and chemotherapy-induced 
change ([T2-T1]/T1), which is the relative difference in DP103 gene expression as a result 
of one cycle of chemotherapy, was extracted for this analysis. 
2.1.2.2 DP103 PROTEIN EXPRESSION ANALYSIS FOR CHEMOTHERAPY 
STUDY 
Patient tumor tissues at different stages of chemotherapy were stained for DP103 
protein expression using Immunohistochemical (IHC) staining. Core biopsies were taken 
from the primary breast tumour and stored in formalin and subsequently embedded in 
paraffin. Five-millimetre sections, stained with haematoxylin and eosin, were obtained to 
identify viable morphologically representative areas of the specimen from which core 
biopsies were taken. Tissue cores with a diameter of 0.6 mm were punched and arrayed on 
a new paraffin block. Five-millimetre sections of these tissue array blocks were cut and 
placed on charged polylysine-coated slides for immunohistochemical analysis. Slides were 
stained with BondMax Autostainer (Leica, Milton Keynes, UK). Antigen retrieval was 
performed at 100 degree celsius with Bond ER2 diluent, followed by 15 minutes 
incubation with DP103 primary antibody (Proteintech, IL, USA). Polymer secondary 
incubation, diaminobenzidine development and haematoxylin counter-staining were 
performed on the Bond system automatically. Cytoplasmic immunostaining of DP103 was 
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scored by two pathologists independently and final IHC score was generated based on 
consensus. IHC immunostaining was graded according to the intensity of positive staining 
in cancer cells. Staining intensity was classified into 4 groups: 0 (negative), 1 (weak), 2 
(moderate) and 3 (strong). Staining scores 0 and 1 were grouped as negative 
immunoreactivity whereas 2 and 3 were grouped as positive immunoreactivity. DP103 
protein expression was determined by the immuno-reactive score. This was calculated by 
multiplication of the staining intensity (mentioned above) and the percentage of positive 
cells. The percentage of positive cells was categorised as 0 (negative), 1 (<10% positive 
cells), 2 (10%–50% positive cells), 3 (51%–80% positive cells) and 4 (>80% positive 
cells).  
2.1.3 ASSOCIATION ANALYSIS BETWEEN DP103 AND ERα EXPRESSION 
A total of 274 human mammary ductal tissues (213 invasive ductal carcinomas 
[IDC] and 61 normal cases) were used to analyze correlation between protein expression 
levels of DP103 and ERα. Clinical materials and the IHC analysis for DP103 and ERα 
association anaylsis was carried out as described herein. Tissue microarray (TMA) slides 
of 274 mammary ductal tissues were obtained from the Department of Pathology, 
Singapore General Hospital. The TMA samples consisted of 213 IDC patients and 61 
normal breast tissues. Clinicopathological characteristics were retrieved for statistical 
analyses, including patient’s age, tumour size, histological grade, lymphovascular 
invasion, presence of lymph node involvement, oestrogen receptor status, progesterone 
receptor status, and HER2 receptor status. Ethics approval for the study was obtained from 
the Institutional Review Board, Singapore General Hospital. 
Anti-DP103 (Proteintech, IL, USA) and anti-ERα (Neomarkers, CA, USA) 
antibodies were used for IHC staining of the TMA slides as described previously (401, 
402). Briefly, the TMA sections were de-paraffinised in Clearene and rehydrated in a 
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graded series of ethanol. Endogenous peroxidase activity was quenched using 3% 
hydrogen peroxide for 30 min. Antigen retrieval was performed through boiling in 10mM 
citrate buffer (pH 6.0) for 20 min in a microwave oven. Blocking was next carried out with 
goat serum for 1 hour prior to overnight incubation at 4
o
C with the respective primary 
antibodies (1:50 dilution). Secondary antibody (DAKO Envision Kit) incubation was 
carried out for 1 hour at room temperature. The sections were visualised using 
diaminobenzidine as the substrate and counterstained with Shandon’s haematoxylin. The 
intensity of the staining in the ductal tissues was graded as absent (0), weak (1+), moderate 
(2+), or strong (3+) by two independent blinded observers, with a scoring of 0 or 1+ 
regarded as 'low', whereas, a score of 2+ or 3+ was regarded as 'high'.  
2.1.4 STATISTICAL ANALYSIS 
For the analysis of data from public domain, dot plot was generated using 
Graphpad Prism for statistical significance evaluation for microarray analysis. For the 
chemotherapy study, correlation between clinical parameters and DP103 IHC status and 
mRNA expression levels was performed using the Chi-square test and the student’s t-test 
respectively. Survival analysis was conducted using Kaplan-Meier and the log-rank test 
employed to compare differences between groups. Serial changes of DP103 IHC status 
over four time points were analyzed with Friedman test. Statistical analyses were 
performed using the SPSS package (version 18.0 for Windows, SPSS Inc., USA) with 
significance set at the 5% level. For the association study between DP103 and ERα 
expression, associations between IHC staining data and clinicopathological parameters 






2.1.5 ASSOCIATION ANALYSIS BETWEEN DP103 AND CDKN1A EXPRESSION 
IN PATIENT DATA-SET 
2.1.5.1 DATA PREPROCESSING OF MICROARRAY GENE EXPRESSION 
Microarray gene expressions of breast carcinoma were downloaded from Gene 
Expression Omnibus (GEO; http://www.ncbi.nlm.nih.gov/gds?db=gds), and from The 
Cancer Genome Atlas (TCGA; http://cancergenome.nih.gov). Two breast cancer dataset 
were compiled using microarray data on (i) Affymetrix U133Plus2 platform (n = 1325), 
including GSE12276 (n = 204), GSE19615 (n = 115), GSE21653 (n = 266), GSE23177 (n 
= 116), GSE23593 (n = 50), GSE26639 (n=226), GSE3744 (n = 47), GSE5460 (n = 127), 
GSE5764 (n = 10), GSE6532 (n = 87), and GSE9195 (n = 77); and (ii) TCGA Agilent 
G4502A_07_03 custom array (n = 538). For this study, we included all of publicly 
available dataset in U133Plus2 platform and TCGA at the time that the analysis was 
initiated in October 2011.  For Affymetrix data, Robust Multichip Average (RMA) 
normalization was performed on each dataset using R bioconductor Affy package. The 
normalized data was subsequently compiled and standardized using ComBat (403) to 
remove batch effect. As for TCGA data, the log ratio of gene expression value was 
quantile normalized by Partek ® Genomics Suite 6.6. Fifty one microarray gene 
expression of breast cancer cell line was extracted from Broad-Norvatis Cancer Cell Line 
Encyclopedia (CCLE; http://www.broadinstitute.org/ccle/home). The arrays were 
subjected to RMA normalization prior to analysis. 
2.1.5.2 IDENTIFICATION OF BC SUBTYPES 
Single sample Gene Set Enrichment Analysis (ssGSEA) (404) was applied to 
compute, for each clinical sample, the enrichment score of breast cancer molecular subtype 
signature (18).  Clinical sample was then assigned to be the breast cancer molecular 
subtype that it has the highest ssGSEA enrichment score. 
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2.1.5.3 STATISTICAL ANALYSIS 
Statistical significance evaluation by Mann-Whitney test and Spearman correlation 
test were computed using Matlab®.  Dot plot was generated using Graphpad Prism. 
2.2 METHODOLOGY FOR IN VITRO STUDY 
2.2.1 CELL LINES AND REAGENTS 
ERα-positive cell lines MCF-7, T47D, and ERα-negative cell lines MDA-MB-231 
and BT549 were obtained from American Type Culture Collection ATCC (Manassas, VA, 
USA). These cell lines were cultured in Roswell Park Memorial Institute (RPMI) 1640 
medium supplemented with 10% Fetal Bovine Serum (FBS), 2mM L-glutamine and 
100U/ml Pen/Strep. The media and supplements were purchased from Hyclone (Logan, 
UT, USA). Docetaxel, Doxorubicin, 17-β-Estradiol (E2), 4-hydroxy-tamoxifen (4OHT) 
and Fulvestrant (Fulv) drug stocks were prepared as recommended by the supplier (Sigma 
Aldrich, LO, USA). All other chemicals and reagents are from Sigma (St Louis, MO) 
unless otherwise indicated. The cell lines were subcultured in 75cm
2 
flasks (NUNC, NY, 
USA) every three days with a preferred split ratio of 1:3. For experiments, cells were 
washed with PBS and resuspended from culture flasks using trypsin. Upon neutralization 
of trypsin with complete media, cells were pelleted by centrifugation at 1300 rpm and the 
supernatant removed. Cells were resuspended in media and counted using a 
haemocytometer before being seeded into six-well plates or 100mm tissue culture dish 
(Falcon, NJ, USA). The cells were then incubated for 48h to allow for attachment before 
performing any transfection or drug treatment. Normal FBS contains abundant supply of 
growth factors and steroid hormones including estrogen. Also, the phenol-red reagent 
present in RPMI medium has the potential of structurally mimicking estrogen. Hence, for 
all estrogen related studies, cells were grown for 3 days in phenol-red free RPMI 
(GIBCO), supplemented with 10% charcoal stripped FBS Hyclone (Logan, UT, USA), 
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2mM L-glutamine and 100U/ml Pen/Strep, before stimulation with E2 or anti-estrogens 
(4OHT or Fulv) for indicated time points. Charcoal stripped FBS is specially formulated 
and is devoid of all growth factors that are present in normal FBS.  
2.2.2 TREATMENT OF CELLS WITH DRUGS 
For drug-treatment experimental setups, cells were trypsinized and re-seeded in 6-
well plates at a density of 0.2 x 10
6 
cells per well. After close to 2 days, when the cells 
reached around 60% confluency, treatment was initiated. Drug stocks of docetaxel, 
doxorubicin, 17-β-estradiol, tamoxifen and fulvestrant were prepared in DMSO and 
stored at -20⁰C. Required amounts of these drugs stocks were diluted with complete 
medium to attain the indicated final concentrations, that was added to the cells for 
indicated time points. DMSO vehicle control always accompanies any experimental set up. 
2.2.3 GENERATION OF DOCETAXEL-RESISTANT CELL LINES 
MCF7 parental cell line (termed docetaxel-sensitive or MCF7-WT) was made 
resistant to docetaxel (termed docetaxel-resistant or MCF7_DoceR) following sequential 
exposure to docetaxel at increasing concentrations. Starting with 1/10
th
 of IC50 of 
docetaxel, cells were allowed to get exposed to increasing concentration of docetaxel for 
24 hours each time, with resting period between subsequent exposures. This was to allow 
cells to adapt and proliferate and probably activate mechanisms of resistance to the 
incumbent drug. The starting dose of docetaxel was 1nM and the dose was doubled each 
time.  After 2-3 months, cell viability and IC50 was compared between parental (wild-
type) and docetaxel resistant (DoceR) cells, to determine the fold-resistance in the 
resistant cells.  
2.2.4 RNA ISOLATION 
Total RNA was extracted from cells using TRIzol® reagent according to the 
manufacturer's instructions (Invitrogen, Life Technologies, Grand Island, NY). Upon 
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completion of the experiment, cells are washed in ice-cold 1X PBS before addition of 
TRIzol®. After 10 mins of trizol treatment that would have ensured complete dissociation 
of nucleoprotein complexes, the homogenate was transferred to 1.7ml eppendoff tubes. 
They were then supplemented with chloroform, vortexed and centrifuged at 13000rpm at 
4⁰C for 15min. Following centrifugation, the mixture separates into a lower red phenol-
chloroform phase, interphase and an upper colorless aqueous phase. RNA remains 
exclusively in the aqueous layer whereas DNA and proteins are in the interphase and 
organic bottom phase respectively. The top aqueous layer was then transferred into a fresh 
tube and equal volume of isoamyl alcohol/Chloroform (24:1) was added to reduce 
foaming and ensure deactivation of RNase. After centrifugation for another 15min at 4⁰C, 
the top colorless layer was transferred to a new tube and equal volume of isopropanol was 
added and frozen at -80⁰C for at least half an hour to ensure complete precipitation of 
nucleic acids. The samples were then thawed and centrifuged for 15min at 4⁰C to spin 
down the precipitated RNA. Precipitated RNA will form gel-like/white pellet at the side 
and bottom of the tube. The supernatant was then carefully discarded and the pellet was 
washed with ice-cold 75% ethanol. The samples were then centrifuged at 13000rpm for 
another 15min at 4⁰C. Supernatant was then removed and pellet was air-dried. The RNA 
pellet was dissolved in ultra-pure water and concentration measured using NanoDrop® 
ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE). 
2.2.5 REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION (RT-
PCR) AND QUANTIATIVE REALTIME PCR (qPCR) 
Each RT reaction contains required 1µg of total RNA, 1X RT buffer, 5mM 
MgCl2, 425µM of each dNTPs, 2µM random hexamers, 0.35U/µl RNase inhibitor and 
1.1U/µl MultiScribe™ reverse transcriptase enzyme. The  RT mixture was then made up 
to 10µl with sterile water. RT reaction was carried out in PCR thermal cycle 
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(Mastercycler gradient, Eppendorf, Hamburg) using the following steps. The reaction mix 
is heated at 25°C for 10min, followed by 37°C for 1h and finally at 95°C for 5min to 
terminate the reaction. A negative control for RT in which sterile water replaced the 
RNA template was included. 
Five microlitres of the 10µl cDNA reaction volume was used in quantitative 
Realtime-PCR using ABI PRISM 7500 (Applied Biosystems, Foster City, CA, USA) with 
18S as an internal control (Applied Biosystems, Hs99999901_s1). Fluorescence was 
measured with the Sequence Detection Systems 2.0 software. Quantitative Realtime PCR 
was performed in multiplex (both target and endogenous control co-amplified in the 
same reaction) with distinct fluorescent dyes. Primers and probes for various human genes 
were purchased as kits from Applied Biosystems with their catalog numbers as follows: 
DP103 (Hs 00200516_m1), TFF1 (Hs 00907239_m1), CCND1 (Hs 00765553)m1), 
GREB1 (Hs 00536409_m1).   
2.2.6 PROTEIN ISOLATION AND CONCENTRATION DETERMINATION 
At time of harvest, cells were washed with ice-cold 1X PBS and a sufficient 
volume of 1X RIPA lysis buffer is added to the cells and incubated on ice for 10 minutes. 
1X RIPA lysis buffer had been supplemented with Phenylmethylsulfonyl fluoride (PMSF, 
serine protease inhibitor), leupeptin (N-acetyl-L-leucyl-L-leucyl-L- argininal, naturally 
occurring protease inhibitor for cysteine, serine and threonine peptidases), pepstatin A 
(aspartic proteases inhibitor) and aprotinin (serine protease inhibitor) and sodium 
orthovanadate or Na3VO4 (tyrosine phosphatase inhibitor). 1% NP-40 serves as detergent 
used to solubilize the lipid in the cell membrane and other lipoproteins in the tissue. 
Deoxycholic acid also serves as detergent to solubilise fats. Sodium dodecyl sulphate 
(SDS) imposes a negative charge on solubilised proteins, thus aiding in protein migration 
during electrophoresis. Cells are then scrapped and harvested into a 1.5ml eppendorf tube 
101 
 
and centrifuged at maximum speed at 4⁰C to collect supernatant that has the cellular 
protein lysate. Protein  concentration  determination  of  cell  lysates  was  carried  out  
using  the Coomassie Dye (PIERCE, IL, USA) in a 96-well format. One microlitre of cell 
lysate was added to 200μl of Coomassie Dye and its absorbance at 595nm was read using 
a Spectrofluoro Plus spectrophotometer (TECAN, GmbH, Grödig, Austria). The 
Coomassie Plus Protein Assay is based on an absorbance shift from 465nm to 595nm that 
occurs when the reagent binds to proteins in an acidic solution. The mechanism of the 
reaction is that the anionic form of the dye complexes with proteins, resulting in a color 
change from brown to blue. The dye interacts mainly with arginine residues and 
weakly with histidine, lysine, tyrosine, tryptophan and phenylalanine residues. The 
reaction reaches a stable endpoint so the absorbance reading does not shift over time. 
Protein standards were prepared using bovine serum albumin (PIERCE, IL, USA). 
2.2.7 SDS-PAGE AND WESTERN BLOT ANALYSIS 
For detection and analysis of protein expression, 30g of total protein per sample 
was mixed with 1X Sample Loading Dye, and incubated at 95°C for 10min before being 
loaded onto the SDS-PAGE (Polyacrylamide Gel Electrophoresis) gel. The gel was run at 
80V for 20min for stacking of the proteins, followed by 125V  for resolution of the 
proteins, using the BioRad Mini- PROTEAN 3 Cell (CA,  USA). Kaleidoscope prestained 
standards  (BioRad,  CA, USA) were also subjected to SDS-PAGE to facilitate the 
estimation of molecular sizes of the protein bands obtained. The resolved proteins were 
then transferred onto nitrocellulose transfer membrane by wet transfer method at 
350mA for 1h 15min using the BioRad Mini Trans-Blot Electrophoretic Transfer Cell 
(CA, USA). After the transfer, the membrane was blocked with 5% fat-free milk in TBS-
T  for  1h.  Tween-20  is  a  mild  detergent  that reduces non-specific binding of antibody 
to lipid and protein. After three washes with TBS-T to remove excess milk, the membrane 
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was incubated with the respective primary antibodies diluted in 5% BSA in TBS-T at 4°C 
overnight. The following day, the membrane was washed with TBS-T to remove 
unbound primary antibody, and then incubated with 1:5000 dilution of IgG-HRP-
conjugated secondary antibodies in 5% (w/v) fat-free milk in TBS-T for one hour at 
room temperature. After three washes with TBS-T to remove unbound secondary 
antibodies, the probed proteins were detected using chemiluminescence on Kodak 
Biomax MR X-ray film with enhanced SuperSignal Chemiluminescent Substrate 
(PIERCE, IL, USA). Human anti-mouse DP103  antibody (1:1000 dilution) and human 
anti-mouse p21  antibody (1:1000 dilution) were purchased from BD Transduction 
Laboratories (San Diego, CA). Human anti-rabbit β-actin antibody (1:5000) was 
purchased from Sigma-Aldrich (MO, USA). Human anti-rabbit ERα antibody (1:1000), 
human anti-mouse p53 antibody (1:1000), and human anti-rabbit p53 antibody (1:1000) 
antibodies were purchased from Santa Cruz, CA, USA. Human anti-rabbit SUMO1 
(1:1000) and human anti-rabbit SUMO2/3 antibodies (1:1000) were obtained from 
Abcam. Human anti-rannit acetyl-p53 antibody (1:1000) was purchased from Cell 
Signaling. Goat anti-mouse and goat anti-rabbit secondary antibodies tagged with Horse 
Radish Peroxidase (HRP) enzymes were obtained from Cell Signaling (MA, USA).  
2.2.8 siRNAs AGAINST DP103 AND TP53 
siRNAs (Stealth RNAi) against the non-conserved coding regions of DP103 
were obtained from Invitrogen, Life Technologies (Grand Island, NY, USA). Sequence 1 
referred to as siDP103#1 (GAU UCC UUG UCU GUC UUC CUU UAA A) and sequence 
2 referred to as siDP103#2 (CCA GUG AUC CAA GUC UCA UAG GUU U) were used 
individually for knock-down experiments as indicated. siRNA sequence for ERα (GCU 
ACU GUG CAG UGU GCA AUG ACU A), referred to as siERα, was obtained from 
Invitrogen. siRNA sequence for p53 (S102655170), referred to as sip53, was obtained 
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from Qiagen (Valencia, CA, USA). Control siRNA (GGAAAUUUGCGUGUGGAGUTT) 
was obtained from Qiagen as well.  
2.2.9 PLASMID CONSTRUCTS 
Full length-hFLAG-DP103-pcDNA3 was cloned from full length 2FLAG-hDP103, 
a kind gift from Christopher Glass from Univeristy of California, San Diego (248). Full 
length-hTP53-pcDNA3 and full length-hESR1-pcDNA3 that overexpressed the TP53 and 
ERα gene, respectively, were generous gifts from Prof. Frances Fuller-Pace, University of 
Dundee, UK. The plasmid backbone pcDNA3, without the DP103 or TP53 gene inserts, 
served as the empty vector (EV) control.  
2.2.10 TRANSFECTIONS 
For transient transfections, 2 x 10
5 
cells or 3 x 10
5 
cells were plated per 6-well 
plate for siRNA or plasmid transfection respectively. After 48hours, transfections were 
carried out using Lipofectamine RNAiMAX (Invitrogen, Life Technologies, Grand 
Island, NY, USA) for siRNA or Lipofectamine 2000 (Invitrogen, Life Technologies, 
Grand Island, NY, USA) for plasmids, according to the manufacturers’ instructions. 
Lipofectamine RNAiMAX and 50nM of siRNAs were separately diluted in serum-free 
media for 5min before mixing together for another 20min of incubation at room 
temperature. The mixture was then added dropwise to the cells and returned to the 5% 
CO2  incubator for overnight transfection. After 24h, the media was removed, cells washed 
with 1X PBS and supplemented with fresh complete media till day of harvest or drug 
treatment or any subsequent step. For plasmid transfection, the same protocol used above 
was followed, with the replacement of siRNAs with the respective plasmid. 
2.2.11 MEASUREMENT OF CELL VIABILITY USING MTT 
Cell growth/cytotoxicity was assessed by determining the mitochondrial 
activity of the cells that corresponds to the health and viability of the cell. MTT 
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assay is based on the ability of mitochondrial dehydrogenase enzyme from viable 
cells to cleave the tetrazolium rings of the pale yellow MTT and form dark blue formazan 
crystals which is largely impermeable to cell membranes, thus resulting in its 
accumulation within healthy cells. Three hours before the end of treatment, MTT solution 
was added into each well containing cells at 1:10 dilution. The cells were then 
incubated at 37°C with 5% CO2. Three hours after the incubation, the medium was 
removed carefully with a pipette tip and DMSO was added to each well to solubilize the 
crystals. The number of metabolically active cells is directly proportional to the level of 
formazan product formed. The quantity of formazan present was determined by  
measuring  its  absorbance  at  570nm  using  the  Spectrofluoro  Plus spectrophotometer 
(TECAN, GmbH, Grödig, Austria). 
2.2.12 MEASUREMENT OF CASPASE 3/7 ACTIVITY 
Caspase-Glo 3/7 Assay System from Promega (G8090) was used to measure the 
caspase 3/7 activity in the cells upon drug treatment. It being a luminescence based assay, 
cells were plated and seeded in white opaque 96-well plates. Upon completion of the 
experiment, reconstituted Caspase-3/7 substrate is added into each well at 1:10 dilution 
and allowed to incubate for 4 hours, before luminescence was measured using a 
luminescence plate reader. The luminescence read-out would be a measurement of the 
amount of caspase-3 and caspase-7 activity in the cells. 
2.2.13 LUCIFERASE-BASED PROMOTER ASSAY 
To measure the transcriptional activity of transcriptional factors such as ERα and 
p53, cells are transfected with a luciferase-reporter construct, where the luciferase reporter 
gene is downstream of the transcriptional factors' consensus binding sequence. In case of 
ERα, the pERE3-TATA-luc plasmid containing six tandem repeats of ERE promoter 
sequences coupled to the luciferase gene was used. Luciferase reporter constructs under 
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the control of p53-responsive promoters, included  pPG13-Luc (the polyomavirus early 
promoter and 13 copies of a synthetic consensus p53‐binding site), and the pGL3-p21-Luc 
(the CDKN1A (p21) promoter). A thymidine kinase promoter Renilla luciferase reporter 
plasmid (RLTK) was used to control for transfection efficiency. All these plasmids were a 
kind gift from Prof. Frances Fuller Pace, University of Dundee, UK. Cells are transfected 
with the respective luciferase reporter plasmid together with Renilla plasmid (Clonetech, 
CA, USA) using Lipofectamine 2000 and manufacturer's instructions. Feeding medium 
was removed from the wells, washed once with 1X PBS, and lysed with ice-cold 100l of 
reporter lysis buffer for a 24-well plate format. The promoter activity was assessed with a 
dual-luciferase assay kit (Promega, Madison, WI). Ten microlitres of cell lysate was then 
added to 50l of luciferase substrate solution to read out the promoter bound luciferase 
value. This is followed by addition of 50l of stop & glow buffer to read out the Renilla 
reading. Bioluminescence generated was measured using a Sirius luminometer (Berthold 
Technologies, Herefordshire, UK). Luminescence reading (ratio of luciferase to renilla) 
was normalized to the protein concentration of the corresponding cell lysate and presented 
as fold difference with reference to the control setup.  
2.2.14 ANCHORAGE-INDEPENDENT CLONOGENIC ASSAY 
A few thousand cells are plated so that they can form distinct colonies at the end of 
the assay. 4000 cells for MCF7 and 8000 cells for T47D were seeded in triplicates in a 6-
well plate, with the media changed every 3 days. In case of a transfection or drug 
treatment, above-mentioned cell numbers are re-seeded post transfection and/or drug 
treatment. After 14 days, cells were washed with PBS and incubated with crystal violet 
solution for ten minutes. Excess crystal violet solution was diligently washed away with 




2.2.15 IMMUNOPRECIPITATION (IP) 
For detection of endogenous protein interactions, whole cell lysate was prepared. 
A total of 3 x 10
6  
cells were treated as indicated and cell pellets lysed in IP lysis 
buffer. 500ug of proteins were pre-cleared with Sepharose G beads (GE Healthcare) for 
1h before rotating with 2μg of indicated antibody or normal mouse or rabbit IgG 
overnight at 4°C to allow antigen-antibody interactions to occur. For pull-down purposes, 
human anti-mouse DP103, human anti-mouse ERα and human anti-mouse p53 
antibodies, were purchased from Santa Cruz. Corresponding IgG control was also 
purchased from Santa Cruz. 30μl of beads were added the next day to allow the capture 
of antigen-antibody complexes onto the beads. After 1½h of rotation,  beads were washed 
four times in cold wash buffer (IP wash buffer). The samples were boiled in 5x SDS 
loading buffer, and proteins were separated by SDS- PAGE. Proteins were then transferred 
to nitrocellulose membranes and subjected to western blotting with the indicated 
antibodies. 
2.2.16 CHROMATIN IMMUNOPRECIPITATION 
Chromatin immunoprecipitation (ChIP) assay was performed as described as 
follows. MCF-7 cells were cultured in phenol-red free RPMI with charcoal treated FBS for 
3 days before treatment with 100nM of E2 for 45 minutes. In case of DP103 knock-down 
experiments, cells were transfected with SiControl or SiDP103 (50nM) using 
Lipofectamine RNAimax for 72 hours, before E2 treatment. Cells were cross-linked by 1% 
formaldehyde for 10 min at room temperature with continuous rocking. To quench the 
reaction, glycine (0.125M) was added followed by washing twice in ice cold phosphate-
buffered saline. Lysis and sonication of the cross-linked pellets was performed to obtain ~ 
500-bp fragments. Debris was then removed by centrifugation; the supernatant was diluted 
10 times by adding ChIP dilution buffer. 1 μg of rabbit anti-ERα antibody (Santa Cruz, 
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CA, USA) was used for ChIP, with rabbit IgG (Santa Cruz) as control, and the tubes were 
rocked overnight at 4°C. 40μl of protein A agarose beads (Santa Cruz Biotechnology) 
were added, and the samples were incubated with constant rocking for 1 hour at 4°C. The 
beads were then washed with low salt wash buffer (20mM Tris, pH 8.1, 2mM EDTA, 
50mM NaCl, 1% Triton X-100, 0.1% SDS) for 5 min at 4°C, followed by one wash with 
high salt wash buffer (10mM Tris, pH 8.1, 1mM EDTA, 0.25M LiCl, 1% Nonidet P-40, 
1% deoxycholic acid) for 5 min at 4°C and then washed with LiCl wash buffer for 5 min at 
4°C. Two washes with cold Tris-EDTA (TE) buffer were performed. After eluting using 
250μl of elution buffer (100mM sodium bicarbonate, 1% SDS) for 15 min at room 
temperature, 10μl of 5M NaCl was added, and the cross-links were reversed at 65°C 
overnight. The samples were then treated with proteinase K for 1 hour. The DNA was 
purified using a Qiagen PCR purification kit. 50μl of each ChIP product was recovered. Q-
PCR was performed using the following conditions: 95°C for 30s, 60°C for 1 min, and 
72°C for 30s, for 40 cycles. DNA from ChIP assay on E2 treated MCF7 cells was 
sequenced to search for an ERα binding site on DP103 promoter region, Details of the 
ChIP primers are in Supplementary Table 4.  
2.2.17 IMMUNOFLUORESCENCE STAINING 
For immunostaining of protein co-localization between DP103 and ERα within the 
cell, cells were seeded onto cover slips in 24-well plates in charcoal-stripped FBS 
containing media. After 48 hours, cells were treated with estradiol for indicated time 
points. Upon completion of the experiment, contents from the well were removed, and 
PBS wash was given once. Cells on the cover slips were then fixed with 4% Para-
formaldehyde for 15 minutes at room temperature. After two washes with 1X PBS, cells 
membrane was allowed to permeabilize with 0.2% of Triton X-100 (Sigma-Aldrich, LO, 
USA) for 15 minutes at room temeperature. Cells were washed twice with PBS. Cells were 
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then incubated overnight at 4⁰C with primary antibody against DP103. The next day, after 
2 more washes with PBS, cells were incubated overnight at 4⁰C with primary antibody 
against ERα. For primary antibodies, anti-rabbit DP103 (Proteintech) and anti-mouse ERα 
antibody (Santa cruz) were selected. After both the primary incubations, cells were washed 
twice with PBS, and incubated with Alexa Fluor 488 rabbit anti-mouse IgG and Alexa 
Fluor 594 goat anti-rabbit IgG (Invitrogen) for 2 hours at room temperature. After last 2 
PBS washes, cover slips were mounted with mounting medium containing DAPI nuclear 
stain, before confocal analysis using Olympus FluoView 1000 (FV 1000; Olympus, 
Japan), with identical acquisition parameters for the same image session. Pictures were 
analyzed with Olympus FLUOVIEW Version 1.7a Viewer.  
2.2.18 DOCKING ANALYSIS OF INTERACTION BETWEEN DP103 AND p53 
Crystal structures of p53 and DP103 were obtained from protein data bank (405, 
406) (PDB ID 2XWR and 3B7G). Solvent molecules were removed using PyMol and the 
crystal structures were docked using ZDOCK (407, 408). No contact residues or restraints 
were applied during docking to get unbiased docking calculations. Top ten best docked 
positions were chosen to further analyze the results. Hydrogen atoms were added to the 
docked structures and these structures were minimized to remove any short contact using 
InsightII (Accelrys Inc. Sandiego CA) software using steepest descent method. Quality of 
the final structures were evaluated by molprobity (409, 410) and analysis was carried out 
by PyMol software. 
2.2.19 STATISTICAL ANALYSIS FOR IN VITRO STUDY 
Statistical analyses for all in vitro experiments were performed using the SPSS 
package (version 15.0 for Windows, SPSS Inc., USA). The Student's t-test analysis was 




2.3 BUFFER AND REAGENT PREPARATION 
 Phosphate buffered saline  (PBS) 
137mM NaCl, 2.7mM KCl, 4.3mM Na2HPO4, 1.4mM KH2PO4, pH 7.4 
 
 Agarose Gel Electrophoresis 
10X TBE: 0.89M Tris, 0.89M Boric Acid, 0.02M EDTA 
 
  6X Sample Loading Buffer 
0.25% (w/v) Bromophenol blue, 0.25% (w/v) Xylene cyanol, 30% (v/v) glycerol 

 SDS-PAGE and Western Blotting 
Tris, pH 8.8: 1.5M Tris base, 0.4% (w/v) SDS, pH adjusted to 8.8 with concentrated  
HCl 
 
Tris, pH 6.8: 0.5M Tris base, 0.4% (w/v) SDS, pH adjusted to 6.8 with concentrated 
HCl 
 
10X SDS-PAGE Running buffer: 0.25M Tris base, 1.92M Glycine, 1% (w/v) SDS 
1X Transfer buffer: 0.025M Tris base, 0.192M Glycine, 20% Methanol 
1X TBS-T: 50 mM Tris HCl (pH 7.4), 150 mM NaCl, 0.1% Tween-20 
Blocking buffer: 5% skim milk powder in 1X TBS-T 
5X Loading Dye: 0.25M Tris HCl (pH 6.8), 0.5M DTT, 0.25% Bromophenol blue, 
50% glycerol, 10% SDS 
 SDS-PAGE gel 
10% Resolving gel (10ml) 
30% Acrylamide  3.3ml 
1.5M Tris (pH 8.8) 2.5ml 
10% SDS   0.1ml 
10% APS   0.1ml 
TEMED   0.004ml 
dH2O   4.0ml 
 
5% Stacking gel (3ml) 
30% Acrylamide  0.5ml 
1.0M Tris (pH 6.8) 0.38ml 
10% SDS   0.03ml 
10% APS   0.03ml 
TEMED   0.003ml 
dH2O   2.1ml 
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 Protein extraction 
1X RIPA buffer: 50mM Tris at pH 7.5, 150mM NaCl, 1% v/v NP-40, 1% v/v  
deoxycholic acid, 0.1% v/v SDS and 1mM EDTA.  
 
Immunopreciptation (IP) lysis buffer: 50mM Tris (pH 7.4), 150mM NaCl,  
0.5% NP-40. 
 
IP wash buffer: 200mM Tris (pH 8), 100mM NaCl, 0.5% NP-40, 2mM DTT.  
To the buffers above, protease and phosphatase inhibitors including PMSF, leupeptin, 
pepstatin A, aprotinin  and Na3VO4  were added freshly before use. 
 Crystal violet solution 
0.75% crystal violet, 50% ethanol, 1.75% formaldehyde, 0.25% NaCl 
 
 MTT Solution 






























CHAPTER 3- RESULTS 
3.1 CORRELATION OF DP103 EXPRESSION WITH BREAST CARCINOGENESIS 
Our lab recently reported DP103's role in increasing metastatic potential in breast 
cancer (256). With less than 30 publications concerning DP103 on pubmed, and very little 
data on its role in carcinogenesis, we set out our initial investigation by comparing the 
expression of DP103 between normal and breast cancer samples.  
3.1.1 COMPARISON OF DP103 EXPRESSION BETWEEN NORMAL AND BREAST 
TUMOR TISSUES 
To achieve this, we extracted a microarray data-set available from the public 
domain 'The Cancer Genome Atlas' (TCGA; http://cancergenome.nih.gov/). The data-set 
consisted of Agilent custom gene-expression microarray (G4502A_07) performed on 536 
invasive ductal breast cancer samples and 63 normal tissue samples. The data was 
imported to Partek ® Genomics Suite 6.6, where the log ratio of gene expression value 
was quantile normalized for further analysis. The 536 invasive ductal breast cancer 
sample-set, however, was a mixture of breast cancer (BC) molecular subtypes. These 
subypes were identified using molecular subtype signature obtained from Prat et al., 2010 
(411). Subsequently, single sample Gene Set Enrichment Analysis (ssGSEA) was 
computed based on the BC subtype signature for each sample. Each sample was then 
assigned to be the subtype that it has the maximum ssGSEA score for. DP103 expression 
was then compared between the invasive ductal BC sample-set (n=536), that comprised of 
luminal and basal subtypes, and normal breast tissue sample-set (n=63).  
It was observed that DP103 mRNA expression is significantly higher in invasive 
ductal carcinomas compared to normal breast tissues (p=0.0156, for normal vs. all 
subtypes combined) (Figure S1). Upon comparison with individual subtypes, normal 
breast tissues had significantly lower DP103 expression compared to the basal subtype 
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(p=2.85e-6), although there was no significant difference between normal and luminal 
subtype (p=0.109, Figure S1). It is however to be noted that basal subtype, which is the 
most aggressive subtype, has significantly higher DP103 expression that the luminal 
subtype (p=1.25e-6, Figure S1), consistent with findings from our lab's report earlier this 
year (256).  
3.1.2 COMPARISON OF DP103 EXPRESSION BETWEEN NORMAL EPITHELIAL 
AND BREAST CANCER CELL LINES 
Using the same approach as in 3.1.1, we then sought to determine the difference in 
DP103 expression between normal and breast cancer cell lines. Breast cancer cell line 
data-set for 20 cell lines with accession number GSE13915 was downloaded from Gene 
Omnibus (GEO). As for molecular subtype of breast cancer cell line, it was assigned 
based on the reported subtype in Neve et al., 2006 (398). Similar to the findings in Figure 
S1, we confirmed that DP103 mRNA expression in breast cancer cell lines with either 
basal (n=7) or luminal (n=8) subtype, is significantly higher than normal breast fibroblasts 
(n=5) (p=0.0012 for normal vs. all subtypes combined) (Figure S2). Individually, there 
was significant difference in DP103 expression between luminal and normal (p=0.0016), 
basal and normal (p=0.0025), but no significance was observed between luminal and basal 
(p=0.281), in a bit of a deviation from what we observe for tumor tissues above.  
Combining the results in Figure S1 and S2, we show that DP103 is highly 
expressed in breast tumor tissues and cell lines, and could thus be a potential novel 
oncogene whose functions in oncogenicity needs to be explored further.   
3.2 EFFECT OF DP103 DEPLETION ON CELL PROLIFERATION 
Oncogenes render a positive impact on tumor growth through a variety of 
mechanisms. Hanahan and Weinberg's hallmarks of cancer include an enhanced 
replicative potential that the oncogene imparts on the cancer cell, enabling them to 
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proliferate at an uncontrolled rate (412). Having observed that breast tumor and cancer 
cells tend to possess a higher expression of DP103, we next questioned if DP103 played 
any role in the aberrant growth and proliferation of cancer cells. 
3.2.1 EFFECT OF DP103 DEPLETION ON CELL PROLIFERATION RATE 
To achieve this, we silenced DP103 in two breast cancer cell lines MCF7 and 
T47D. Two different siRNAs against DP103 were used (SiDP103#1 and SiDP103#2), 
with control siRNA used as a negative control. Cells were transfected with 50nM of the 
respective siRNAs in a 10cm dish, and equal number of cells re-seeded in 96-well plates 
the next day (day 1). Cell viability was measured using MTT at different time points post-
transfection, including day 3, 6, 9, 12 and 15. Clearly, silencing of DP103 drastically 
affected the cell proliferation rate of both the cell lines (Figure 6). We realized that DP103 
silencing may not have a significant impact on short term cell viability, and the 
difference in proliferation rate between control and knockdown set starts building up after 
6 days of DP103 silencing. More experiments are needed to determine if DP103 
silencing had any influence on cell cycle and apoptotic regulation.  
    
Figure 6. Depletion of DP103 reduces Cell Proliferation rate. MCF7 (A) and T47D 
cells (B) were seeded in 10cm dishes and transfected with either control siRNA or 
siRNAs against DP103 (SiDP103#1 and SiDP103#2). After 24 hours (Day 1), cells 
were re-seeded into 96 well plates. Cell viability was measured on Day 3, 6, 9, 12 
and 15 using MTT assay. The percentage of cell viability was then calculated, setting 
the absorbance reading on Day 3 for each category as 100%. Data represents the average 
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reading of three independent experiments. *P < 0.05 
 
3.2.2 EFFECT OF DP103 DEPLETION ON CLONOGENIC GROWTH 
Clonogenic assay or colony formation assay is an in vitro 2-D cell growth assay 
based on the ability of a single cell to grow into a colony. Cancer cells possess this 
property where every cell in its population can undergo 'unlimited' division to produce 
individual colonies. In the same experimental set-up as above, we also looked at the effect 
of DP103 silencing on long term anchorage-independent clonogenic ability of breast 
cancer cells. Equal number of transfected cells were re-seeded in 6-well plates the next 
day. Cells were allowed to grow for the next two weeks in the same dish and media 
changed every 3 days. At the end of the assay, colonies were stained with crystal violet 
solution. It can be observed that silencing of DP103 drastically reduced the clonogenic 
ability of both the cell lines (Figure 7). This affirms DP103's role as a novel oncogene, 
playing a critical role in breast cancer cells' ability to proliferate and grow in an 
anchorage-independent manner. It has to be noted that T47D forms much smaller colonies 
than MCF7. 
   
Figure 7. Depletion of DP103 reduces clonogenic ability of breast cancer cells. 
MCF7 (A) and T47D cells (B) were seeded in 10cm dishes and transfected with either 
control siRNA or siRNAs against DP103. After 24 hours, cells were re-seeded in 
triplicates into 6 well plates. Anchorage-independent growth was measured by 




3.2.3 EFFICIENCY OF DP103 KNOCKDOWN 
Assays in section 3.2.1 and 3.2.2 involved knock-down transfections. It is thus 
important to ensure that knockdown of DP103 indeed worked. We ran MCF7 and T47D 
lysates representing DP103 knockdown on day 3. Evident from the figures below, the 
knockdown efficiency was pretty good (Figure 8).  
                    
Figure 8. DP103 knockdown efficiency in MCF7 and T47D. Cell lysates 
representing DP103 knockdown with SiDP103#1 and SiDP103#2, in MCF7 (A) and 
T47D cells (B), on day 3, post transfection. 
 
3.3 ROLE OF DP103 IN BC CHEMORESPONSE 
Prompted by DP103's potential novel oncogenic role, combined with an earlier 
report of DP103's role in p53 repression (255), we were curious to explore DP103's role in 
drug response. We wanted to start with looking at if DP103 expression profile could bear 
any association with clinical response to chemotherapy. In other words, we were 
wondering if DP103 could serve as a biomarker of chemotherapy response. Biomarkers to 
drug responses are generally identified using gene- and protein-expression profiling of 
drug-treated patient samples (413). To achieve this, we collaborated with Dr. Lee Soo 
Chin to utilize patient data-set and frozen samples from her prospective phase II study, 
that studied serial changes in several key cellular genes and proteins upon neoadjuvant 
chemotherapy (399). This neoadjuvant chemotherapy was a combination of docetaxel and 
doxorubicin, that has been highly preferred in the treatment of advanced breast cancer.  
3.3.1 CLINICAL AND TUMOR CHARACTERISTICS 
Hundred female patients were recruited and randomized to two treatment arms 
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with sequential administration of 75mg/m
2 
of either docetaxel (T) or doxorubicin (A) (A-
T-A-T-A-T, n=49, denoted as sequence 1; T-A-T-A-T-A, n=51, denoted as sequence 2). 
The entire schematic of the clinical study is in Figure 9. The drugs were administered 
every 3 weeks for six cycles. Bi-dimensional tumor assessments were performed at every 
cycle to determine tumor clinical response. Accordingly, clinical responders were 
categorized as those who achieved complete or partial response, while non-responders 
were those who achieved only stable or progressive disease as their best overall response 
after 6 cycles of chemotherapy. Tumor core biopsies were taken from each patient at 4 
time points: before chemotherapy (baseline), 3 weeks after the first, second and sixth 
cycle of chemotherapy, for DP103 immunohistochemistry (IHC) and transcript level 
analysis. Further details are given in materials and methods.  
 
Figure 9. Schematic diagram for chemotherapy study. 
 
Baseline patient and tumour characteristics are as follows. The median age of 
patients was 50, ranging from 26 to 68. The patient cohort represented different races, 
including 65 Chinese, 26 Malay, 7 Indian and 2 others. Of these, 31 possessed metastatic 
disease. Tumors belonged to different grades as well, with 7 patient tumors belonging to 
grade 1, 45 tumors to grade 2, 39 tumors to grade 3, and 9 tumors were unknown. The 
objective clinical response rate with neoadjuvant chemotherapy was 83.6% (11.2% CR, 
72.4% PR). There was no difference in the clinical response rate between the two 
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treatment arms (P = 0.12).  
3.3.1.1 CHANGES IN DP103 mRNA EXPRESSION WITH CHEMOTHERAPY 
Now that the data-set and samples from the 2011 study were available, we then 
questioned if there was any correlation between DP103 expression and chemoresponse. 
Tumor transcript levels of DP103 at baseline and after one cycle of chemotherapy were 
analyzed. Upon analysis, there was no correlation between baseline and post-
chemotherapy expression of DP103 mRNA with tumor-stage, presence of metastatic 
disease, progression-free or overall survival (Supplementary Table 1 and 2). However, 
clinical responders exhibited significantly lower baseline and post-treatment DP103 
mRNA expression levels compared to non-responders (baseline mean expression 
2321±949 vs 3040±1303, p=0.036; post-treatment mean expression 2092±778 vs 
3019±1030, p=0.004; Figure S3). Alternatively, this piece of data could also be construed 
as DP103 expression decreasing with chemotherapy in case of responders (baseline 
expression 2321±949 vs post-treatment expression 2092±778), but not in case of non-
responders (baseline expression 3040±1303 vs post-treatment expression 3019±1030). 
The above analysis was done on all patient samples combined, irrespective of their 
hormone-receptor status. However, it is known that different BC molecular subtypes 
exhibit differential response to chemotherapy. Especially, ERα-positive and ERα-negative 
tumors could have varied responses to many chemotherapies. We then wondered if ER 
status re-defined the way DP103 mRNA expression profile associated with 
chemoresponse. Stratification of patients by the receptor status revealed 64 ERα-postive 
and 36 ERα-negative patients. Upon analysis, ERα-positive patients had greater relative 
chemotherapy-induced reduction in DP103 mRNA expression levels than ERα-negative 
tumors (mean relative chemotherapy-induced change -0.09±0.32 vs 0.11±0.35, p=0.047; 
Figure S4A). No difference in baseline or post-treatment DP103 mRNA expression levels 
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was observed between responders or non-responders with ERα-negative tumors (Figure 
S4B). In contrast, ERα-positive tumors had significantly lower post-treatment DP103 
mRNA expression levels than ERα-negative tumors (mean post-treatment expression 
2021±694 vs 2565±1015, p=0.021, Supplementary Table 1). In addition, among ERα-
positive patients, responders had numerically lower baseline (mean expression 2304±889 
vs 2914±1175, p=0.173; Figure S4C) and significantly lower post-treatment DP103 
mRNA expression levels (mean expression 1825±444 vs 3485±396, p<0.001; Figure S4C) 
than non-responders. Alternatively, there is a decrease in DP103 expression with 
chemotherapy among ERα-positive responders (2304±889 vs 1825±444), and a slight 
increase (2914±1175 vs 3485±396) among ERα-positive non-responders.  
From section 3.3.1.1, we observe that DP103 mRNA expression profile serves as a 
predictive marker of chemotherapy response. A decrease in DP103 transcript levels 
corresponded with a favourable response, with the non-responders showing no change. 
Upon stratification by receptor status, DP103's biomarker potential was limited to only 
ERα-positive patients, where a decrease in its expression was observed only in responders 
with receptor positive status.  
3.3.1.2 CHANGES IN DP103 PROTEIN EXPRESSION UPON CHEMOTHERAPY 
To further validate the observed trend in DP103 mRNA expression profile above, 
we stained patient tissues from the same study for protein expression of DP103 by 
immunohistochemistry (IHC). However, unlike mRNA analysis that took into 
consideration only baseline and post-cycle 1 samples, protein analysis was done on 
samples at all four-collection points. Thus, IHC analysis of DP103 would be more 
comprehensive and representative of changes that happen during chemotherapy.  
IHC analysis showed no correlation between baseline and DP103 expression after 
different cycles, with tumor-stage, presence of metastatic disease, ERα status, clinical 
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response, progression-free or overall survival (Supplemetary Table 3 and 4). However, a 
progressive decrease in DP103 positivity was observed in responders, with increasing 
number of chemotherapy cycles (55%, 42%, 34% and 29% at baseline, after 1, 2, and 6 
chemotherapy cycles respectively, p=0.022), but not in case of non-responders. 
Chemotherapy-induced change in DP103 protein expression was observed to be 
decreasing with different cycles of chemotherapy in clinical responders (p=0.002, Figure 
S5A) but not in non-responders (p=0.225, Figure S5A). Representative IHC images show 
DP103 staining intensity to be decreasing with chemotherapy from 3+ to 1+ for a clinical 
responder with Partial Response (Figure S5B), whereas representative non-responder with 
Progressive Disease showed no change (remained 3+ throughout) (Figure S5B). When 
patients were stratified by ERα status, a decrease in DP103 protein expression was 
observed in tumors with ERα positive status (Figure S5C, p=0.02 and Figure S5D) but not 
ERα-negative status (Figure S5C, p=0.664 and Figure S5D).  
Thus, we see that protein profile of DP103 complement mRNA expression profile 
in predicting chemotherapy response. A decrease in both mRNA and protein expression 
corresponded with a favourable response, predominantly in patients with ERα-positive 
status, whereas, a non-favourable response was associated with no change in DP103 
expression.  
3.3.1.3 DP103- A CHEMORESPONSE MARKER FOR DOCETAXEL OR 
DOXORUBICIN? 
So far, we have determined that expression change in DP103 associates with 
chemoresponse in breast cancer, with this association significant only in case of ER-
positive breast cancer. The chemotherapy regimen in this study included sequential and 
alternative treatment of docetaxel and doxorubicin. These are drugs that mediate their 
effects through separate mechanisms, targeting different molecular pathways. Microarrays 
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have shown different drugs affecting expression of different genes. We next asked if 
DP103 expresion profile showed a similar or differential response to docetaxel and 
doxorubicin.  
To achieve this, we analyzed samples at the end of the very first cycle of 
chemotherapy. Figure 12 shows that treatment arm 1 included sequential addition of 
doxorubicin followed by docetaxel, and treatment arm 2 included docetaxel followed by 
doxorubicin. Hence, analysis of samples at the end of cycle 1, until which patients have 
been subjected to only one of the two drugs, would give us a view of the effect of the 
individual drugs. When patients, who were randomized to start with either doxorubicin or 
docetaxel in the first cycle, were analyzed separately to determine drug-specific effects, 
no significant doxorubicin-induced DP103 expression change was observed in either 
ERα-positive or negative tumors. However, one cycle of docetaxel induced significant 
reduction in DP103 gene expression in ERα-positive, but not ERα-negative tumors (mean 
relative expression change of -0.22±0.23 vs 0.15±0.47, p=0.024; Figure S6). 
Thus, we observe that the expression profile of DP103 serves as a predictive 
marker of docetaxel and not doxorubicin response. Moreover, DP103 expression profile is 
able to predict docetaxel response only in patients with ERα-positive status.  
3.3.2 IN VITRO AND CELL-LINE CHARACTERISTICS 
To validate the clinical data on DP103's biomarker role in chemotherapy, we made 
use of breast cancer cell lines. We would like to see if we could reiterate the clinical data 
in an in vitro scenario. To represent ERα-positive and -negative breast cancer patients, we 
chose MCF7 and T47D as ERα-positive cell lines, and MDA-MB-231 and BT-549 as 
ERα-negative cell lines. It has to be remembered that these wild-type cell lines are like the 
clinical responders, responding well to the drugs in an in vitro scenario. Cell viability was 
determined with docetaxel treatment for 72 hours in MCF7, T47D and MDA-MB-231, 
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and the viability data showed that the drug was equally effective in all these cell lines 
(Figure 10 A), with the IC50 between the range of 3nM and 10nM (Figure 10 B). This 
implied that these cell lines were almost equally responsive to docetaxel, and no one cell 
line was inherently more resistant than the others. This is a reason why we ruled out 
studying inherent resistance to the drugs anywhere in this project, and focussed our efforts 
only on acquired resistance to docetaxel.   
 
Figure 10. IC50 of docetaxel. Computation of IC50 of docetaxel in MCF7, T47D and 
MDA-MB-231 cells. Cells were treated with docetaxel for 72 hours, before MTT assay 
was used for measurement of cell viability. Values corresponding to DMSO vehicle 
control for each cell line was converted into 100% and all other values were calculated 
relative to that. The values were then fed into Graph-Pad prism software, to generate the 
IC50 graph (A) and the respective IC50 values (B) for each cell line. The graph in (A) 
has % viability plotted against log of docetaxel concentration.  
 
For our subsequent experiments, drug treatment was carried out in a dose-
dependent manner for a shorter period spanning 24 hours and a longer period spanning 72 
hours. Based on our IC50 calculations above, we chose concentrations between 1nM and 
20nM for 72 hours of drug treatment, and between 10nM and 100nM for 24 hours of drug 
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treatment. Doxorubicin concentrations were chosen to be the same, keeping in view of the 
clinical study where same concentrations of both the drugs (75mg/m
2
) were administered 
to the patients. Upon treatment of the cells for indicated doses or time point, dead and 
floating cells were washed off, and only adherent and metabolically active/viable cells 
were collected to extract either mRNA or protein for further analysis.  
3.3.2.1 EFFECT OF DOCETAXEL AND DOXORUBICIN ON DP103 
EXPRESSION IN ERα-NEGATIVE BREAST CANCER CELL LINES 
We first evaluated the effect of both the drugs on DP103 expression in ERα-
negative cell lines. 100nM of docetaxel was also administered to the cells in a time-
dependent manner, ranging from 2 to 24 hours. In either case, consistent with the clinical 
data, docetaxel did not affect DP103 expression in ERα-negative cell lines, MDA-MB-
231 (Figure 11 A and C and E) and BT-549 (Figure 11 B and D and F). Even doxorubicin 
treatment of these cells did not affect DP103 expression in them (Figure 11 G and H). β-
actin was used as the house-keeping control. 
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Figure 11. Docetaxel and doxorubicin do not affect DP103 protein expression in 
ERα-negative cell lines. Effect of docetaxel (doce) for 24 hours and 72 hours on DP103 
protein expression in MDA-MB-231 (A and C, respectively) and BT-549 (B and D, 
respectively). Effect of 100nM of docetaxel (doce) for different time points in MDA-MB-
231 (E) and BT-549 (F). Effect of doxorubicin (doxo) for 72 hours on DP103 protein 
expression in MDA-MB-231 (G) and BT-549 (H), respectively.  
 
3.3.2.2 EFFECT OF DOCETAXEL ON DP103 EXPRESSION IN ERα-POSITIVE 
BREAST CANCER CELL LINES 
We then went on to look at the effect of docetaxel on DP103 expression in ER-
positive cell lines, MCF7 and T47D. We saw that docetaxel treatment for both 24 and 72 
hours decreased mRNA expression of DP103. The decrease was seen to occur in a dose-
dependent manner (Figure 12). This implies that the drug docetaxel controls the 






   
    
Figure 12. Docetaxel decreases DP103 mRNA expression in ERα-positive cell lines. 
Effect of docetaxel for 24hours and 72 hours on DP103 mRNA expression in MCF7 (A 
and C, respectively) and T47D (B and D, respectively). * P < 0.05.  
 
 We next evaluated the effect of docetaxel on DP103 protein expression in these 
two cell lines. Consistent with the mRNA data, docetaxel decreased protein expression of 
DP103 in a dose-dependent manner, with a decrease starting to occur at 20nM with 24 
hours treatment (Figure 13, A and B) and 5nM with 72 hours treatment (Figure 13, C and 
D). We also treated the cells with a fixed concentration of docetaxel (100nM) over 
different time points. In this case, DP103 protein expression started decreasing as early as 
6 hours of drug treatment (Figure 13, E and F). 
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Figure 13. Docetaxel decreases DP103 protein expression in ERα-positive cell lines. 
Effect of docetaxel (doce) for 24 hours and 72 hours on DP103 protein expression in 
MCF7 (A and C, respectively) and T47D (B and D, respectively). Effect of 100nM of 
docetaxel (doce) for different time points in MCF7 (E) and T47D (F), respectively.  
 
3.3.2.3 EFFECT OF DOXORUBICIN ON DP103 EXPRESSION 
Having tested docetaxel above, we next wanted to study the effect of doxorubicin 
on DP103 protein expression in ER-positive cell lines. Depicted in Figure 14, and 
consistent with the clinical data, doxorubicin was seen to render no effect on DP103 
expression whatsoever.  
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Figure 14. Doxorubicin does not affect DP103 expression in ERα-positive cell lines. 
Effect of doxorubicin (doxo) for 24 hours and 72 hours on DP103 protein expression in 
MCF7 (A and C, respectively) and T47D (B and D, respectively).  
 
3.3.2.4 EFFECT OF DOCETAXEL ON DP103 EXPRESSION IN DOCETAXEL-
RESISTANT CELL LINES 
So far, we have worked with wild-type ER-positive breast cancer cell lines that are 
highly responsive to docetaxel and represent the clinical responders, characterized by a 
decrease in their DP103 expression with docetaxel treatment. In order to study clinical 
non-responders that exhibit acquired resistance, we generated drug-resistant cell line in 
MCF7, that were made to acquire resistance to chemotherapy.  
Viability graph and computed values in Figure 15 A and B, respectively, shows 
that docetaxel-resistant cells (MCF7_DoceR) were close to 6 times more resistant to 
docetaxel when compared to the wild-type cells (MCF7_WT). Upon comparison, there 
did not seem to be a change in the basal protein expression of DP103 between the two, as 
shown in Figure 15 C. We next looked  at the expression of DP103 in the resistant cells 
with docetaxel treatment. Unlike the wild-type cells shown earlier where DP103 
decreases, there was no drug-induced change in DP103 protein expression in these 
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resistant cells (Figure 15 D and E). These observations are in line with the clinical data 
where DP103 expression did not change with chemotherapy cycles in non-responding 
patients.  
                                   
  
           
Figure 15. Characterization and effect of docetaxel on DP103 expression in 
Docetaxel-Resistant cell line. Computation of IC50 of docetaxel in MCF7 wild-type 
parental cell line (MCF7_WT) and its docetaxel-resistant variant (MCF7_DoceR). Cells 
were treated with docetaxel for 72 hours, before MTT assay was used for measurement 
of cell viability. Values corresponding to DMSO vehicle control for each cell line was 
converted into 100% and all other values were calculated relative to that. The values 
were then fed into Graph-Pad prism software, to generate the IC50 graph (A) and the 
respective IC50 values (B). The graph in (A) has % cell viability plotted against log of 
docetaxel concentration. Western blot showing basal DP103 protein expression 
comparison (C) between MCF7 wild-type parental cells (MCF7_WT) and docetaxel-
resistant subtype (MCF7_DoceR). Effect of docetaxel (doce) for 24 hours and 72 hours on 





In summary, we have observed from both clinical and in vitro study, that DP103 
expression decreases with docetaxel treatment in responders and remains unaffected in 
non-responders, among ER-positive patients. This implies that DP103 could serve as a 
promising predictive biomarker for docetaxel response in a subset of breast cancer 
patients with hormone-receptor positive status. 
3.3.3 DP103 MODULATES SENSITIVITY TO DOCETAXEL 
 From studies above, we have inferred that DP103 expression profile associates 
with docetaxel response in ER-positive tumors and cell lines. A decrease in DP103 
expression accompanies a favourable response to docetaxel, whereas, an unfavourable 
response does not any change on DP103 expression. It seems like a decrease in DP103 
expression is required for ER-positive tumors to respond to docetaxel. On the contrary, 
any dysregulated increase in DP103 expression instead, would worsen the drug response 
by helping cells evade drug's effect and survive better. This raises the question if a 
deliberate alteration of DP103 expression could modulate the response of the cells to 
docetaxel.  
3.3.3.1 ALTERATION OF DP103 ON SENSITIVITY TO DOCETAXEL 
  To check if DP103 alteration affected docetaxel senstivity, we modulated the 
levels of DP103 in MCF7 and T47D, by either siRNA-mediated knockdown or plasmid-
based overexpression. Cells were transfected in 10 cm dishes with either Empty Vector 
(EV), DP103 overexpression plasmid (DP103), control siRNA (CtSiRNA) or siRNA 
against DP103 (SiDP103). After 24 hours, cells were re-seeded in 96 well plates. The next 
day, 10nM of docetaxel was added for 24 hours, with DMSO as vehicle control. Viability 
was measured using MTT. Values representing DMSO control were set at 100%, and all 




From the viability data in Figure 16, it is evident that depletion of DP103 
sensitizes the cells to docetaxel, whereas, DP103 overexpression makes the cells more 
resistant. Docetaxel treatment was seen to reduce viability of MCF7 cells by 40-50%, and 
T47D cells by around 30%. DP103 overexpression (DP103) increased resistance of cells 
to docetaxel by around 20% in both MCF7 (Figure 16 A) and T47D (Figure 16 C), 
compared to their respective empty vector sets (EV). On the other hand, depletion of 
DP103 (SiDP103) was shown to increase docetaxel sensitivity by around 40% in MCF7 
cells (Figure 16 B)  and T47D cells (Figure 16 D). Protein samples were analyzed by 
western blot to check for DP103 overexpression (Figure 16 E) and knockdown efficiency 
(Figure 16 F) in MCF7 and T47D cells. 
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Figure 16. Alteration in DP103 expression modulates docetaxel sensitivity. MTT 
assay was used to measure viability of MCF7 (A and B) and T47D (C and D) cells. 
Transfections involved either empty vector (EV), DP103 overexpression (DP103), control 
siRNA (CtSiRNA) or siRNA against DP103 (SiDP103). Cells were either treated with 
DMSO or 10nM of docetaxel. DMSO values were set as 100% and all other values were 
calculated relative to them. Western blot was run to determine the overexpression (E) and 
knockdown efficiency (F) in MCF7 and T47D. * P < 0.05, ** P < 0.01. 
 
3.3.3.2 ALTERATION OF DP103 ON DOCETAXEL-INHIBITED CLONOGENIC 
ABILITY 
Cells's ability to form colonies in presence of constant stress such as drug 
treatment, would enable us to get a measure of the efficacy of the drug and also 
understand the effect of an oncogene in response to that drug. Docetaxel is known to 
cause cell cycle arrest and drastically impair clonogenic ability of the cells. We wanted to 
study if alterations in DP103 could, like in the case of the viability assays above, modulate 
cell's clonogenic ability upon docetaxel induced stress.  
To achieve this, we used the same MCF7 cells from the set-up in 3.3.3.1, that were 
transfected and re-seeded for docetaxel treatment. However, unlike the viability assay 
above, cells were treated with 5nM of docetaxel for 24 hours, before re-seeded again for 
clonogenic assay. 4000 cells were counted and seeded in 6-well plates in triplicates, to 
allow colonies to form in 2 weeks. Upon analysis, 5nM of docetaxel decreases the colony 
forming ability of the cells (Figure 17 A, bottom left panel). DP103 depletion alone 
(Figure 17 A, top right panel) and in combination with docetaxel (Figure 17 A, bottom 
right panel), inhibited clonogenic ability of MCF7 cells much further, with almost no 
colonies observed with docetaxel treatment. In contrast, DP103 overexpression (Figure 17 
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B, right panels) has a lot more colonies than the EV group (Figure 17 B, left panels), both 
with and without docetaxel. DP103 overexpression is thus providing resistance, survival 
and proliferation advantage, rescuing docetaxel-mediated inhibition in clonogenic ability.   
 
 
Figure 17. Alteration of DP103 on docetaxel-inhibited clonogenic potential of cells. 
MCF7 cells were transfected with either CtSiRNA or SiDP103 (A), and EV or DP103 (B). 
Cells are treated for 24 hours with DMSO control, indicated as Vehicle, or 5nM of 
docetaxel, indicated as (Doce), before re-seeded in 6-well plates in triplicates. At the end 
of 2 weeks, colonies were stained using crystal-violet solution and pictures taken. 
 
3.3.3.3 ALTERATION OF DP103 ON DOCETAXEL-INDUCED CASPASE ACTIVITY 
In the previous two sections, we have seen that DP103 modulates senstivity of the 
cells to docetaxel. Depletion of DP103 would increase cell sensitivity and overexpression 
would increase cell resistance. We next wanted to ask if caspases had any role to play in 
DP103-mediated docetaxel response. Docetaxel is known to induce caspase-3/7 activation 
to cause apoptosis. We used Promega's Caspase-Glo 3/7 reagent assay system to measure 
the caspase activity in the cells. In a similar experimental set-up as in section 3.3.3.1, we 
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transfected MCF7 cells with CtSiRNA or SiDP103 or EV or DP103. After 24 hours, cells 
were re-seeded in 96 well white plates compatible for luminescence. Cells were treated 
with docetaxel 10nM for 24 hours, and caspase 3/7 activity measured soon after.  
Upon analysis, we first confirmed that without any gene alteration, there is close to 
50% induction in caspase activity with docetaxel treatment. Further analysis revealed that 
DP103 overexpression had quenched docetaxel-induced caspase-3/7 activation by 30% 
(Figure 18 A). On the other hand, an opposite trend was seen with DP103 knockdown. 
DP103 depletion had potentiated caspase-3/7 activation and increased it by almost double 
with docetaxel treatment (Figure 18 B). These findings suggest that DP103 mediates 
docetaxel sensitivity through modulation of caspase-3/7 channel. 
           
Figure 18. Alteration of DP103 expression on docetaxel-mediated caspase-3/7 
activation. Caspase-3/7 activity was measured in MCF7 cells. Transfections involved 
either empty vector (EV) and DP103 overexpression (DP103) in (A), or control siRNA 
(CtSiRNA) and siRNA against DP103 (SiDP103) in (B). Cells were either treated with 
DMSO or 10nM of docetaxel. DMSO control values were set at 100% and all other values 
were calculated relative to them. * P < 0.05. 
 
3.3.4 ASSOCIATION BETWEEN DP103 AND ERα 
We have observed that docetaxel treatment decreases DP103 expression only in 
ERα-positive patients and cell lines. We next wondered if there was any association 
betwen DP103 and ERα expression, which may be a reason why we see the phenotypes 
only in ERα-positie cases. 
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3.3.4.1 EFFECT OF DOCETAXEL ON ERα EXPRESSION 
To explore why docetaxel-induced decrease in DP103 expression occurs only in 
ERα positive cells, we looked at the expression of ERα itself upon docetaxel treatment. 
This is because an earlier study had reported a paclitaxel-induced decrease in proteins 
levels of ERα (414). In our study, we observed similar findings. ERα exhibited a similar 
expression profile as DP103, with docetaxel decreasing ERα mRNA and protein 
expression in MCF7 (Figure 19 A, C, E) and T47D cells (Figure 19 B, D and F). 
Interestingly, docetaxel treatment did not affect ERα expression in docetaxel resistant 
MCF7 cells (Figure 19, G and H), implying that resistant cells are probably characterised 
by a stabilisation of both DP103 and ERα expression, and suggesting a possible DP103-
ERα axis in chemoresponse to docetaxel.  
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Figure 19. Effect of docetaxel on ERα expression. Effect of docetaxel (doce) for 24 
hours on ERα mRNA expression in MCF7 (A) and T47D (B). Effect of docetaxel (doce) 
for 24 hours and 72 hours on ERα protein expression in MCF7 (C and E, respectively) and 
T47D (D and F, respectively). Effect of docetaxel (doce) for 24 hours and 72 hours on 
ERα protein expression in MCF7-DoceR (G and H, respectively). 
 
3.3.4.2 DP103, A NOVEL ERα-RESPONSIVE GENE 
There has been no previous report on association of DP103 with ERα. Since 
docetaxel treatment decreases both DP103 and ERα expression, we next questioned if a 
cross-talk exists between DP103 and ERα, with a possibility that ERα may regulate 
expression of DP103.  
3.3.4.2.1 ESTROGEN INDUCES EXPRESSION OF DP103 
To achieve this, we carried out experiments to see if DP103 was regulated by ERα. 
We observed an E2-stimulated induction in DP103 expression in ERα-positive cells 
MCF7 and T47D, at both mRNA (Figure 20 A and B, respectively) and protein levels 
(Figure 20 C-F), while no induction in DP103 expression was observed in ERα-negative 
MDA-MB-231 cells (Figure 20 G). The induction in DP103 mRNA levels was seen to 
occur in a time-dependent manner (Figure 20 A and B). To rule out the increase in DP103 
expression due to some E2-mediated artefacts, we observed that E2-stimulated induction 
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in DP103 mRNA expression was abrogated when ERα activity in MCF7 was 
pharmacologically inhibited using anti-estrogens such as 4-hydroxy-tamoxifen (4OHT) 
and fulvestrant (Fulv) (Figure 20 H), validating that DP103 indeed is regulated by an 
ERα-dependent transcriptional process. For the experiment in 20 H, Cyclin D1 (CCND1) 
mRNA level (Figure 20 I) was included as a control for a known ERα-responsive gene. 
We also show that DP103 transcript levels decrease when ERα is silenced in MCF7 
(Figure 20 J) and T47D (Figure 20 K), with TFF1 mRNA levels shown as a control for an 
ERα-responsive gene. In contrast, there was an increased expression of DP103 protein 
when ERα was overexpressed in MCF7 (Figure 20 L).  
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Figure 20. DP103 is an ERα responsive gene. Effect of E2 (100nM) treatment for 
indicated time points on DP103 mRNA levels in MCF7 (A) and T47D (B). Effect of E2 
treatment (24 hours) at indicated doses on DP103 protein levels in MCF7 (C) and T47D 
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(D). Effect of E2 (100nM) treatment for indicated time points on DP103 protein levels in 
MCF7 (E), T47D (F) and MDA-MB-231 (G). Effect of ER modulators (E2 or anti-
estrogens such as 4OHT and Fulv) on DP103 (H) and Cyclin D1 (CCND1) (I) mRNA 
levels in MCF7. Cells were pre-incubated with or without anti-estrogens for 24 hours 
before E2 treatment for another 24 hours. Effect of ERα depletion on DP103 mRNA levels 
in MCF7 (J) and T47D (K), with TFF1 expression shown as a control for a known ERα-
responsive gene. Effect of ERα overexpression on DP103 protein levels in MCF7 (L). *P 
< 0.05. 
 
 These data above establish DP103 as a novel ERα-responsive gene. It is for the 
first time that an association has been established DP103 and ERα, where ERα is 
transcriptionally regulating the expression of DP103. 
3.3.4.2.2 CHIP ASSAY PREDICTS ERα BINDING SITE ON DP103 PROMOTER 
To validate if DP103 was indeed regulated by ERα, we performed an ERα 
Chromatin Immunoprecipitation (ChIP) assay in MCF7. For this, cells were grown in 
charcoal-stripped FBS containing media for 48 hours, before estradiol (E2) stimulation for 
45 mins. Ethanol (ETOH) was used as the vehicle control. ChIP-seq assay done on E2-
stimulated MCF7 cells revealed an ERα-binding site on DP103 promoter region 
approximately 15.8kb upstream of its transcription start site (Figure 21 A, lower panel). 
The binding site differed from ERα consensus (highlighted in red) by a two base-pair 
mismatch, highlighted in blue in Figure 21 (B). This finding was further validated by 
ChIP-qPCR assay showing increased recruitment of E2-stimulated ERα to the putative 
ERα binding site on DP103 promoter (Figure 21 C). The primers used for ChIP-qPCR are 
as follows (FW: 5’-GAC CCT ACC GCA GTG TTT G-3’, RP: 5’-AGT CCC TCC CCG 
TAA AAC TG-3’). This finding, combined with data from Figure 21, confirm DP103 as a 








Figure 21. ERα ChIP predicts an ERα-binding site on DP103 promoter. Screenshot of 
ERα ChIP-seq data showing DP103-associated ERα binding site, approximately 15.8kb 
upstream of the gene transcription start site (A). ChIP assay was performed for MCF7 cells 
treated with or without E2 (100nM) for 45 minutes, and the DNA from the ChIP assay was 
sequenced to determine the binding site. -/+250bp of DP103-associated ERα binding site 
(B) was scanned for presence of ERE. The observed motif (highlighted in red) differed 
only by a 2 base-pair mismatch (highlighted in blue) from the consensus ERE 
(GGTCANNNTGACC). ERα ChIP validation assay performed on MCF-7 cells treated 
with or without E2 (100nM) for 45 min to assess its binding at DP103-associated ERα 
binding site (C). Ethanol (ETOH) was used as vehicle control.  
 
3.3.4.3 CLINICAL ASSOCIATION BETWEEN DP103 AND ERα 
Having established DP103 as a novel ERα-responsive gene in breast cancer cell 
lines, we were curious in knowing if there existed a clinical correlation between 
expression of DP103 and ERα. To achieve this, we obtained 274 human mammary ductal 
tissues (213 IDC and 61 normal cases) from the Singapore General Hospital, Singapore. 
Clinicopathological features of these patients are summarised in Supplementary Table 5. 
Patient tissues were stained for protein expression of DP103 and ERα by IHC. Due to 
tissue loss, only 175 IDC and 38 normal breast tissues were available for evaluation. 
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Analysis showed that DP103 expression is lower among normal ductal tissues (Figure S7 
A) when compared to Luminal A (Figure S7 B) and Luminal B (Figure S7 C) ductal 
carcinomas, which are predominantly ER positive. There was indeed a significant 
correlation of DP103 expression with different ductal tissue types (Figure S7 D). Analysis 
for ERα also showed a similar trend with normal ductal tissue (Figure S7 F) having lower 
ERα expression compared to Luminal A (Figure S7 G) and Luminal B (Figure S7 H) 
ductal carcinomas. There was also a significant correlation of ERα status with different 
ductal tissue types (Figure S7 E). Importantly, we observed a positive correlation between 
DP103 and ERα positivity (Figure S7 I), suggesting that these two molecular players are 
tightly linked in ERα-positive pathogenesis.  
3.3.4.4 EFFECT OF DP103 ON MODULATION OF ERα ACTIVITY 
We have thus far established DP103 as a novel ER-responsive gene, supported by a 
clinical association between the two in patient samples. Members of the DEAD-box 
family, DDX5 and DDX17, have been known to co-activate ERα transcriptional activity 
(193, 230) which prompted us to explore if DP103 could also modulate ERα activity. To 
achieve this, we altered the expression of DP103 and looked at ER transcriptional activity 
and other ER-related functional outcomes. We made use of two conditions, one in which 
cells were grown in complete media (Unstimulated condition) and the other were cells 
were incubated in charcoal-stripped FBS containing phenol-red free media for 48 hours 
before E2 treatment (Stimulated condition). In the unstimulated condition, the complete 
media has substantial levels of estrogen already in the serum, hence it does not require any 
extraneous stimulation with E2. In the stimulated condition, charcoal-stripped FBS is used 
that is deprived of almost all steroid growth factors including estrogen. Hence, any 




3.3.4.4.1 EFFECT OF DP103 ON ERα DNA BINDING ACTIVITY 
Firstly, we looked at ERα transcriptional activity, which can be measured by the 
ERα DNA-binding assay that involves a 6x tandem ERE consensus sequence tagged to 
luciferase reporter construct. Binding of ERα to the ERE could be quantified using the 
luciferase read-out. Cells are altered for DP103 expression, followed by transfection with 
the ERE-luciferase plasmid the next day. Cells were then allowed to grow for two more 
days before any subsequent treatment or cell lysis.  
In the unstimulated condition, siRNA-mediated depletion of DP103 in MCF7 cells, 
decreased ERα DNA-binding activity by around 30% compared to the control siRNA 
transfected cells (Figure 22 A). In contrast, over-expression of DP103 in MCF7 increased 
ERα DNA-binding activity by around 70% compared to the EV transfected cells (Figure 
22 B). Similar results were observed in the E2-stimulated condition. Depletion of DP103 
inhibited E2-induced time-dependent stimulation in ERα activity (Figure 22 C), whereas, 
DP103 overexpression further enhanced E2-induced time-dependent stimulation in ERα 
activity (Figure 22 D). Even in T47D cells, depletion (Figure 22 E) and overexpression 
(Figure 22 F) of DP103 was seen to decrease and increase E2-stimulated ERα activity, 
respectively.  
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Figure 22. Effect of DP103 alteration on ERα DNA-binding activity. Effect of DP103 
depletion (A) and overexpression (B) on ERα DNA-binding activity in MCF7 in 
unstimulated condition. Effect of DP103 depletion (C) and overexpression (D) on E2-
stimulated ERα DNA-binding activity at indicated time points in MCF7. Effect of DP103 
depletion (E) or overexpression (F) on ERα DNA-binding activity with 6 hours of E2 
stimulation in T47D. *P < 0.05, **P < 0.01. 
 
3.3.4.4.2 EFFECT OF DP103 ON ERα-RESPONSIVE GENES 
Concomitantly, we measured changes in transcript levels of ERα-responsive genes 
such as TFF1 and GREB1 upon DP103 alteration. Similar to the results seen in the DNA-
binding assay above, depletion of DP103 in both unstimulated (Figure 23 A and B) and 
E2-stimulated condition at various time points (Figure 23 C-F), reduced mRNA expression 
of ERα target genes in MCF7 and T47D. DP103 depletion is demonstrated by changes in 
its mRNA expression levels in Figure 23 A and B. On the other hand, overexpression of 
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DP103 in MCF7 cells further enhanced E2-stimulated expression of ERα target genes 
(Figure 23 G and H).  
             




                  
Figure 23. Effect of DP103 alteration on ERα-responsive genes. Effect of silencing of 
DP103 on the mRNA expression of ERα target genes such as TFF1 and GREB1 in MCF7 
(A) and T47D (B) in the unstimulated condition. Effect of silencing of DP103 on E2-
stimulated expression of TFF1 and GREB1 at indicated time points in MCF7 (C and D, 
respectively) and T47D (E and F, respectively). Effect of over-expression of DP103 on E2-
stimulated expression of TFF1 and GREB1 at indicated time points in MCF7 (G and H, 
respectively). *P < 0.05. 
 
3.3.4.4.3 EFFECT OF DP103 ON RECRUITMENT OF ERα TO ERE 
Transcriptional factors including ERα, are required to sit on the chromatin to 
execute their transcriptional activity. Many transcription factors have faltered 
transcriptional activity when their recruitment to the chromatin is affected. Having shown 
that DP103 modulates ERα activity and expression of ERα-responsive genes, we next 
wondered if DP103 modulates the recruitment of ERα to the chromatin. We employed 
ChIP assay to determine ERα's recruitment to the ERE binding sites on the promoter 
region of known target genes TFF1 and GREB1 in MCF7 cells. Primers for these known 
ERα-responsive EREs are listed in Table 2. In the absence of E2 stimulation, there was a 
very little enrichment for ERα on the concerned EREs. As predicted, E2 stimulation 
enhanced ERα recruitment to the EREs by 4-fold (compare 2nd and 4th bar in all the 





 bar) to the concerned ERE site on TFF1 (TFF1-ERE, Figure 24 
A) and two known ERE sites on GREB1 (GREB1-ERE1, Figure 24 B and GREB1-ERE2, 
Figure 24 C). Thus, we conclude that DP103 depletion decreases ERα transcriptional 
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activity by affecting its recruitment to the chromatin.  
 
         
Figure 24. Effect of DP103 depletion on ERα recruitment to the chromatin . MCF-7 
cells were transfected with CtSiRNA or SiDP103 for 72hrs, followed by estradiol (E2) 
treatment for 45mins. ChIP assay was carried out using IgG (control) or ERα antibody and 
binding of ERα to the EREs was investigated by qPCR using primers for TFF1-ERE (A) 
and GREB1-ERE1 (B) and GREB1-ERE2 (C). For each PCR, enrichment is shown 
relative to the % of Input, as mean values for three replicates. ***P value < .001, **P 
value < .01, *P value < .05. 
 
Table 2: List of primers used for qPCR for ERα ChIP experiment 
Binding Site        ChIP Primer Sequences 












3.3.4.4.4 EFFECT OF DP103 ON ESTROGEN-STIMULATED CELL GROWTH 
Reports have shown that estradiol promotes growth, proliferation and survival of 
receptor-positive breast cancers (230). Since DP103 modulates ERα transcriptional 
activity, we next asked if DP103 modulated estrogen-dependent cell growth as well. To 
achieve this, we depleted DP103 in MCF7 and T47D cells grown in charcoal-stripped FBS 
containing media, and measured viability using MTT assay after 5 days of E2 treatment. 
Upon analysis, estrogen (E2) stimulated cell growth in both the cell lines (Figure 25 A and 
B, compare bar 1 and 3). Depletion of DP103 was seen to repress E2-driven cell growth 
(Figure 25, A and B, compare bar 3 and 4). We then asked if this novel modulator of ER 
activity had any role in response to anti-estrogen therapy. Would an enhanced ER activity 
modulate sensitivity to anti-estrogens? To achieve this, we tested the effect of anti-
estrogens such as 4-hydroxy-tamoxifen (4OHT) and fulvestrant (Fulv) on cell viability in 
MCF7 cells by MTT assay. Compared to EV transfected cells, DP103 overexpressing cells 
resisted cell death caused by anti-estrogens (1μM of 4OHT and 100nM of Fulv for 5 days) 
(Figure 25 C, compare bar 3 with 4, and bar 5 with 6).  




Figure 25. Effect of DP103 alteration on estrogen and anti-estrogen dependent cell 
growth. Effect of silencing of DP103 on E2-stimulated cell growth in MCF7 (A) and 
T47D (B) cells grown with E2 stimulation for 5 days. Effect of DP103 overexpression on 
cell viability to anti-estrogens such as 4-hydroxy-tamoxifen (4OHT) (1μM) and fulvestrant 
(Fulv) (100nM) in MCF7 (C). *P < 0.05. 
 
These data confirm that DP103 is essentially necessary for ERα-dependent 
transcriptional activity and estrogen-dependent cell growth. On one hand, depletion of 
DP103 decreases ERα-dependent transcriptional activity and growth, and on the other 
hand, DP103 overexpression enhances ERα activity and provides resistance towards 
endocrine therapy. Thus, we establish DP103 as a novel co-activator of ERα activity. 
3.3.5 HOW DOES DP103 MODULATE ERα ACTIVITY 
 We next wanted to know the mechanism by which DP103 co-activates ERα. In 
case of DDX5 and DDX17, they have been shown to interact with ERα and increase its 
transcriptional activity in response to estrogen (239). We next questioned if DP103 also 
interacted with ERα in order to modulate its activity. One hypothesis is that it could 
probably interact with ERα and be a part of the transcription complex that modulates ER 
activity. The other possibility is that it may be recruited to the chromatin on the EREs, 
independent of an interaction with ER, and modulate ER activity by actually modulating 




3.3.5.1 DP103 NEITHER INTERACTS WITH ERα, NOR IS RECRUITED TO 
THE EREs 
 To test the first hypothesis, we carried out immunoprecipitation to check for 
interaction between DP103 and ERα. We pulled down DP103 in MCF7 cells that were 
grown in charcoal-stripped FBS and treated with estrogen. We chose 15 and 30 minutes of 
estrogen treatment since ER transcriptional activity is thought to occur very rapidly, and 
many reports test for ER interactions around this time frame (415). IP analysis showed 
that DP103 did not interact with ERα even with E2 stimulation (Figure 26 A). This rules 
out the first hypothesis that DP103 could be modulating ERα through direct interaction 
and complex formation.  
We then went on to check for the second hypothesis where DP103 could be 
recruited to the EREs on the chromatin, independent of an interaction with ER. We carried 
out a ChIP assay for DP103 to check for its recruitment to ERE site on TFF1. We included 
ERα ChIP as a positive control to ensure that our ChIP protocol had worked. However, 
unlike ERα, DP103 was not recruited to these ERE site, with or without estrogen 
stimulation of MCF7 cells. There was no signal detected for DP103, in contrast to 
significant enrichment and recruitment seen for ERα (Figure 26 B).  
           
Figure 26. DP103 does not interact with ERα. MCF7 cells were treated with E2 for 15 
and 30 minutes, and whole-cell lysate immunoprecipitated with DP103 and IgG control 
antibodies. Immunoprecipitate material and lysate were analyzed by immunoblotting 
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with indicated antibodies (A). MCF-7 cells were incubated with estradiol (E2) treatment 
for 45mins. ChIP assay was carried out using IgG (control) or ERα or DP103 antibody and 
binding of ERα and DP103 to the ERE site on TFF1 promoter was investigated (B). For 
each PCR, enrichment is shown relative to the % of Input, as mean values for three 
replicates. ***P value < .001, **P value < .01, *P value < .05.  
   
3.3.5.2 DP103 DOES NOT CO-LOCALIZE WITH ERα 
 To completely rule out an interaction between DP103 and ERα, we wanted to 
perform immunofluorescence (IF) analysis to check for co-localization pattern between 
the two proteins. It so happens that proteins at times could be part of a much bigger 
complex that it dilutes an interaction between them when analyzed by 
immunoprecipitation. Microscopic analysis would tell us if they co-localize and be a part 
of a much bigger complex, that would tune future experiments accordingly. IF would also 
tell us if they co-localize in a particular section or compartment of the cell.  
Upon microscopic analysis, we found that these two proteins did not seem to co-
localize anywhere in the cell (Figure 27). Irrespective of estrogen stimulation, DP103 was 
predominantly localized in the cytoplasm (shown in green). In contrast,  ERα was 
scattered across the cytoplasm in the absence of estrogen (Vehicle control), and 
translocated into the nucleus with estrogen stimulation for 1 hour (shown in red). But 
these proteins did not seem to co-localize anywhere. DP103 does not even get inside the 
nucleus (shown in blue), implicating that it may not be involved in estrogen-stimulated 
ERα-transcriptional activity in the nucleus. This is consistent with the ChIP data result, 
where DP103 was not found to be recruited to the chromatin on the EREs. Interestingly, 
there is a vivid pattern to DP103 with and without estrogen stimulation. It is low in 
expression and scattered throughout cytoplasm in absence of estradiol (top panel shown in 
green). However, upon estrogen stimulation, there seems to be an increase in DP103 
expression (bottom panel shown in green). It also looks like DP103 is getting concentrated 
just around the nucleus in presence of estrogen stimulation, something that warrants 
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further investigation.   
 
Figure 27. DP103 does not co-localize with ERα. MCF7 cells were treated with 
DMSO as Vehicle control (top panels) or 100nM of E2 for 1 hour (bottom panels), and 
immunofluorescence analysis was performed. Red ERα staining, green DP103 staining 
and blue DAPI staining were viewed under confocal microscope.  
 
3.3.5.3 DOES DP103 MODULATE ERα ACTIVITY THROUGH INHIBITION OF  
p53? 
 From the preceding setion, we understand that DP103 may not be modulating ERα 
directly. Immunoprecipitation, immunofluoresecence and ChIP assay for DP103 have 
ruled out a physical interaction between the two. This implies that DP103 could still be 
modulating some step upstream of ERα transcriptional activity, that would obviate and 
explain a lack of physical interaction between the two. In other words, DP103 could be 
modulating another cellular player that ERα cross-talks with. Of the few cellular 
players that DP103 is known and reported to interact and associate with, p53 
immediately comes to mind as it is reportedly known to cross-talk with ERα. DP103 is 
a known repressor of p53 (255), and p53 is a known repressor of ERα (360, 361). It 
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would be very interesting to see if DP103 represses p53 to negate its repressive effect 
on ERα. 
3.3.5.3.1 VALIDATION OF  DP103 AS A p53 REPRESSOR 
 There were only two reports in literature, highlighting DP103's role as a repressor 
of p53. One demonstrates that DP103 could be repressing the transcription of p53 itself 
(254), while the other shows that DP103 protein physically interacts with p53 and keeps it 
repressed from binding to the DNA (255). Thus, there exists two possible mechanisms by 
which DP103 represses p53. We wanted to test both the hypothesis in our system. Upon 
depletion of DP103, we observe that both the mRNA (Figure 28 A) and protein 
expression (Figure 28 B) of p53 increased, confirming the first report that DP103 
represses transcription of p53. To test the second report, we made use of two constructs, 
one that had the p53 consensus binding sequence, and the other that had the binding 
sequence specific for p21 promoter, both of which were cloned into a luciferase construct. 
Upon DP103 depletion in the same experimental setup above, we observe that p53 
transcriptional activity increased on both the constructs (Figure 28 C and D). This was 
followed by a concomitant increase in both mRNA (Figure 28 E) and protein expression 
(Figure 28 F) of p21, confirming the second report that DP103 represses the 
transcriptional activity of p53. Thus, we show that DP103 represses p53 and keeps the 
expression of both p53 and CDKN1A (p21) repressed in normal scenario. In fact, there 
was a negative correlation between DP103 and CDKN1A gene expression, when we 
compiled microarray data-set available online,  corresponding to tumor samples (Figure 
S8 A and B) and cell lines (Figure S8 C and D), attesting the clinical relevance of this 
association between DP103 and p53 target gene, p21.  
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Figure 28. DP103 represses p53. Effect of DP103 depletion on mRNA (A) and protein 
levels (B) of p53. Effect of DP103 depletion on p53 transcriptional activity on its 
consensus binding sequence (C) and p21 promoter-specific sequence (D). Effect of 
DP103 depletion on mRNA (E) and protein levels (F) of p21. All experiments were 




3.3.5.3.2 CONSEQUENCE OF DP103 DEPLETION ON p53-DEPENDENT 
FUNCTIONAL OUTCOMES 
We showed above that DP103 depletion mediated an increase in expression of 
p53, along with an increased p53 transcriptional activity and an increase in p21 
expression. We next asked the functional consequence of this increase in p53 expression 
upon DP103 depletion? In the beginning of the results section, we reported that DP103 
depletion resulted in a decrease in cell proliferation rate (Figure 6 and 7). Could this 
decrease in cell proliferation rate be due to an increase in p53 expression? To achieve this, 
we performed cell viability and clonogenic assay, with transfections thats included control 
siRNA, siRNA for DP103 or p53 alone, and siRNA combined for both. The rationale 
behind depletion of DP103 and p53 together, would be block any increase in p53 
expression upon DP103 depletion.  
In Figure 29 A, we observe again that compared to control siRNA transfected cells 
(blue line), there was a decrease in the proliferation rate in DP103 depleted cells (red 
line), and an increase in proliferation rate in p53-depleted cells (green line). Upon 
depletion of both together, there was a blockade/rescue in the decrease in proliferation rate 
of the cells (purple versus red line) compared to DP103 depletion alone (red line). The 
same trend was seen on the clonogenic assay where the inhibition in the colony forming 
ability of DP103-depleted cells (Figure 29 B, bottom left panel), was recued when DP103 
was depleted together with p53 (Figure 29 B, bottom right panel). Knockdown efficiency 





Figure 29. DP103 depleted cells proliferate slower due to an increased p53 
expression. MCF7 were transfected with either control siRNA (CtSiRNA) or siRNAs 
against DP103 (SiDP103) or p53 (Sip53), or both together (SiDP103+Sip53). After 24 
hours (Day 1), cells were re-seeded into 96 well plates. Cell viability was measured 
on Day 3, 6, 9 and 12 (A). MTT solution was added and absorbance read at 570nm to 
measure cell viability. The percentage of cell viability was then calculated, setting the 
absorbance reading on Day 3 for each category as 100%. Data represents the average 
reading of three independent experiments. Same transfected cells (CtSiRNA, SiDP103, 
Sip53 and SiDP103+Sip53) were re-seeded in appropriate dilutions in triplicates into 6 
well plates. Cells were allowed to grow for 2 weeks, and colonies were stained with 
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crystal-violet solution and pictures taken (B), after 14 days of transfection. 
Knockdown transfection efficiencies are shown in (C).  
 
3.3.5.3.3 VALIDATION OF  DP103 AS AN INTERACTING PARTNER OF p53 
The second report from Cai et al (255) suggests that DP103 inhibits p53 through 
protein-protein interacions. To validate this, we wanted to check if a physical 
interaction exists between DP103 and p53. To achieve this, we collected lysate from 
MCF7 cells and immunoprecipitated DP103 and immunoblotted for both DP103 and 
p53. Upon analysis, we detected an interaction between DP103 and p53 (Figure 30 A, 
compare lane 3 with 4). We also performed reciprocal IP for p53 and detected DP103 
in the immunoprecipitate complex (Figure 30 A, compare lane 6 with 7). This 
interaction could thus be vital in the repression of p53, as demonstrated by Cai et al.  
In context of ER activity, we wanted to study the interaction between DP103 
and p53 in an estrogen stimulated condition. We had MCF7 cells grown in charcoal-
stripped FBS containing media and supplemented with estrogen for 15 and 30 minutes. 
Like in the case of normal growth conditions above (Figure 30 A), DP103 interacted 
with p53. This interaction was however independent of estrogen stimulation (Figure 30 
B), since the interaction between DP103 and p53 did not get affected by estrogen 
stimulation (Figure 30 B, lanes 5-7). This indicates that the interaction between DP103 
and p53 could be estrogen-independent, and that DP103 could just be a general p53 






Figure 30. DP103 interacts with p53. MCF7 cells were either grown in normal 
medium (A) or in charcoal stripped FBS containing media (B) supplemented with E2 
for 15 and 30 minutes, and whole-cell lysate immunoprecipitated with DP103 and IgG 
control antibodies. Immunoprecipitate material and lysate were analyzed by 
immunoblotting with indicated antibodies.  
 
3.3.5.3.4 EFFECT OF DP103 DEPLETION ON ERα ACTIVITY IS RESCUED BY 
SIMULTANEOUS DEPLETION OF p53 
 p53 is known to repress ERα activity by preventing its binding to the EREs 
(360). We have observed earlier that DP103 depletion results in a decreased ERα activity. 
Since DP103 is a repressor of p53, its depletion would be expected to activate p53. 
Could this activated p53, in turn, result in a decrease in ER activity and associated 
phenotypes, that we see with DP103 depletion? To test this, we repeated assays to 
measure ERα DNA binding activity and expression of ERα target gene TFF1. We had 
transfections that included control siRNA, siRNA against DP103, siRNA against p53, 
and a combination of both the siRNAs. The rationale behind using combination of the 
two siRNAs is that, if DP103 silencing resulted in increased levels of p53, then 
combination knockdown would abrogate that increase in p53 upon DP103 knockdown, 
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and we can study if the functional outcomes with DP103 depletion were dependent on 
p53 or not.  
Upon analysis, we observe that estrogen stimulation for 6 hours in MCF7 
increases ERα activity by 4.5 fold, that is abolished and reduced to just 2-fold when 
DP103 was depleted (Figure 31 A, bar 2 versus bar 4). Depletion of p53 did not have 
much of an effect on ERα activity (31 A, bar 6). However, when DP103 and p53 were 
silenced together, the repression in ERα activity that was seen with DP103 depletion 
alone, was rescued significantly (31 A, bar 4 versus bar 8). The ERα activity increased 
from 2-fold in case of DP103 knockdown to 3.5-fold in case of combination 
knockdown. To complement the ERα DNA binding assay, we also looked at the mRNA 
expression of TFF1 and GREB1, that are known ERα-responsive genes. In the same 
experimental setup, we observe a similar trend with TFF1 expression (Figure 31 B-C) 
that we see with ERα binding assay. Upon estrogen stimulation, there was a decrease in 
the TFF1 expression with DP103 depletion, compared to control siRNA (31 B-C, bar 2 
versus 4), that was almost completely rescued when DP103 was depleted along with 
p53 (31 B-C, bar 4 versus 8). To further verify if the decrease in ERα activity with 
DP103 depletion was due to an increased repressive effect from p53, we measure p53 
DNA-binding activity with DP103 depletion in estrogen stimulated condition. From 
Figure 31 D, it is evident that control siRNA transfected cells (31 D, dark grey bars), 
do not allow any change in p53 activity upon estrogen stimulation. However, with 
DP103 depletion (31 D, light grey bars), there is an increase in p53 transcriptional 
activity even upon estrogen stimulation, that could possibly be the reason behind a 
decrease in subsequent ERα activity that is generally with DP103 depletion. These 
three figures confirm that a decrease in ERα activity with DP103 depletion is due to an 






       
Figure 31. Effect of single and combination knockdown of DP103 and p53 on ERα 
DNA-binding activity and expression of ERα-responsive gene. Effect of control 
siRNA (CtSiRNA), DP103 depletion (SiDP103), p53 depletion (Sip53) and combination 
depletion (SiDP103+Sip53) on ERα DNA-binding activity (A) with 6 hours of E2 
stimulation in MCF7. Effect of control siRNA (CtSiRNA), DP103 depletion (SiDP103), 
p53 depletion (Sip53) and combination depletion (SiDP103+Sip53) on TFF1 (B) and 
GREB1 (C) mRNA expression with 6 hours of E2 stimulation in MCF7. Effect of control 
siRNA (CtSiRNA) or DP103 depletion (SiDP103) on p53 DNA-binding activity (D) with 
E2 stimulation for indicated time points in MCF7. *P < 0.05, **P < 0.01. 
 
3.3.5.3.5 EFFECT OF DP103 OVEREXPRESSION ON ERα ACTIVITY IS 
RESCUED BY SIMULTANEOUS OVEREXPRESSION OF p53 
Having conducted the knockdown experiments above, we wanted to carry out 
the overexpression experiments and look at similar ER-associated functional outcomes. 
Since DP103 is a repressor of p53, its overexpression would be expected to repress p53 
further. Could this enhanced repression in p53, result in an enhanced ERα activity and 
associated phenotypes, that we see with DP103 overexpression? To test this, we 
repeated assays to measure ERα DNA binding activity and expression of ERα target 
genes TFF1 and GREB1. We had transfections that included empty vector, DP103 
overexpression, p53 overexpression and a co-expression of both DP103 and p53. The 
rationale behind co-expression is that, if DP103 overexpression resulted in repressed 
levels of p53, then co-expression would compensate for the increased repression in p53 
upon DP103 overexpression, and thus negate the effect of DP103 overexpression.  
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Upon analysis, we observe that estrogen stimulation for 6 hours in MCF7 
increases ERα activity by 3.5 fold, that is further enhanced to 5.5-fold with DP103 
overexpression (Figure 32 A, bar 2 versus bar 4). In contrast to p53 depletion that did 
not affect ERα activity in Figure 31, p53 overexpression disrupted the increase in 
estrogen-stimulated ERα activity (2.5-fold only), compared to the empty vector set (32 
A, bar 2 versus bar 6). And when DP103 and p53 were co-expressed, the ERα activity 
had increased by 4.5-fold, mid-way between the activity observed when either of them 
is overexpressed alone (32 A, bar 4 versus bar 8, and bar 6 versus bar 8). To 
complement the ERα DNA binding assay, we also looked at the expression of TFF1 
and GREB1, that are known ERα-responsive genes. In the same experimental setup, we 
observe a similar trend with both TFF1 (Figure 32 B) and GREB1 expression (Figure 
32 C), that we see with ERα binding assay. Upon estrogen stimulation, DP103 
overexpression is seen to increase the expression of both these genes (32 B-C, bar 2 
versus bar 4). On the other hand, p53 overexpression completely abrogated any 
increase in the expression of these genes (32 B-C, bar 2 versus bar 6). However, when 
co-expressed, the inhibitory effect of p53 overexpression was blocked due to 
simultaneous DP103 overexpression (32 B-C, bar 6 versus bar 8. These figures confirm 
that an increase in ERα activity with DP103 overexpression is due to an increased 
repression of p53, that in turn, results in an increased de-repression of ERα. To further 
verify if the increase in ERα activity with DP103 overexpression was due to a 
decreased repressive effect from p53, we measure p53 DNA-binding activity with 
DP103 overexpression in estrogen stimulated condition. From Figure 32 D, it is evident 
that with DP103 overexpression (32 D, light grey bars), there is a decrease in p53 
transcriptional activity upon estrogen stimulation, that could possibly be the reason 
behind an increase in subsequent ERα activity that is observed generally with DP103 
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overexpression. These three figures confirm that an increase in ERα activity with 







Figure 32. Effect of single and co-expression of DP103 and p53 on ERα DNA-
binding activity and expression of ERα-responsive genes. Effect of empty vector 
(EV), DP103 overexpression (DP103), p53 overexpression (p53) and co-expression 
(DP103+p53) on ERα DNA-binding activity (A) with 6 hours of E2 stimulation in MCF7. 
Effect of empty vector (EV), DP103 overexpression (DP103), p53 overexpression (p53) 
and co-expression (DP103+p53) on TFF1 (B) and GREB1 (C) mRNA expression with 6 
hours of E2 stimulation in MCF7. Effect of empty vector (EV) or DP103 overexpression 
(DP103) on p53 DNA-binding activity (D) with E2 stimulation for indicated time points in 
MCF7. *P < 0.05, **P < 0.01.   
 
3.3.6 DP103-p53 CROSS-TALK IN DOCETAXEL SENSITIVITY 
 So far, we have established the role of DP103 and p53 in modulation of ER 
activity. p53 is a known repressor of ER, and DP103 has recently been reported to repress 
p53. We deduced a mechanism whereby, DP103, without a direct interaction with ER, 
positively modulates its activity, by negatively regulating the ER-repressor, p53. This 
cross-talk between DP103, ER and p53 holds potential consequences to ER-dependent 
signaling.  
3.3.6.1 INVOLVEMENT OF p53 IN DOCETAXEL-MEDIATED EFFECTS 
We have shown earlier that DP103 modulates docetaxel sensitivity in ER-positive 
cells. We next asked if the cross-talk between DP103 and p53 was also involved in 
modulation of docetaxel sensitivity. To achieve this, we first had to confirm if docetaxel 
induced and activated p53, before studying its relationship with DP103 in docetaxel 
sensitivity. Treatment of MCF7 cells with docetaxel in a dose-dependent manner, was 
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seen to increase p53 expression (Figure 33 A), confirming that docetaxel indeed activated 
p53. Interestingly, the expression of p53 in docetaxel-resistant cells (MCF_DoceR) was 
almost dinished, compared to the wild-type cells (Figure 33 B). This implies that 
docetaxel-resistant cells employ mechanisms to suppress p53 expression, thereby, 
becoming insensitive to the drug. 
            
Figure 33. p53 in involved in docetaxel-mediated effects. Effect of indicated doses of 
docetaxel for 72 hours on p53 expression in MCF7 (A). Comparison of p53 expression (B) 
between wild-type (MCF7_WT) and docetaxel-resistant MCF7 cells (MCF7_DoceR). 
 
3.3.6.2 DP103 DEPLETION INCREASES SENSITIVITY TO DOCETAXEL 
THROUGH INDUCTION OF p53 
 Docetaxel is known to induce and activate p53. We next asked if DP103 depletion 
could alter docetaxel-induced p53 activity and cell death. To achieve this, we employed 
luciferase assay to measure p53 DNA-binding activity on its consensus as well as on the 
p21 promoter sequence. We chose 5nM of docetaxel treatment for 6 hours. We observe 
that docetaxel increased p53 transcriptional activity on both the constructs in control cells 
(Figure 34 A and B, first two bars). This increase in p53 activity was further enhanced in 
DP103 depleted cells (34 A-B, bar 2 versus bar 4). Thus, we see that DP103 modulates 
p53 activity upon docetaxel treatment. This prompted us to check if DP103-modulated 
docetaxel sensitivity, seen earlier in Figure 16, was also dependent on p53. To achieve 
this, we used the same approach of single and combination knockdown of DP103 and p53. 
Upon docetaxel treatment, we observe that DP103 depletion heightened the sensitivity of 
the cells to docetaxel (Figure 34 C, bar 2 versus 4), whereas p53 depletion decreased the 
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sensitivity slightly (34 C, bar 2 versus 6). However, upon depletion of both DP103 and 
p53, there was a decreased sensitivity of cells to docetaxel, compared to DP103 depletion 
alone (34 C, bar 4 versus bar 8), implying that the increased p53 that occurs with DP103 
depletion alone was the reason for the increased sensitivity to docetaxel.  
    
                                 
Figure 34. Effect of single and combination depletion of DP103 and p53 on 
docetaxel sensitivity. Effect of control siRNA (CtSiRNA) or DP103 depletion (SiDP103) 
on p53 transcriptional activity on the consensus sequence (A) and the p21 promoter 
specific sequence (B), in MCF7 cells treated with either DMSO or 5nM of docetaxel 
(Doce) for 6 hours. MTT was used to measure the effect of control siRNA (CtSiRNA), 
DP103 depletion (SiDP103), p53 depletion (Sip53) and combination depletion 
(SiDP103+Sip53) on cell viability (C) with either DMSO or 10nM of docetaxel (Doce) for 







3.3.6.3 DP103 OVEREXPRESSION DECREASES SENSITIVITY TO 
DOCETAXEL THROUGH REPRESSION OF p53 
We see above that DP103 depletion-mediated increase in docetaxel sensitivity was 
due to induction of p53. We next asked if DP103 overexpression would block docetaxel-
induced p53 activation. In a similar experimental setup as above, we observe that 
docetaxel increased p53 transcriptional activity on both the constructs in control cells 
(Figure 35 A and B, first two bars). This increase in p53 activity was however blocked in 
DP103 overexpressing cells (35 A and B, bar 2 versus bar 4). Furthermore, we used the 
same approach of single and co-expression of DP103 and p53 to see if DP103 
overexpression increases cell resistance through increased repression of p53. Upon 
docetaxel treatment, we observe that DP103 overexpression decreased the sensitivity of 
the cells to docetaxel (Figure 35 C, bar 2 versus 4), whereas p53 depletion increased the 
sensitivity even further when compared to the empty vector cells (35 C, bar 2 versus 6). 
However, upon co-expression of both DP103 and p53, there was an increased sensitivity 
compared to DP103 overexpression alone (35 C, bar 4 versus bar 8) or a decreased 
sensitivity compared to p53 overexpression alone (35 C, bar 6 versus bar 8), implying that 
the increased repression of p53 that is expected to occur with DP103 overexpression 
alone, was the reason for the decreased sensitivity to docetaxel.  






                                     
Figure 35. Effect of single and co-expression of DP103 and p53 on docetaxel 
sensitivity. Effect of empty vector (EV) or DP103 overexpression (DP103-OE) on p53 
transcriptional activity on the consensus sequence (A) and the p21 promoter specific 
sequence (B), in MCF7 cells treated with either DMSO or 5nM of docetaxel (Doce) for 6 
hours. MTT was used to measure the effect of empty vector (EV), DP103 overexpression 
(DP103), p53 overexpression (p53) and co-expression (DP103+p53) on cell viability (C) 
with either DMSO or 10nM of docetaxel (Doce) for 24 hours in MCF7. *P < 0.05, **P < 
0.01. 
 
3.3.7 COMPARISON OF DP103 INTERACTION BETWEEN WILD-TYPE AND 
MUTANT p53 
So far, we have studied the inter-play between DP103 and wild-type p53 in 
MCF7. We have shown that DP103 represses the transcript levels of p53, and also 
interacts with p53 in MCF7. To validate this interaction, we chose MCF7 and another 
wild-type p53 containing breast cell line, ZR751, and performed DP103 
immunoprecipitation to demonstrate that DP103 interacts with wild-type p53 in both 
MCF7 and ZR751 (Figure 36 A). However, we were interested in knowing if DP103 
also interacted with the mutant p53. To achieve this, we compared DP103-p53 
interaction between MCF7 and T47D. T47D is known to possess one copy of the 
mutant p53 allele. We collected lysates from both MCF7 and T47D and 
immunoprecipitated DP103 and immunoblotted for both DP103 and p53. Upon 
166 
 
analysis, DP103 interacted with both wild-type and mutant p53 (Figure 36 B). 
However, it has to be noted that T47D has much more p53 expression that MCF7 (36 
B, see input). Since the amount of immunoprecipitated DP103 was the same in both the 
cell lines, if we were to calculate the ratio of immunoprecipitated p53 to the amount of 
p53 in the input, we would realise that DP103 seems to have a much stronger affinity 
towards the wild-type p53 over the mutant (Figure 36 C).  Thus, we deduce that DP103 
preferentially binds to wild-type p53. 
 
     
Figure 36. Comparison of DP103 interaction between wild-type and mutant p53. 
Whole-cell lysates were collected from two wild-type p53 containing cells, MCF7 and 
ZR751 cells, and immunoprecipitated with DP103 and IgG control antibodies (A). 
Whole-cell lysates were collected from one wild-type p53 containing cell line MCF7 
and the other mutant p53 containing cell line T47D, and immunoprecipitated with 
DP103 and IgG control antibodies (B). Immunoprecipitate material and lysate were 
analyzed by immunoblotting with indicated antibodies. Graph showing the comparison 








3.3.8 DOCKING ANALYSIS OF DP103 INTERACTION WITH p53 
To propose a model for the interaction between p53 and DP103, protein docking 
method was used. ZDOCK is a docking method that uses fast Fourier transform based 
protein docking method and searches all possible binding modes in the translational and 
rotational space between the two proteins (407, 408). The docked structures are evaluated 
with energy-based function that scores the low energy docked structures. The crystal 
structures used did not have full length protein. p53 3D structure had residues 91-289 
containing the DNA binding domain and DP103 structure had residues from 62-266. The 
low energy structures obtained by ZDOCK could be classified into two groups. Structures 
that interact with N-terminal part of p53 and structures that interact with other region of 
p53. Most of the low energy docked structures had DP103 interacting with N-terminal 
part of p53. The structures minimized by InsightII were evaluated for quality of the 
structure of the complex generated by ZDOCK. The top six docked structures that were 
obtained, showed good quality structure with more than 99% in the allowed region of 
Ramachandran map. The most optimum docked strucutre is shown in Figure S9 A, with 
its surface representation shown in Figure S9 B. Structure S9 A shows the interaction of 
N-terminal part of p53 with the C-terminus of DP103. Structures S9 A shows W91 and 
P92 in the N-terminus of p53 interacting with K237 of DP103. The interaction between 
the proteins involved hydrogen bonding, electrostatic interaction as well as hydrophobic 
interactions. 
3.3.9 DP103 AS A NOVEL SWITCH BETWEEN SUMOYLATION AND 
ACETYLATION STATUS OF p53 
We have shown that DP103 could be transcriptionally controlling p53. We have 
also shown that DP103 interacts with wild-type p53, that could be in accordance with Cai 
et al's report on DP103's repression of p53 through protein-protein interaction. We next 
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wanted to know the mechanism by which DP103 protein represses p53 transcriptional 
activity. DP103 is known to sumoylate SF-1 (246) and repress its activity. p53 is also 
known to get sumoylated (389) and the authors report that p53 sumoylation at lysine 386 
represses its transcriptional activity, by preventing subsequent acetylation of lysine 382 
that is needed for p53's DNA-binding activity. Could DP103 be involved in the 
sumoylation-dependent repression of p53? 
To test this, we depleted MCF7 cells of DP103 and immunoprecipitated p53 to 
check for sumoylation status with SUMO-1 and SUMO-2/3 specific antibodies. 
Interestingly, depletion of DP103 decreased both SUMO-1 and SUMO-2/3 status of p53 
(Figure 37 A, top two blots), with a pronounced effect on SUMO-1 status. This is 
consistent with other reports where p53 has been reported to be predominantly modified by 
SUMO-1. To check for acetylation status of p53, we used two individual sets of siRNAs 
(SiDP103#1 and #2) to deplete MCF7 cells of DP103. Upon p53 immunoprecipitation, we 
observe that the SUMO-1 status of p53 decreased with both the siRNAs, whereas, the 
acetylation status of p53 increased with DP103 depletion (Figure 37 B, top two blots). 
Thus, we deduce that depletion of DP103 decreases p53 sumoylation and increases its 
acetylation, that could result in its probable activation. It is highly probable that DP103 
keeps p53 repressed through increased sumoylation and decreased acetylation. This is 
consistant with our previous data that shows that DP103 depletion results in an enhanced 
activation of p53 activity, and DP103 overexpression results in a decreased activation of 
p53. This DP103-sumoylation/acetylation-p53 switch could also explain our findings in 
context of ERα activity and docetaxel sensitivity.  
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Figure 37. DP103 modulates SUMO/Acetyl switch of p53. Whole-cell lysates were 
collected from MCF7 cells that were depleted of DP103 with SiDP103, and 
immunoprecipitated with p53 antibody (A). Immunoprecipitate material and lysate were 
analyzed by immunoblotting with indicated antibodies including SUMO-1, SUMO-2/3 
and p53. Whole-cell lysates were collected from MCF7 cells that were depleted of 
DP103 with SiDP103#1 and SiDP103#2, and immunoprecipitated with p53 antibodies 
(B). Immunoprecipitate material and lysate were analyzed by immunoblotting with 
indicated antibodies including SUMO-1, Acetyl-p53 and p53.  
 
 Thus, we show for the first time, that DP103 could play a potentially important 
role in modulating the switch between sumoylation and acetylation status of p53. We 
postulate that DP103 keeps p53 repressed through increased sumoylation and decreased 
acetylation. We end our results sections with the following questions to be addressed. 
Could this sumoylation-dependent repression of p53 play a critical role in p53 
regulation? Could DP103 expression determine the level of activation of p53 upon 
stress stimulation? Could stress stimulation or situation that causes DP103 depletion 
(like docetaxel treatment in responders), result in freeing p53 from DP103-mediated 
sumoylation, that eventually becomes permissive to acetylation and leads to its 
subsequent activation? And could resistant cells have an increased sumoylation of p53, 






4.1 LIMITATIONS IN BREAST CANCER TREATMENT MODALITIES  
Breast carcinoma is the most common malignancy among women, contributing to 
more than 20% of all female cancers reported. According to National Cancer Institute's 
SEER database, the 5-year survival rate is much higher for breast cancer cases associated 
with lower stages and decreases drastically as the cancer stage increases. For example, the 
5-year survival rate is 100% for stage 0 and 1, and 93% for stage 2, and rapidly declines to 
72% for stage 3 and a meagre 22% for stage 4. One reason for the increased survival rate 
during the early stages is the availability of early detection facilities, including 
mammogram. Despite this, most breast cancer cases are left undiagnosed without regular 
mammogram tests until later stages of the cancer, which worsens the chances of treatment 
and survival. As discussed in the introduction, treatment for breast cancer depends on a 
variety of factors, ranging from cancer grade, stage and receptor status to different 
molecular subtypes. Certain established biomarkers pertaining to breast cancer, help in 
making a decision on the most appropriate treatment option available. The most widely 
used biomarker system includes characterization of the receptor status of  the breast 
tumor. Status of the tumor's estrogen receptor (ER), progesterone receptor (PR) and 
HER2 receptor, has been the gold standard for selection of treatment for breast cancer. 
Accordingly, anti-estrogen or endocrine therapy is administered to ER-positive tumors, 
Trastuzumab or other anti-HER2 therapies are administered for HER2-positive tumors, 
whereas, chemotherapy is generally recommended for the highly aggressive triple-
negative breast cancer.  
Endocrine therapy is usually the first-line of defense against ERα-positive tumors, 
although there are cases of endocrine resistance or tumor recurrence with prolonged 
treatment (416). This might necessitate the need for other treatment options such as 
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chemotherapy on these endocrine non-responsive tumors. It was initially thought that 
chemotherapy may not be effective on ER-positive tumors, however, recent trials have 
shown that chemotherapy may be beneficial for all breast cancer types, irrespective of the 
receptor status (41). In addition, several recently concluded randomized trials have 
reported that chemotherapy could improve outcome in ER-positive disease as well (39, 
417). Other studies suggest that, although less chemosensitive, ER-positive disease 
includes a subset of patients which derives a significant benefit from adjuvant 
chemotherapy (40, 418, 419). Specially in postmenopausal women with ER-positive 
cancers, response rate and time to response was similar between chemotherapy and 
endcorine therapy (420). Thus, chemotherapy serves as a good treatment option for all 
breast cancer types.  
4.2 LIMITATIONS WITH CHEMOTHERAPY 
Chemotherapy has been highly successful as a post-surgical treatment option, 
either alone or in combination with other treatment strategies. However, owing to 
increased heterogeneity among patient tumors, the response to chemotherapy might be 
variable, and there is no way to tell the extent of response and the degree of side effects 
that the patients might suffer through. Unfortunately, there is a striking increase in the 
number of patients who develop resistance or show relapse and tumor progression to 
chemotherapy (421, 422). Chemoresistance has thus become a major clinical burden, 
leaving the patients with much lesser alternatives, after all the side effects and toxicities 
that they might have gone through. One approach to counter that is to develop new 
chemotherapeutics. However, that would take years of research, and millions of dollars of 
investment, and the caveat is that there is no guarantee that any new drug in the market 
may not face the same issue of chemoresistance later. The other approach is to work with 
some of the existing and effective chemotherapeutics, and develop a sound understanding 
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of the molecular mechanism behind chemoresistance to these drugs. This would help 
identify molecular players within the cell or the tumor that could serve as biomarkers of 
tumor response to chemotherapy. A better understanding of molecular biology of 
chemoresistance would also help identify potential therapeutic targets that can be targeted 
in synergy with chemotherapy. These predicitve biomarkers are ones that possibly 
associate with the drug-response pathway, and most probably, modulate other players or 
get modulated by others or the drug itself, to alter the drug-response pathway. For 
example, an oncogene if involved in chemoresponse such as Akt or Bcl-2, would either be 
overexpressed or functionally altered to promote survival and suppress other tumor 
suppressor genes, to resist drug effect and drug-mediated cell death. Identifying predictive 
biomarkers would also enable the clinicians to better select those patients who are more 
likely to benefit from chemotherapy, while avoiding toxic effects in those patients who 
may not reap benefits from chemotherapy. Discovery of such biomarkers in cancer 
treatment is rapidly evolving and is being investigated at the genetic, transcriptional and 
protein level. Although the use of biomarkers to select chemotherapy is not the standard 
approach, several potential biomarkers have been identified and a few prospective trials 
are ongoing. Identification of novel biomarker(s) has largely been aided through studies 
and trials involving neoadjuvant chemotherapy.  
4.3 NEOADJUVANT THERAPIES AID IDENTIFICATION OF NEW 
BIOMARKERS 
The neoadjuvant approach to treat breast cancer has become popular for selected 
high-risk breast cancers, with tumours ≥ 2cm and for locally advanced and aggressive 
breast cancer disease. Administered prior to surgery or other treatments, it can shrink the 
tumor so that it is easily operated upon by surgery or endocrine therapy, thereby, 
increasing the rate of breast conserving therapy rather than mastectomy. Neoadjuvant 
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chemotherapy is also beneficial is terms of its ability to down-stage tumors and decrease 
the proportion of lymph node-positive tumors. Neoadjuvant therapy was apparently 
comparable to adjuvant therapy in terms of overall survival and recurrence-free survival 
rate (423). Other published studies have reported that the use of neoadjuvant approach led 
to a significant or near-significant increase in the proportion of 5 years disease-free 
survival rate (424, 425) compared to adjuvant chemotherapy.  
Importantly, neoadjuvant chemotherapy is viewed as a platform for testing the 
activity of novel and potentially promising therapeutic approaches in managing cancer 
disease. It allows for monitoring of treatment response and discontinuation of inactive 
therapy in the event of disease progression, thus saving the patient exposure to potentially 
toxic therapy. Neoadjuvant chemotherapy also facilitates the study of cancer molecular 
biology. Because the primary tumor remains intact during therapy, it provides a unique 
opportunity to investigate expression of tumour-related genes and proteins during 
chemotherapy. This has enabled profiling of gene- and protein-expression in the tumor 
upon chemotherapy (426, 427). The same approach has also predicted biomarkers of 
chemoresponse in breast cancer studies (428, 429). Changes in gene- and protein-
expression in the tumor can be very tightly linked to the manner in which the tumor 
responds to therapy. In a general cohort of patients that undergo chemotherapy, there are 
always patients who respond well to the therapy, and alongside them are those who do not 
reposnd so well to the therapy due to intrinsic or acquired resistance to chemotherapy. 
Microarray-styled comparison of dysregulated genes or proteins between samples from 
responding and non-responding patients would suggest molecular players that are 
potentially involved in chemoresponse and chemoresistance. Gene or proteins that are up-
regulated in responding patients and down-regulated in non-responding patients, are 
considered to be involved in aiding the tumor to respond to the therapy, and thus represent 
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tumor-suppressors that directly or indirectly correlate to a positive chemoresponse. In 
contrast, genes or proteins that are down-regulated in responding patients and up-
regulated in non-responding patients, could be seen hindering the effect of the drug or 
promoting survival, and thus belong to the family of oncogenes that inversely correlate to 
a positive chemoresponse. In this manner, many genes and proteins had been predicted to 
be potential biomarkers of chemoresponse, although, many have failed in successful 
implementation in the clinic. For example, as discussed with docetaxel resistance in the 
introductory chapter, none of the predictive biomarkers, that include Akt, Bcl-2, Pgp, β-
tubulin and p53, have been reported to be successfully implemented in the clinic. The 
need of the hour is to identify new biomarkers and organise a detailed study on the 
molecular mechanisms behind the role and involvement of these new biomarkers in 
chemoresponse. This would help us better understand the mechanism of chemoresistance 
and also enable clinicians to predict chemoresponse in breast cancer.   
4.4 WHY STUDY DP103 IN CHEMORESPONSE?  
The purpose of this project was to see if a putative oncogene that our lab is 
interested in, is involved in chemoresponse. DP103, also known as DDX20 or Gemin 3, is 
a relatively new member of the DEAD-box family of RNA helicases (240). Members of 
the family have been involved in a wide range of RNA-associated metabolisms. Although 
family members have been widely implicated in oncogenesis, to our knowledge, there is 
no report that implicates any family member in drug resistance. Until recently, there were 
no publications on DP103 that would hint at its involvement in drug responses. However, 
a 2011 report interestingly found out that DP103 represses p53 (255).  Under the influence 
of EBV virus's latent protein EBNA3C, DP103 prevents p53 from binding to the DNA, 
thereby decreasing its tumor-suppressive transcriptional activity and apoptosis. In 
addition, our lab has recently published the role of DP103 in breast cancer metastasis 
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(256). It was found that DP103 is overexpressed in breast tumors and positively modulates 
NFκB transcriptional activity to promote metastasis in triple negative breast cancers. 
Thus, we had two important studies linking DP103 to p53 and NFκB. These two 
transcription factors are highly studied with respect to various facets of cancer biology, 
including drug responses and drug resistance. On one hand, p53 is either mutated or its 
function is inactivated in the development of resistance (430, 431). On the other hand, 
NFκB has been well characterized to promote drug-resistance in various cancers (432-
434). With DP103 modulating these two molecular players, we questioned if DP103 was 
also involved in drug response and drug resistance. This had set the hypothesis for my 
PhD project, that was to investigate the role of DP103, if any, in chemoresponse. 
However, in our present study, we could only investigate DP103 and its relation with p53, 
and not NFκB; with respect to chemoresponse in breast cancer, that will be discussed 
later.  
4.5 ADVANTAGES OF OUR CHEMOTHERAPY STUDY 
Recent advances in cancer biology has definitely improved our knowledge of 
some of the events that happen during tumorigenesis, including chemoresponse. It has 
permitted us to investigate biomarkers that may be targeted by chemotherapy, to either 
elicit a positive or negative response. As discussed in the introductory chapter, various 
mechanisms have been implicated in docetaxel resistance. These range from defects in β-
tubulin defects, alterations in expression of Pgp, MAPs, pro-survival and pro-apoptotic 
pathway players such as Bcl-2, Akt and p53. However, to our knowledge, there has been 
no biomarker that has been successfully employed in the clinic to help predict patient 
outcome to docetaxel-based chemotherapy.  
One major drawback with other biomarker prediction studies has been the 
limitation in the number of sample collection/analysis points. For example, earlier studies 
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have compared changes in biomarkers with neoadjuvant chemotheray at only two points: 
before and after chemotherapy (435-437). This limts our knowledge on the progressive 
change in expression of genes/proteins of interest, through the entire course of 
chemotherapy. It also means that the biomarker analysis could be done only at the end of 
chemotherapy, by which patients would have either turned resistant, or would have 
suffered through many side effects without any possible benefit from the therapy. In this 
manner, the prediction analysis that occurs just at the end of the therapy, offers no help to 
the patients in the choice and continuation of the therapy. To make matters worse, it also 
lets the tumors in the non-responders develop multi-drug resistance (MDR), that is 
refractory to most other treatments that may follow. What would be more helpful is, if the 
biomarker analysis could be done at different stages of chemotherapy, helping predict if 
the tumor is going to respond or regress with the remaining sessions of therapy, and a 
consensus decision could be then made to either keep the patient on the same therapy or 
switch to an alternative mode. In this manner, we make a prediction of a positive or 
negative chemoresponse pretty early during chemotherapy, instead of waiting all the way 
until the end. Another major benefit is that it might help avoid emergence of MDR, so that 
the patients can still respond to an alternative treatment option, without having to go 
through the toxicities of the first therapy that may not have worked. 
This is exactly what our chemotherapy study achieves, providing a better insight 
into serial changes in the expression of genes/proteins of our interest, through different 
stages of chemotherapy. Many earlier studies have focussed only on mRNA expression 
that may or may not translate into protein expression changes and thus, prediction based 
on mRNA expression is not highly reliable. Although many other studies have studied 
protein expression changes, our study is the first of its kind to evaluate both the mRNA 
expression changes, and the serial changes in protein expression at four different time 
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points, providing us with a better understanding about the time-course changes in the 
mRNA and protein expression of our biomarker. Since tumor response was measured at 
the end of every cycle that the biomarker analysis was done at, we also get a sense of an 
association between changes in biomarker expression and clinicopathological features and 
patient outcome.  
4.6 INVESTIGATING DP103 AS A NOVEL CHEMORESPONSE MARKER 
In our collaborator's chemotherapy study that was published in 2011 (399), the 
authors studied the serial changes in COX-2 expression with chemoresponse. They found 
that COX-2-positive tumors at baseline correlated with advanced tumor stage, metastatic 
potential and poor PFS, compared to COX-2-negative tumors. The expression of COX-2 
decreased with chemotherapy mainly in clinical responders, with patients showing a 
decrease exhibiting a better PFS. The authors however found no significant changes in 
IHC expression of ER, PR, HER2, Ki67 and p53 with chemotherapy.  
Our protein of interest, DP103 has never been implicated in drug response or 
chemoresistance. However, its association with repression of p53 and our lab's ongoing 
work on its involvement in the NFκB pathway, had prompted us to study its role in 
chemoresponse. With the help of data-set and samples from the abive study, we then 
questioned if there was any correlation between DP103 expression and chemoresponse, 
that yielded some interesting trends upon analysis. There was no correlation between 
baseline and post-chemotherapy expression of DP103 mRNA with tumor-stage, presence 
of metastasis, progression-free or overall survival (Supplementary Table 1 and 2). This is 
in contrast to our lab's recent report on DP103's metastatic potential and its association 
with tumor staging. One possible reason for this disparity could be the much smaller 
sample size of patients with metastasis (see Supplementary Table 1), that can confound 
data and bias results. Moreover, association of chemotherapy-induced changes in DP103 
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expression with metastasis and tumor grading is further complicated by the presence of 
other parameters such as receptor status. A subset analysis of patients with or without 
metastasis, categorized by confounding factors such as the receptor status, would give us a 
clear picture of the association between DP103 and metastasis. Nevertheless, clinical 
responders exhibited a significant decrease in DP103 mRNA expression levels compared 
to non-responders (Figure S3), suggesting that DP103 might have a role in 
chemoresponse.  
This study involved patients with both ERα-positive and ERα-negative patients. 
Numerous studies have shown that patients with different ERα status exhibit differential 
response to chemotherapy (37, 38). In our study, we then wondered if ERα status could 
alter/re-define the way DP103 expression associated with chemoresponse. Stratification of 
patients by the receptor status revealed 64 ERα-postive and 36 ERα-negative patients, 
consistent with statistics that there is a higher percentage of patients with ERα-positive 
tumors than ERα-negative tumors. Upon analysis, ERα-positive patients had greater 
relative chemotherapy-induced reduction in DP103 mRNA expression levels than ERα-
negative tumors (Figure S4A), suggesting an ERα-dependent expression profile changes 
of DP103 in chemoresponse. No difference in baseline or post-treatment DP103 mRNA 
expression levels was observed between responders or non-responders with ERα-negative 
tumors (Figure S4B). In contrast, responders among ERα-positive patients had 
numerically lower baseline and significantly lower post-treatment DP103 mRNA 
expression levels (Figure S4C) than non-responders, which meant that there was a 
chemotherapy-induced decrease in DP103 expression among ERα-positive responders but 
not in ERα-positive non-responders. Thus, we observed that DP103 mRNA expression 
profile could serve as a predictive marker of chemoresponse among ERα-positive patients.  
However, growing number of studies have raised doubts on the applicability of 
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biomarker qualification based on mRNA expression alone. Moreover, the problem with 
our mRNA expression analysis above is that, only baseline and post-cycle 1 samples were 
considered for transcript analysis, which may not be completely reflective of the entire 
chemotherapy schedule. To counteract this, we validated DP103's predictive role at 
protein levels using IHC, at all four time points, making the protein analysis much more 
robust and indicative of the changes in biomarker expression throughout chemotherapy. 
Similar to mRNA expression, IHC analysis showed no correlation between baseline and 
DP103 expression with tumor-stage, presence of metastasis, ERα status, clinical response, 
progression-free or overall survival (Supplemetary Table 3 and 4). However, 
chemotherapy-induced change in DP103 protein expression was observed to be 
decreasing with different cycles of chemotherapy in clinical responders but not in non-
responders (Figure S5A). When patients were stratified by ERα status, a decrease in 
DP103 protein expression was observed in tumors with ERα positive status, but not ERα-
negative status (Figure S5C and Figure S5D). Thus, we see that even protein expression 
profile of DP103 could serve as biomarker for predicting chemoresponse in a subset of 
breast cancer patients with ER positive status.  
This chemotherapy study involved two drugs in sequential order: docetaxel and 
doxorubicin. These two drugs acting via completely different mechanisms, with docetaxel 
causing mitotic arrest and doxorubicin causing genotoxic stress-induced DNA damage, 
could alter a totally different set of genes. To see if DP103-mediated predictive response 
was applicable to any single drug or both, we made use of samples at the end of the very 
first cycle of therapy, where the patients had undergone treatment with either docetaxel or 
doxorubicin. Upon analysis, no significant doxorubicin-induced DP103 expression change 
was observed in either ERα-positive or negative tumors. However, one cycle of docetaxel 
induced significant reduction in DP103 gene expression in ERα-positive, but not in ERα-
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negative tumors (Figure S6).  
In the in vitro scenario too, we demonstrated similar results with cell lines 
representing either ERα-positive or negative cases to mimic the clinical responders, and 
in-house generated docetaxel-resistant cells to mimic the clinical non-responders. We see 
that docetaxel, and not doxorubicin, decreased DP103 expression at both mRNA and 
proteins levels, in ERα-positive cell lines and not in ERα-negative cell lines. On the other 
hand, docetaxel-resistant cells managed to evade a reduction in DP103 expression upon 
docetaxel treatment, consistent with the observation with non-responders in the clinic. It 
however, has to be noted that DP103 expression did not seem to differ between the 
parental wild-type and docetaxel-resistant cells, that we will discuss later with respect to 
p53. Interestingly, we also found ERα expression decreasing in wild-type parental cells 
upon docetaxel treatment, but not in resistant cells, indicating an association between 
DP103 and ERα. We however, do not know the mechanism by which docetaxel decreases 
ERα, although one study with paclitaxel suggest that it inhibits translation of ERα mRNA 
(414), probably through p53 induction, resulting in a decrease in the steady-state level of 
ERα protein. ERα promoter was shown to have a site that was highly responsive to 
paclitaxel, thus regulating ERα transcript levels. Could docetaxel be regulating ERα 
through similar mechanisms? At this point of time, we could only speculate that docetaxel 
either binds to ERα promoter to inhibit its transcription, or it inhibits ERα protein 
synthesis in a p53-dependent manner. In context of DP103, we speculate that docetaxel 
could be transcriptionally controlling it, either directly binding to its promoter, or 






4.7 POTENTIAL APPLICATION OF DP103 AS A CHEMORESPONSE MARKER 
IN THE CLINIC 
Having showed that DP103 expression profile could serve as a predictive marker 
of docetaxel response in a subset of breast cancer patients with ERα-positive status, we 
would like to discuss the possible implications of this finding on chemotherapy studies, 
and also dwell into some of the drawbacks and limitations in the approach that we had 
taken.  
To firmly establish DP103 as a predictive biomarker of docetaxel response in the 
clinic, we need to carry out more comprehensive trials, with bigger patient 
numbers/cohort size and possibly many different races. Our study involved only hundred 
patients, which is a pretty small sample size. Among these patients, when categorization 
and stratification occurs based on different parameters such as the response status or the 
ER status, the sample size in each group reduces even further. For example, in 
Supplementary Table 1 and 3, the sample size for non-responders is either a single digit or 
slightly above ten. This could be a rather puny number to determine significance and 
proper associations. Although the numbers tell that DP103 expression do not change with 
docetaxel in non-responders, we still don't the significance of this piece of finding because 
of such small number of non-responders and insignificant P values. Having a bigger 
sample size would definitely help calculate significance of the study and characterize the 
role of the putative biomarker better. Other limitations include the fact that tumor 
heterogeneity has led to concerns that the core biopsies anaysed for each patient and each 
cycle, may not be robustly representative of the tumor tissue as a whole. Moreover, IHC 
analysis is highly subjective, and prone to errors and bias due to lack of standard scoring 
systems.  
That being said, DP103 expression profile could still impact current docetaxel-
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based chemotherapy practices for treating ERα-positive patients. Instead of waiting until 
the end of the therapy, serial changes in the expression of DP103 at different cycles could 
help predict the extent of response in the individual patients. For example, comparison of 
the baseline and post-cycle 1 expression of DP103 would tell if there is a decrease in its 
expression, that would imply most probably that patients might go on to respond to the 
therapy. The expression has to be tracked at every cycle though and observed to be 
progressively decreasing for a positive chemoresponse. However, if the expression stops 
decreasing at any cycle, if might indicate the emergence of resistance, and immediate 
interventions could be called in. One problem, however, that is reckoned with this system, 
is that how much of a decrease in DP103 expression should be considered as a safe bench 
mark for continued treatment or discontinuation of the drug? That is why bigger and more 
robust trials would be needed to estimate the significance of this study.  
 Another clarification that would be needed here, is that, when we say DP103 
serves as a predictive marker for docetaxel response only in ER-positive tumors, it is not 
to be confused with ER-negative tumors not responding to the therapy. ER-negative 
tumors are responsive to the therapy as well. However, DP103 expression profiling is able 
to predict chemoresponse only in patients with ER-positive status, and not in ER-negative 
status, because of reasons unknown yet. Although, discussed later, we would postulate a 
possible reason as to why we see such effects only in ER-positive cases.  
 And finally, we don't know for sure if and how, DP103 could serve as a predictive 
marker only for docetaxel and not doxorubicin response. This is because of two reasons. 
Firstly, this finding was based on mRNA analysis with samples at baseline and post-cycle 
1 therapy (Figure S6). We are not very certain if this mRNA data could be trusted upon, 
as there is no supporting protein expression data for the same. Secondly, discussed later, 
we postulate that DP103 mediates docetaxel sensitivity through induction of p53. So how 
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could doxorubicin, which is a gold-standard p53-inducing agent, not show similar 
responses as docetaxel, if they are both known to activate p53? Moreover, Figure S6 
depicts individual drug-induced change in DP103 expression after one cycle of therapy, 
but does not show if, and the extent to which, this change is associated with response to 
either doxorubicin or docetaxel. As such, DP103 analysis throughout chemotherapy is a 
mixed response of the tumor to a sequential treatment of both the drugs, and it would be 
be biased to say that the response and change is DP103 expression profile was exhibited 
only to docetaxel and not doxorubicin. In the in vitro scenario, where we show DP103 
expression not changing with doxorubicin treatment, it has to be remembered that 
doxorubicin is a genotoxic-stress inducing agent that requires prolonged and higher doses 
(μM range) to cause cell death and p53 induction, equivalent to what docetaxel might 
cause with just nM dosage. Hence, the working doxorubicin concentration, both in the 
clinic and in cell line studies, might not have been optimized enough to impart a change in 
DP103 expression with just one cycle of therapy. To answer this better, we think, two 
different trials, one involving only docetaxel and the other only doxorubicin, would be 
appropriate to better study the association of DP103 expression to these two drugs. 
Nevertheless, we would take-home the message that DP103 could be used as a response 
marker for docetaxel based therapy in breast cancer patients with ERα-positive tumors.   
4.8 POTENTIAL APPLICATION OF DP103 AS A THERAPEUTIC TARGET IN 
CHEMOTHERAPY 
Another major impact from this study could be the role of DP103 as a therapeutic 
target of docetaxel-based therapy. From Figure 16-18, we have shown that DP103 could 
modulate docetaxel sensitivity in ERα-positive cell lines. DP103-depleted cells were more 
sensitive to docetaxel, exhibiting an increased caspase-3/7 activity, and in contrast, DP103 
overexpressing cells were more resistant to docetaxel with a quenched caspase activity. 
184 
 
Pre-incubation with caspase inhibitors would confirm if the above effects are indeed 
caspase-dependent. We have currently initiated an animal model study to see if xenografts 
with DP103 overexpressing cells were indeed more resistant to docetaxel in mice. This 
could have therapeutic implications in the clinic and DP103 inhibition could be employed 
as a measure to further potentiate docetaxel therapy. We, however, did not check if the 
docetaxel-resistant cells could be re-sensitized to docetaxel treatment upon silencing of 
DP103. We have been facing problems with maintenance of good resistance in these 
resistant cells, that tend to revert back to being sensitive soon upon withdrawal of the drug 
in their maintenance and selection. We are currently trying to generate a fresh batch of 
docetaxel resistant cells, and if it works, then we would test if DP103 depletion could re-
sensitize them to docetaxel. This could transform DP103 into a vital target in reversing 
chemoresistance. What would also be interesting to see is, if DP103 could modulate 
sensitivity to doxorubicin and other DNA-damage inducing agents, since we show later 
that DP103 represses p53 to modulate docetaxel sensitivity, and it thats true, it should also 
be modulating sensitivity to doxorubicin and the other drugs. Finally, we would like to see 
if DP103 can modulate drug sensitivity in ERα-negative cell lines. 
4.9 ASSOCIATION STUDIES BETWEEN DP103 AND ERα 
4.9.1  ERα TRANSCRIPTIONALLY REGULATES DP103 
 Since, we saw a decrease in both DP103 and ERα with docetaxel treatment, we 
next wondered if there was an association between the two. ChIP analysis showed an 
estrogen-stimulated binding site for ERα on DP103 promoter region, around 16kb 
upsteam of the transcription start site (Figure 20). Such a distal regulation of DP103 is 
possible, since ERα has been shown to regulate gene transcription through long-range 
chromatin interactions (438, 439). Through various other assays, we confirmed that 
DP103 is transcriptionally regulated by ERα in an estrogen-stimulated manner. This could 
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explain why luminal breast tumors have a higher expression of DP103 compared to 
normal breast tissues (Figure S7). This is the first report on transcriptional regulation of 
any DEAD-box protein by ERα.  
4.9.2  DP103 REGULATES TRANSCRIPTIONAL ACTIVITY OF ERα 
Members of the DEAD-box family, DDX5 and DDX17 have been widely studied 
as co-activators of ERα (193, 230). Since DP103 has been reported as a modulator of 
transcriptional processes (246), we next questioned if it could also be involved in 
modulation of ERα activity. Indeed, depletion and overexpression of DP103, abrogated 
and enhanced estrogen-stimulated ERα transcriptional activity, respectively, as measured 
by its DNA binding activity (Figure 22), expression of its downstream target genes 
(Figure 23) and also estrogen-stimulated cell growth. DP103 depletion inhibited ERα 
transcriptional activity by preventing its recruitment to the ERE sites on the chromatin 
(Figure 24). Above data indicates that DP103 might be regulating ERα through its ligand-
dependent transactivation domain (AF-2). Since ERα has been shown to be activated in a 
ligand-independent manner as well (440, 441), it remains to be ascertained if DP103 could 
modulate ERα activity through its ligand-independent transactivation domain (AF-1).  
Many co-activators of ERα have been shown to physically interact with the 
receptor to influence its activity, with the same holding true for DDX5 and DDX17. 
However, we did not observe any interaction between DP103 and ERα (Figure 26), 
suggesting that DP103's role in maintenance of ERα activity, could be through interaction-
independent mechanisms. At present, we could think of a few reasons why we don't see an 
interaction between DP103 and ERα. Firstly, there actually may not be an interaction 
between the two. Secondly, activated ERα might be tightly bound to the chromatin, that 
doesn't show up on regular immunoprecipitation assays, and hence, DNAase or sonication 
treatment would be required to release all the chromatin-bound ERα for IP detection. 
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Thirdly, as part of ERα turn-over, ERα might have been ubiquitinated and degraded with 
estrogen treatment, so that nothing shows up on DP103 IP. This could be blocked with 
MG132 (442), a proteosomal inhibitor. Finally, interaction studies performed on whole-
cell lysates could sometimes dilute interactions that are specific to certain compartments 
in the cell, such as the nucleus. For example, if the interaction between ERα and DP103 
were to occur only in the nucleus and were to be very transient in nature, then 
immunoprecipitation carried out on whole-cell lysates may not so easily capture such 
volatile transient interactions.  
Although, we intend to study the interaction in separated nuclear and cytoplasmic 
fractions, we are doubtful if an interaction between the two exists anywhere, since 
immunofluorescence on estrogen-stimulated cells showed no co-localization anywhere in 
the cell (Figure 27), suggesting that DP103 and ERα may not be a part of a complex. It 
also has to be noted from Figure 30 that, as ERα translocates to the nucleus upon estrogen 
stimulation, scattered DP103 tends to concentrate around the nucleus, without actually 
entering the nucleus. This aspect of DP103's localization just around the nucleus is of 
intense curiousity to us, and we shall discuss this with respect to p53-ERα cross-talk later. 
As with DP103 induction studies with estrogen stimulation earlier (Figure 21), we would 
also like to separate the nuclear and cytoplasmic fractions of estrogen stimulated cells, and 
find out the compartment where the increase in DP103 protein expression occurs. This 
would implicate the role of DP103 in that particular compartment in estrogen stimulated 
physiological conditions. IF data showing DP103's predominant cytoplasmic localization 
upon estrogen stimulation also explains the DP103 ChIP data on ERα-ERE sites. Upon 
estrogen stimulation, there was absolutely no recruitment of DP103 on ERE sites, 
suggesting that DP103 is not recruited to the chromatin to be a part of the ERα 
transcriptional machinery. Then, how is DP103 modulating ERα activity? 
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One possibility is that DP103 modulates estrogen-stimulated ERα phosphorylation 
and nuclear translocation, without interacting with ERα itself. To test this, we will silence 
or overexpress DP103 in cells and check for ERα phosphorylation and translocation status 
upon cellular fractionation. A second possibility is that DP103 alters the sumoylation 
status of ERα, thereby affecting its transciptional activity. SUMO1, Ubc9 and PIAS1 have 
been confirmed to work in tandem to mediate sumoylation of lysine residues 266 and 268 
in the hinge region of ERα (380), that occurs strictly under estradiol stimulated conditions 
and increases the transcriptional activity of ERα, without affecting ERα nuclear 
localization. In contrast, SENP2 mediated desumoylation was found to be repressing ERα 
activity in breast cancer (382). Thus, sumoylation of ER might have a significant role to 
play in ERα-dependent signaling in breast cancer, and since DP103 has been known to be 
involved in sumoylation of another nuclear receptor SF-1 (246), we speculate a role of 
DP103 in estrogen-dependent ERα sumoylation. In this regard, we would like to study if 
DP103 stimulates ERα sumoylation and interaction with other sumoylation players such as 
SUMO1, Ubc9, PIAS1 and SENP2. A third possibility is that DP103 alters ERα 
interaction/association with its known interacting partners such as CBP/p300, HDACs, 
RNA Pol II, SRC-1, NCoR, SMRT, Akt and p53. With respect to this, we will be 
discussing DP103's modulation of ERα-p53 cross talk further. 
4.10 DOES DP103 MODULATE ERα THROUGH REPRESSION OF p53? 
Assuming from available data that DP103 does not interact with ERα, we 
hypothesized that DP103 could me modulating another molecular player(s) that associates 
with ERα. ERα expression and its activity has been known to be modulated by so many 
other players. Finding a player that DP103 modulates, would be equivalent to finding a 
needle in the hay stack. However, available literature on DP103 reports on its p53-
repressive potential (255). And p53 protein, on its part, has been reported to repress ERα 
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activity by preventing its binding to the DNA (360, 361). This made us speculate if there 
was some kind of a connection between the three of them, that regulates ERα activity. 
Could DP103 be helping ERα-positive tumors and cells repress p53, such that ERα is let 
free from p53-mediated repression to execute its transcriptional activity? 
4.10.1 VALIDATION OF DP103 AS A p53-REPRESSOR 
 To test this, we first had to validate if DP103 was indeed a repressor of p53. There 
have been two reports on association of DP103 with p53. One (254), that says that DP103 
controls the transcriptional regulation of p53 expression. The other (255), that says that 
DP103 regulates p53 activity through protein-protein interaction and prevents it from 
binding to the DNA. We wanted to test both the scenarios in our system. 
 Upon depletion of DP103, we observed an increase in mRNA levels of p53, that 
translated into an increase in its protein levels as well (Figure 28 A and C). This 
confirmed Guo et al's report on DP103's repression of transcriptional regulation of p53. 
On the other hand, DP103 depletion also increased p53 transcriptional activity, evident 
from the DNA-binding assay and the mRNA and protein levels of its downstream target 
gene, p21 (Figure 28), confirming Cai et al's report. Thus, DP103 seems to be employing 
a dual mechanism of p53 regulation and inhibition. We had earlier demonstrated that 
DP103 depletion drastically reduced cell proliferation rate (Figure 6). DP103's effect on 
cell proliferation could be through various mechanisms that we still don't yet. However, 
we speculated if DP103 depletion caused a reduction in cell proliferation through 
induction of p53, that would either cause cell-cycle arrest or apoptosis. To test this, we 
depleted p53 together with DP103, to make sure that there is no increase in p53 upon 
DP103 depletion. Upon analysis, we observed that there was a rescue, although not 
complete, in the proliferation rate of the cells with double knockdown, indicating that 
decrease in cell proliferation upon DP103 depletion was atleast partially through induction 
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of p53. It however, remains to be seen if DP103-depletion mediated increase in p53, 
results in cell cycle arrest or apoptosis or cell senescence, to cause a functional impact on 
cell proliferation. 
These data are on MCF7 that has wild-type p53. We are still not in a position to 
comment if DP103 has similar or a different impact on mutant p53. Analysis of gene-
expression data available from different public domains, demonstrated a negative 
correlation between DP103 and p53 target gene CDKN1A (or p21) in breast tumors 
(Figure S8, A-B) and breast cancer cell lines (Figure S8, C-D). This anaylsis was done 
between DP103 and p53, irrespective of p53's mutation status, and it would be worth 
looking if we could distinguish DP103's association between the wild-type and mutant 
p53 containing tumors and cell lines, that would give us a clearer picture about the 
association between DP103 and p53 mutation status. 
4.10.2 DP103 COULD BE SUPPRESSING p53 TO ACTIVATE ERα 
 In context of ERα activity, we wanted to explore the relationship between DP103 
and p53 further. We first validated that DP103 interacts with p53, and in an estrogen 
stimulated condition, this interaction was found to be ligand-independent (Figure 30), an 
aspect that we would discuss later. We then wanted to explore if DP103 modulated ERα 
through modulation of p53. To test this, we looked at ERα transcriptional activity, 
measured by its DNA-binding activity and expression of its downstream target genes. 
From Figure 22 and 23, we understand that DP103 depletion decreased and overexpression 
enhanced estrogen-stimulated ERα transcriptional activity. To see if such effects were due 
to an inverse regulation of p53 by DP103, we silenced p53 together with silencing of 
DP103 (double knockdown), or overexpressed p53 together with overexpression of DP103 
(co-expression). From Figure 31 and 32, it is evident that DP103 keeps p53 repressed, to 
de-repress or activate ERα. Although p53 depletion alone did not decrease ERα activity, 
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p53 overexpression alone had a repressive effect on ERα activity. Furthermore, double 
knockdown rescued the decrease in ERα transcriptional activity that is generally observed 
with DP103 knockdown alone, whereas, co-expression could be either seen decreasing 
ERα activity compared to DP103 overexpression alone, or rescuing the decrease in ERα 
activity compared to p53 overexpression alone. This indicates that a decrease in DP103 
results in a definite increase in p53 expression or activity, that results in a repression in 
ERα activity, and this effect could be abolished if p53 was depleted together with DP103. 
Interestingly, p53 DNA binding activity was seen to increase with DP103 depletion upon 
estrogen stimulation, confirming that DP103 depletion lets p53 free to execute its 
transcriptional activity, and probably also inhibit ERα activity. On the other hand, DP103 
overexpression is probably keeping p53 repressed further to enhance ERα activity, and a 
co-expression of both DP103 and p53 would abolish this effect.  
 We propose to investigate this DP103-p53-ERα axis further. We raise a few 
questions to be answered to understand this mechanism better. p53 is known to interact 
with ERα and prevent its binding to the DNA. However, estrogen stimulation is expected 
to affect this interaction, allowing ERα to bind to the DNA. This implies that this 
interaction would be probably taking place in the nucleus. However, from our IF data 
study, DP103 does not enter the nucleus upon estrogen stimulation, so how does it repress 
p53 in an estrogen stimulated condition to let ERα free? From the IF data, we infer that 
DP103 is localized around the nucleus upon estrogen stimulation. This implies that DP103 
could be playing a critical role in estrogen signaling in the cytoplasm, probably keeping 
p53 repressed in the cytoplasm?  
To achieve this, we propose to study the co-localization pattern of these players in 
estrogen stimulated conditions, by IF and analysis of western blot of nuclear-cytoplasmic 
fractionated samples. This will tell us if and how, these players change their 
191 
 
localization/co-localization pattern in the cell upon estrogen stimulation, with ERα known 
to translocate into the nucleus and DP103 assumed to stay in the cytoplasm (from the IF 
data). It would be interesting to know p53 pattern in the cell. Upon knowing this, we will 
have to compare estrogen-dependent interactions between DP103 and p53, and between 
p53 and ERα, in the cytoplasm and the nucleus, and ascertain if there is a difference and 
preferred compartment for interaction. One hypothesis is that DP103 interacts with p53 
much more strongly in the cytoplasm than in the nucleus, keeping p53 repressed in the 
cytoplasm, disallowing it to either interact with ERα in the cytoplasm, or disallowing p53 
to enter the nucleus to further interact with ERα in the nucleus, thus letting ERα free in 
either case. Concomitantly, if were to knockdown DP103, then consistent with decreased 
ERα activity and increased p53 activity data from Figure 31, co-localization or interaction 
pattern of p53 and ERα in the cytoplasm or the nucleus, could be different, creating a 
scenario that is expected to strengthen the interaction between them, in either of the two 
compartments, further repressing ERα activity. These studies would definitely shed some 
more light on the role of DP103, if any, in the complex relationship between p53 and ERα 
in ERα-positive breast cancers.  
4.11 DP103-p53 CROSS-TALK IN MODULATING DOCETAXEL SENSITIVITY 
We have so far established prospective clues that p53 could be involved in 
modulation of ERα by DP103. We have also proposed further experiments that would be 
needed to explore this avenue further. In context of p53, we have validated DP103 as a 
repressor of p53. We have shown that DP103 interacts with p53, and that DP103 depletion 
increases p53 expression and p53 transcriptional activity (Figure 28). We have also shown 
that DP103 alteration modulates docetaxel sensitivity (Figure 16), with DP103 depletion 
increasing docetaxel sensitivity and DP103 overexpression increasing resistance. 
Interestingly, docetaxel is also known to exert its effect through induction of p53 (96-99). 
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We then asked if DP103, which is a p53-repressor, could be modulating docetaxel 
sensitivity through negative regulation of p53? We first confirmed in our system if 
docetaxel activated p53. Lower doses of docetaxel seemed to induce p53 protein 
expression (Figure 33 A), implicating a role of p53 in docetaxel-mediated anti-cancer 
effects. This is consistent with reports of transcriptional regulation of wild-type p53 by 
docetaxel (97). In this report, promoter region (-78 to +129) of p53 was highly responsive 
to lower doses of docetaxel, resulting in increased p53 expression, that in turn, repressed 
MDR-1 expression, making the cells more sensitive to docetaxel. In fact, our lab-generated 
docetaxel resistant cells, were found to have diminished expression of p53 (Figure 33 B), 
suggesting that cancer cells employ mechanism to suppress p53 expression, to evade drug 
effects.  
Having established the requirement of p53 in docetaxel sensitivity, we then asked if 
DP103 modulated docetaxel sensitivity through p53? Using p53 DNA-binding assay, we 
show that docetaxel activates p53 transcriptional activity, that is further enhanced if DP103 
was silenced (Figure 34). In contrast, docetaxel-induced p53 activity was kept quenched if 
DP103 was overexpressed (Figure 35). To verify if the change in docetaxel sensitivity with 
DP103 alteration (Figure 16) involved p53, we used the double knockdown or co-
expression approach. Upon depletion of both DP103 and p53 together, cells were found to 
be not as sensitive to docetaxel as DP103 depletion alone, suggesting that induction in p53 
was required for enhanced sensitivity (Figure 34). In contrast, when DP103 and p53 were 
overexpressed together, cells lost their resistance to docetaxel compared to DP103 
overexpression alone, suggesting that a suppression of p53 expression or activity was 
required for enhanced resistance (Figure 35). Thus, we show that DP103 modulates 
docetaxel sensitivity in breast cancer cells through modulation of p53.  
This also explains why DP103 expression decreases in ER-positive responders with 
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docetaxel treatment, so that wild-type p53 is free to execute its anti-cancer effects. 
However, in non-responders that are either characterized by loss of wild-type p53 or 
mutant p53, DP103 expression does not decrease, thus keeping a tight control on p53. 
Since our docetaxel-resistant cells showed a diminished expression of p53 (Figure 33 B), 
we would also be interested in knowing if this repression was due to DP103? We would 
silence DP103 in these resistant cells and see if there is a marked induction in p53 
expression and activity, implicating a role of DP103 in suppression of wild-type p53 
expression in drug resistance, and a possible approach to reverse resistance by silencing 
DP103. What also remains to be seen is if, DP103 and p53 exhibit an interaction/co-
localization pattern throughout the cell or in some preferred compartments like the 
cytoplam or the nucleus. We would also want to know if docetaxel treatment affects this 
pattern of DP103-p53 interaction/co-localization, thereby explaining how docetaxel 
treatment could disrupt the interaction between the two, and free p53 from DP103 to 
execute its transcriptional activity. Although, we are still at its infancy, could DP103 
expression be differentially regulated in various compartments of the cell, specially the 
nucleus and the cytoplasm, to modulate or dictate chemoresponse? Could there be a 
nucleo-cytoplasmic shuttling event for DP103 to elicit or block chemoresponse? Could 
there be mutations or SNPs on DP103 that make it so relevant to chemoresponse, drug 
resistance and p53 repression? Could there be other interacting partners of DP103, that we 
don't know of yet, and could the interaction between them be altered or affected in 
mediating oncogenicity and chemoresistance? 
4.12 DP103 ACTS AS THE SWITCH BETWEEN SUMOYLATION AND 
ACETYLATION OF p53 
It is quite puzzling that p53 decreases in expression, although DP103 expression 
remained the same in docetaxel-resistant cells, suggesting a much more complex 
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mechanism involved in DP103-mediated repression of p53. We know that DP103 involves 
in sumoylation process. It sumoylates SF-1 and represses its transcriptional activity (246). 
On the other hand, p53 is also known to get sumoylated, that inhibits its transcriptional 
activity (387, 389). Could DP103 be involved in sumoylation and subsequent repression of 
p53? 
To answer this, we depleted cells of DP103, and showed that sumoylation of p53 
with both SUMO1 and SUMO2/3 was decreased, suggesting that DP103 sumoylates p53. 
Consistent with Wu et al's report on cross-talk between sumoylation and acetylation (389), 
we show that DP103 depletion not only decreased p53 sumoylation, but it also increased 
p53 acetylation at lysine 382, that is associated with its activation status. This cross-talk 
occurs because of steric hindrance offered by the bigger SUMO moiety attached to lysine 
386, that prevents the smaller acetyl group to bind to lysine 382. We postulate that DP103 
keeps p53 sumoylated at lysine 386, thereby preventing subsequent acetylation and 
activation of p53. A depletion of DP103 would shift the balance towards a decreased 
sumoylation and an increased acetylation and increased transcriptional activity of p53. 
Thus, DP103 could act as a switch between sumoylation and acetylation status of wild-
type p53, that would dictate its activity. It would be interesting to compare sumoylation of 
p53 between the cytoplasm and the nucleus, and see if DP103 sumoylates p53 only in a 
specific compartment or both. Further mechanistic studies would be needed to determine 
the other players among the PIASs and the SENPs involved in DP103-mediated 
sumoylation of p53.  
Another question to be answered would be, if sumoylation of p53 promotes its 
subsequent ubiquitination and degradation? This is because MDM2 has also been 
implicated in sumoylation of p53 (392). Since MDM2 is predominantly known to 
ubiquitinate p53, we wonder if MDM2's involvement in sumoylation implies at 
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sumoylation being a pre-requisite for subsequent ubiquitination. In this regard, it would be 
interesting to see how MDM2 fits into DP103-mediated sumoylation of p53. We would 
also be keen to know if docetaxel affects sumoylation status of p53. Docetaxel treatment 
would be expected to decrease the sumoylation of p53, thereby increasing its acetylation 
status and activation. And of course, we would see if DP103 could resist docetaxel-
induced repression of p53 sumoylation. It would also be interesting to study the 
sumoylation status of p53 in docetaxel-resistant cells and the involvement of DP103 in 
keeping the expression of p53 suppressed.  
4.13 ASSOCIATION OF DP103 WITH MUTANT p53 
 Most of the our DP103-p53 studies were carried out in MCF7 cells that contain 
wild-type p53. It thus is pretty clear that DP103 represses wild-type p53. However, we 
could not study the impact of DP103 on mutant p53. Interaction studies showed that 
DP103 might have a higher preference for wild-type p53 over the mutant (Figure 36). 
Moreover, since wild-type p53 behaves like a tumor-suppressor and the mutant behaves 
like an oncogene, we would assume that DP103 may not have similar repressive effects on 
mutant p53. DP103 could just be involved in repression of tumor-suppressive wild-type 
p53, getting the cancer cells  rid of anti-cancer effects of wild-type p53. However, we still 
have to perform assays that study the impact of DP103 on transcriptional regulation, 
transcriptonal activity, docetaxel sensitivity and sumoylation status of mutant p53. On the 
contrary, if DP103 does not repress mutant p53, then, how do we explain its effect on ERα 
activity in T47D cells, that contains one copy of mutant p53 allele. One explanation is that 
the T47D cells have one copy of wild-type p53 allele, that still performs ERα-repressive 
functions. The second explanation is that, mutant p53 also represses ERα and that DP103 
keeps mutant p53 repressed to a certain extent to de-repress ERα. Mutant p53 has been 
shown to repress ERα, although to a much lesser extent than the wild-type p53 (361). 
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Moreover, mutant p53 is known to cause epigenetic silencing of ERα promoter (362, 363), 
thereby reducing its expression in the cell. Thus, DP103 would be repressing these two 
functions of mutant p53 in T47D cells to promoter ERα activity.  
4.14 PROPOSED MODEL OF DP103-P53-ERα AXIS TO MODULATE 
ONCOGENICITY AND DOCETAXEL SENSITIVITY 
Through my PhD study and this thesis, we have uncovered a novel role of DP103 
in chemoresponse to docetaxel in breast cancer. We have identified DP103 as a predictive 
biomarker of docetaxel-response, and also as a promising therapeutic target of docetaxel-
based therapy. To investigate DP103's role in chemoresponse, we took a retrospective 
approach and utilized a Phase II study that was carried out by our collaborator (399). This 
study looked at serial changes in the expression of breast cancer-related proteins in 
response to neoadjuvant chemotherapy involving docetaxel and doxorubicin. When we 
looked at DP103, its expression profile associated with the kind of response that was 
exhibited to docetaxel. A progressive decrease in DP103 expression was seen in clinical 
responders, with the non-responders showing no change, indicating that serial changes in 
DP103 expression could predict chemoresponse. When the patients were stratified by the 
ERα status, the response-predictive potential of DP103 was applicable only in ERα-
positive patients. Responders among ERα-positive patients showed a progressive decrease 
in DP103 expression, with the non-responders exhibiting no change to a slight increase. 
However, there was no significant association between DP103 expression and the clinical 
response among ERα-negative patients, indicating a possible association between DP103 
and ERα in breast cancer. Through various biochemical assays, we identified DP103 as a 
novel ERα-responsive gene. We also identified a positive feed-back loop between DP103 
and ERα, where DP103 that was ERα-responsive, also promoted estrogen-stimulated ERα 
transcriptional activity. Since p53 is reported in literature to repress ERα activity, our 
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further investigation revealed that DP103 promoted ERα activation through repression of 
p53, in accordance with the previous report on DP103's role as a novel p53 repressor in B-
cell lymphomas. Interestingly, we also observed that DP103 overexpression increased 
docetaxel resistance, whereas DP103 depletion increased cell sensitivity to docetaxel, 
establishing DP103 as a promising therapeutic target of docetaxel therapy. DP103's ability 
to modulate docetaxel response was due to its ability to modulate both caspase-3/7 and 
p53 activation. In essence, DP103 kept p53 repressed to block docetaxel-mediated cell 
death. Finally, we validated DP103 as an interacting partner of p53, preferring wild-type 
alleles over the mutant, and most importantly, we show that DP103 could be repressing 
p53 through increased sumoylation and decreased acetylation of p53.  
Our study also helps postulate why we observed DP103 expression correlating 
with docetaxel response only in ERα-positive patients. ERα-positive tumors are generally 
thought to harbor wild-type p53. In case of ERα-positive responders, docetaxel activates 
wild-type p53, that in turn, represses ERα activity and expression of its downstream target 
genes, including DP103. This is why DP103 expression would be decreasing with 
docetaxel treatment in responders. In contrast, the non-responders have a suppressed 
expression of p53, that does not affect ERα activity and expression of DP103. However, 
DP103 in a feed-back loop, would keep promoting ERα activity, and also quench either 
transcriptional regulation of p53 or transcriptional activity of p53 through sumoylation, 
promoting surviival and increasing chemoresistance. Overall, our study establishes DP103 
as a novel biomarker of chemoresponse in breast cancer, through modulation of ERα and 
p53 activity.  
To summarize, we have generated three schematic models for explaining DP103-
p53-ERα axis and its involvement in oncogenicity and chemoresponse in ERα-positive 
breast cancers. Our first model (Figure 38 A) depicts the hypothesized physiological 
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condition in an ERα-positive breast tumor, where DP103 represses p53 (either in the 
cytoplasm or the nucleus), to involve in a feed-back loop with ERα and promote ERα-
driven pathogenesis. The other two models are putative models of how DP103 expression 
profile associates with docetaxel response in ERα-positive tumors that are representative 
of a clinical responder (Figure 38 B) and a non-responder (Figure 38 C), respectively. The 









Figure 38. Schematic model of involvement of DP103 in breast cancer oncogenesis 
and chemoresponse. Normal physiological condition and roles of DP103 and p53 and 
ERα hypothesized in an ERα-positive breast cancer cell (A). DP103-p53-ERα axis in 










CHAPTER 5-FUTURE DIRECTIONS AND CONCLUSION 
The steroid hormone estrogen, essential for normal mammary gland physiology, is 
a potent mammary mitogen whose aberrant signaling is closely related to the development 
of ERα-positive breast cancer. We first found expression of DP103 to be significantly 
upregulated in breast cancer patient tissue specimens compared to normal breast tissues, 
suggesting that DP103’s expression may be modulated by oncogenic factors. Because of 
its link to activity of p53 and that p53 activity is important in responses to drug treatment 
such as docetaxel, we sought to explore from a Phase II study if expression of DP103 may 
be a predictive marker of docetaxel response. Analysis of mRNA and protein expression 
analysis show differential expression of DP103 before and after docetaxel treatment 
between clinical responders and non-responders. These clinical and subsequent in vitro 
data also identified DP103 as tightly linked to docetaxel sensitivity in ERα-positive 
patients. DP103 expression profile showed a decrease with a favourable response to 
docetaxel in ERα-positive responders, with no change in its expression profile observed in 
ERα-positive non-responders. These data suggest that DP103 expression may be utilized 
as a marker to identify patient subpopulations with ERα-positive status, that would most 
benefit from docetaxel chemotherapy.  
Using a range of biochemical assays, we uncover that DP103, which itself is an 
ERα target gene, can directly interfere with ERα transcriptional activity. A schematic 
diagram based on our clinical and in vitro findings is modelled in Figure 38. We envisage 
that in ERα-positive patients responding to docetaxel treatment, drug-induced decrease in 
expression of ERα in turn decreases gene expression of DP103 and its known downstream 
ER responsive genes. Atleast from our preliminary data, we believe that p53 could be 
instigating the decrease in ERα and DP103 expression upon docetaxel treatment. With 
lowered levels of DP103, p53 is activated and in turn, represses ERα transcriptional 
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activity, thus weakening ERα-mediated tumor cell survival or drug resistance. In the case 
of non-responders or resistant cells, cells ensure that p53 expression is kept suppressed, 
resulting in an increased stabilization of both ERα and DP103 expression. We however, do 
not know if DP103 plays a role in suppression of p53 in drug-resistance scenario. 
Nonetheless, sustained ERα activity maintains a hyper-activated DP103 scenario which, in 
a feed-back loop, represses p53 and also maintains high activity of ERα to drive tumor 
progression and drug resistance.  
Importantly, we have established DP103 as a promising therapeutic target for 
docetaxel-based therapy in ERα-positive cancers. This is because of DP103-mediated 
repression of wild-type p53. Loss or inactivation of p53 has been implicated in docetaxel 
resistance and thus, therapeutic interventions aimed at restoration of p53, would help 
resensitize resistant tumors to docetaxel therapy. We show that DP103 represses either 
transcriptional regulation of p53, or its transcriptional activity, thus blocking docetaxel-
mediated increase in p53 expression and activity. Depletion of DP103 would thus restore 
p53 expression and allow docetaxel to induce p53 further, sensitizing the cells to the drug. 
A combination of drugs that inhibit DP103, with docetaxel-based therapy, would be 
postulated to work well in the clinical scenario to help patients show a better response. 
This combination can also be used to reverse chemoresistance in non-responders, although, 
in vitro studies are needed to test if DP103 depletion could sensitize resistant cells to 
docetaxel. There are currently no drugs that target DP103, and thus, future studies would 
be needed to design drugs or small-molecule inhibitors against DP103 that would act as 
siRNAs in the patient tumor and deplete cells of DP103. Additionally, efforts could be 
concentrated on designing inhibitors against DP103-p53 binding pocket, that would 
compete for and disrupt this interaction, and disallow DP103 from repressing p53 any 
further. Thus, p53 expression and activity would be restored in the tumor to execute 
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tumor-suppressive functions.  
The highlight of this study is the finding that DP103 represses p53 through 
sumoylation. We show for the first time that DP103 could act a switch between 
sumoylation and acetylation status of p53, that would dictate its activity in the cell. Since, 
sumoylated p53 seems to constitute only 5% of its physiologically available fraction, it is 
interesting to know how significant is DP103-mediated sumoylation of p53 in the 
physiological condition, and how much of an impact would DP103 have on modulation of 
p53 activity in a givel pool of p53 molecules in a cell. MDM2 is also known to sumoylate 
p53, and it would be interesting to see if there is any inter-play between DP103 and 
MDM2 in sumoylation and repression of p53. With respect to drugs and chemotherapy, we 
speculate that if DP103 could mediate docetaxel response through p53, there is a high 
probability that it would also be involved in response to other drugs that induce and 
activate p53 such as doxorubicin, camptothecin and etoposide, among a few. However, 
based on our docetaxel story, we would assume that DP103 would associate with drug 
responses only in wild-type p53 containing tumors. Studies could be carefully designed to 
compare association of DP103 betwee wild-type and mutant p53 containing tumors, in 
prediction and modulation of chemoresponse to the respective drugs. The studies need not 
be limited to breast cancer and could explore DP103's novel roles as a chemoresponse 
predictive biomarker and a therapeutic target in other tumors that express wild-type p53 as 
well. At the momemt, we do not know the inter-play of DP103 with mutant p53, and any 
further understanding of this, would hopefully enable us to deal with mutant p53 
containing tumors better.  
Although additional studies are warranted to fully establish a complete 
biochemistry, we believe we have gathered enough clinical and in vitro evidences to 
present DP103 with its ability to predict docetaxel response in ERα-positive breast cancer 
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patients. In addition, we show DP103 as a novel estrogen-inducible gene that in turn 
modulates ERα transcriptional activity through repression of p53, which may offer an 
explanation to resistance to docetaxel. Since DP103 is an RNA helicase, it would be 
interesting to know if its RNA helicase activity is required for sumoylation-dependent 
repression of p53 and modulation of docetaxel sensitivity, and experiments would be 
performed to achieve that.  
Future studies may be directed at understanding DP103-p53 axis better. 
Incorporation of mutant p53 would also be beneficial since p53 is mutated in almost 50% 
of all cancers. Drugs targeting DP103 or DP103-p53 binding pocket would be able to 
provide benefits to wild-type p53 containing tumors, thereby breaking the Achilles’ heel of 
the negative regulation of p53 by DP103, to restore p53 expression and activity. More 
comprehensive trials would be needed to designate a more confident role of DP103 in 
























CHAPTER 6-SUPPLEMENTARY DATA 
 
Figure S1. DP103 gene expression in normal versus invasive ductal breast 
carcinomas. Dot plot of DP103 gene expression in breast cancer tumors (n=536) and 
normal (n=63). The gene expression value of DP103 (y-axis) is plotted for basal (Triple-
negative + Claudin-Low), ER+ (Luminal) breast cancer and normal breast tissue. 
Color: green = normal, blue = ER+ breast cancer, and red = basal type breast cancer. 
 
 
Figure S2. DP103 gene expression in normal breast fibroblasts versus breast 
cancer cell lines. Dot plot of DP103 gene expression in breast cancer cell lines (n=15) 
and normal breast fibroblasts (n=5). The gene expression value of DP103 (y-axis) is 
plotted for basal (Triple-negative + Claudin-Low), ER+ (Luminal) breast cancer and 
normal breast fibroblasts. Color: green = normal, blue = ER+ breast cancer, and red = 








Supplementary Table 1: Correlation of DP103 mRNA expression 
levels with clinical parameters 
  DP103 mRNA expression at 
baseline 
DP103 mRNA expression 
after cycle 1 
chemotherapy 
Non-T4 tumor 2440±1031 (n=20) 2227±985 (n=21) 
T4 tumor 2464±1045 (n=47) 2225±799 (n=36) 
  P=0.932 P=0.992 
No metastasis at diagnosis 2447±1061 (n=45) 2173±853 (n=42) 
Metastasis at diagnosis 2477±996 (n=22) 2371±908 (n=15) 
 P=0.911 P=0.451 
ER positive 2378±933 (n=41) 2021±694 (n=34) 
ER negative 2631±1178 (n=25) 2565±1016 (n=22) 
  P=0.337 P=0.021 
Clinical responder 2321±949 (n=54) 2092±778 (n=48) 
Non-responder 3040±1303 (n=11) 3019±1030 (n=8) 
  P=0.036 P=0.004 
 
Supplementary Table 2: Correlation of DP103 mRNA expression levels 
with progression-free and overall survival 
  Median Progress-free survival 
(95% confidence interval; 
months) 
Overall survival           
(95% confidence interval; 
months) 
DP103 mRNA expression at 
baseline 
    
Lower than median (n=34) 29 (19-39) 49 (24-74) 
Higher than median (n=33) 28 (3-53) 75 (--) 
  P=0.991 P=0.103 
DP103 mRNA expression 
after cycle 1 chemotherapy 
    
Lower than median (n=29) 30 (0-64) 75 (--) 
Higher than median (n=28) 35 (4-65) 75 (61-90) 






       
Figure S3. DP103 mRNA expression change in Responders vs. Non-responders. 
Box plots of tumor DP103 mRNA expression levels at baseline (p=0.036) and after one 
cycle of chemotherapy (p=0.004), in responders versus non-responders 
 





Figure S4. DP103 mRNA expression change in ER negative vs. positive tumors. Box 
plots of tumor DP103 mRNA relative expression change after chemotherapy in ERα 
negative versus positive tumors (p=0.047; A). Box plots of tumor DP103 mRNA 
expression change in clinical responders and non-responders in ERα negative patients (B) 
at baseline (p=0.215) and after one cycle of chemotherapy (p=0.958). Box plots of tumor 
DP103 mRNA expression change in clinical responders and non-responders in ERα 
positive patients (C) at baseline (p=0.173) and after one cycle of chemotherapy (p<0.001). 
 
Supplementary Table 3: Correlation of DP103 IHC status with clinical parameters 
  DP103 positivity       
at baseline                    
(%) 
DP103 positivity after 
cycle 1 chemotherapy 
(%) 
DP103 positivity after 
cycle 2 chemotherapy 
(%) 
DP103 positivity after 
cycle 6 chemotherapy  
(%) 
Non-T4 tumor 50% (n=14) 47% (n=17) 40% (n=15) 43% (n=7) 
T4 tumor 53% (n=49) 43% (n=35) 31% (n=36) 28% (29) 
  P=0.840 P=0.775 P=0.514 P=0.431 




























ER positive 55% (n=40) 41% (n=32) 34% (n=32) 31% (n=29) 
ER negative 48% (n=21) 53% (n=19) 28% (n=18) 29% (n=7) 
  P=0.583 P=0.405 P=0.631 P=0.899 
Clinical responder 55% (n=49) 45% (n=42) 33% (n=39) 29% (n=31) 
Non-responder 39% (n=13) 44%  (n=9) 33% (n=12) 40% (n=5) 




Supplementary Table 4: Correlation of DP103 IHC expression levels with  
progression-free and overall survival 
  Median Progress-free survival 
(95% confidence interval; 
months) 
Overall survival                            
(95% confidence interval;     
months) 
DP103 IHC at baseline     
Negative (n=30) 26 (0-60) 72 (47-97) 
Positive (n=33) 25 (3-48) 49 (21-78) 
  P=0.580 P=0.518 
DP103 IHC after cycle 1 
chemotherapy 
    
Negative (n=29) 56 (30-81) 72 (52-93) 
Positive (n=23) 25 (1-50) 49 (15-83) 









Figure S5. DP103 IHC expression change. Serial changes in tumor DP103 expression 
levels (A) in clinical responders (p=0.002) and non-responders (p=0.225). DP103 IHC 
staining of tumor biopsies (B) from responder with Partial Response and a non-responder 
with Progressive Disease. Serial changes in tumor DP103 expression levels (C) in ERα 
positive (p=0.02) and negative tumors (p=0.664) tumors. DP103 IHC staining of tumor 




Figure S6. Effect of Doxorubicin or Docetaxel on DP103 mRNA expression. Box 
plots of tumor DP103 mRNA relative expression change after one cycle of doxorubicin 
(p=0.618) and docetaxel (p=0.024), stratified by ER status. 
 
Supplementary Table 5: Clinicopathological features of 274 
cases of normal breast and IDC cases 
Clinicopathological features Number of cases Value (Years) 










Tumour type   
  
Normal 61 
Luminal A 175 













Figure S7. Clinical association between DP103 and ERα. Expression of DP103 in 
normal ductal tissues (A), Luminal A (B) and Luminal B (C) ductal carcinoma. Correlation 
of DP103 expression with different ductal tissue types (D). Correlation of ERα status with 
different ductal tissue types (E). Expression of ERα in normal ductal tissues (F), Luminal 
A (G) and Luminal B (H) ductal carcinoma. Correlation of DP103 expression with ERα 




    
    
Figure S8. Clinical association between DP103 and CDKN1A. Correlation plot of the 
gene expression value of DP103 (x-axis) and CDKN1A (y-axis) in Affymetrix (A) and TCGA (B) 
breast cancer panels. Correlation plot of the gene expression value of DP103 (x-axis) and 
CDKN1A (y-axis) in breast cancer cell line data-set extracted from Broad-Norvatis Cancer Cell 
Line Encyclopedia. The red dotted line is fitted by linear regression. Rho and p-value were 













Figure S9. Docking analysis for DP103-p53 interaction. Structure of p53 (green) 
interacting with DP103 (red) (A). Residues that are present in the interface region is shown 
as sticks. Structure shown is the most possible docked structures with low energy of 
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